



- (51) **International Patent Classification:**
C12Q 1/68 (2006.01)
- (21) **International Application Number:**
PCT/EP2012/058502
- (22) **International Filing Date:**
9 May 2012 (09.05.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/EP2011/057716 12 May 2011 (12.05.2011) EP
- (71) **Applicant (for all designated States except US):** **NOVIO-
GENDIX RESEARCH B.V.** [NL/NL]; Geert Grooteplein-
Zuid 34, NL-6525 GA Nijmegen (NL).
- (72) **Inventor; and**
- (75) **Inventor/Applicant (for US only):** **SMIT, Franciscus,
Petrus** [NL/NL]; Wedesteinbroek 1440, NL-6546 RN
Nijmegen (NL).
- (74) **Agent:** **VAN KOOLJ, Adriaan;** Arnold + Siedsma,
Sweelinckplein 1, NL-2517 GK Den Haag (NL).
- (81) **Designated States (unless otherwise indicated, for every
kind of national protection available):** AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every
kind of regional protection available):** ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) **Title:** MOLECULAR MARKERS IN PROSTATE CANCER

(57) **Abstract:** The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, HG, PrCa Met and CRPC. Specifically, the present invention relates to methods for in vitro diagnosing prostate cancer in a human individual comprising: 1) determining the expression of one or more genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15; and 2) establishing up regulation of expression of said one or more genes as compared to expression of the respective one or more genes in a sample from an individual without prostate cancer thereby providing said diagnosis of prostate cancer.



MOLECULAR MARKERS IN PROSTATE CANCER**Description**

The present invention relates to methods for
5 diagnosing prostate cancer (PrCa) and to the detection of
locally advanced disease (clinical stage T3).

In the Western male population, prostate cancer has
become a major public health problem. In many developed
countries it is not only the most commonly diagnosed
10 malignancy, but it is the second leading cause of cancer
related deaths in males as well. Because the incidence of
prostate cancer increases with age, the number of newly
diagnosed cases continues to rise as the life expectancy of
the general population increases. In the United States,
15 approximately 218,000 men, and in Europe approximately
382,000 men are newly diagnosed with prostate cancer every
year.

Epidemiology studies show that prostate cancer is
an indolent disease and that more men die with prostate
20 cancer than from it. However, a significant fraction of the
tumors behave aggressively and as a result approximately
32,000 American men and approximately 89,000 European men
die from this disease on a yearly basis.

The high mortality rate is a consequence of the
25 fact that there are no curative therapeutic options for
metastatic prostate cancer. Androgen ablation is the
treatment of choice in men with metastatic disease.
Initially, 70 to 80% of the patients with advanced disease
show response to the therapy, but with time the majority of
30 the tumors will become androgen independent. As a result
most patients will develop progressive disease.

Since there are no effective therapeutic options
for advanced prostate cancer, early detection of this tumor

is pivotal and can increase the curative success rate. Although the routine use of serum prostate-specific antigen (PSA) testing has undoubtedly increased prostate cancer detection, one of its main drawbacks has been the lack of
5 specificity. Serum PSA is an excellent marker for prostatic diseases and even modest elevations almost always reflect a disease or perturbation of the prostate gland including benign prostatic hyperplasia (BPH) and prostatitis. Since the advent of frequent PSA testing over 20 years ago, the
10 specificity of PSA for cancer has declined due to the selection of a large number of men who have elevated PSA due to non-cancer mechanisms. This results in a high negative biopsy rate.

Therefore, (non-invasive) molecular tests, that can
15 accurately identify those men who have early stage, clinically localized prostate cancer and who would gain prolonged survival and quality of life from early radical intervention, are urgently needed. Molecular biomarkers identified in tissues can serve as target for new body fluid
20 based molecular tests.

A suitable biomarker preferably fulfils the following criteria: 1) it must be reproducible (intra- en inter-institutional) and 2) it must have an impact on clinical management.

25 Further, for diagnostic purposes, it is important that the biomarkers are tested in terms of tissue-specificity and discrimination potential between prostate cancer, normal prostate and BPH. Furthermore, it can be expected that (multiple) biomarker-based assays enhance the
30 specificity for cancer detection.

Considering the above, there is an urgent need for molecular prognostic biomarkers for predicting the biological behaviour of cancer and outcome.

For the identification of new candidate markers for prostate cancer, it is necessary to study expression patterns in malignant as well as non-malignant prostate tissues, preferably in relation to other medical data.

5 Recent developments in the field of molecular techniques have provided new tools that enabled the assessment of both genomic alterations and proteomic alterations in these samples in a comprehensive and rapid manner. These tools have led to the discovery of many new
10 promising biomarkers for prostate cancer. These biomarkers may be instrumental in the development of new tests that have a high specificity in the diagnosis and prognosis of prostate cancer.

 For instance, the identification of different
15 chromosomal abnormalities like changes in chromosome number, translocations, deletions, rearrangements and duplications in cells can be studied using fluorescence in situ hybridization (FISH) analysis. Comparative genomic hybridization (CGH) is able to screen the entire genome for
20 large changes in DNA sequence copy number or deletions larger than 10 mega-base pairs. Differential display analysis, serial analysis of gene expression (SAGE), oligonucleotide arrays and cDNA arrays characterize gene expression profiles. These techniques are often used
25 combined with tissue microarray (TMA) for the identification of genes that play an important role in specific biological processes.

 Since genetic alterations often lead to mutated or altered proteins, the signalling pathways of a cell may
30 become affected. Eventually, this may lead to a growth-advantage or survival of a cancer cell. Proteomics study the identification of altered proteins in terms of structure, quantity, and post-translational modifications. Disease-

related proteins can be directly sequenced and identified in intact whole tissue sections using the matrix-assisted laser desorption-ionization time-of-flight mass spectrometer

(MALDI-TOF). Additionally, surface-enhanced laser

5 desorption-ionization (SELDI)-TOF mass spectroscopy (MS) can provide a rapid protein expression profile from tissue cells and body fluids like serum or urine.

In the last years, these molecular tools have led to the identification of hundreds of genes that are believed
10 to be relevant in the development of prostate cancer. Not only have these findings led to more insight in the initiation and progression of prostate cancer, but they have also shown that prostate cancer is a heterogeneous disease.

Several prostate tumors may occur in the prostate
15 of a single patient due to the multifocal nature of the disease. Each of these tumors can show remarkable differences in gene expression and behaviour that are associated with varying prognoses. Therefore, in predicting the outcome of the disease it is more likely that a set of
20 different markers will become clinically important.

Biomarkers can be classified into four different prostate cancer-specific events: genomic alterations, prostate cancer-specific biological processes, epigenetic modifications and genes uniquely expressed in prostate
25 cancer.

One of the strongest epidemiological risk factors for prostate cancer is a positive family history. A study of 44,788 pairs of twins in Denmark, Sweden and Finland has shown that 42% of the prostate cancer cases were
30 attributable to inheritance. Consistently higher risk for the disease has been observed in brothers of affected patients compared to the sons of the same patients. This has

led to the hypothesis that there is an X-linked or recessive genetic component involved in the risk for prostate cancer.

Genome-wide scans in affected families implicated at least seven prostate cancer susceptibility loci, HPC1 (1q24), CAPB (1p36), PCAP (1q42), ELAC2 (17p11), HPC20 (20q13), 8p22-23 and HPCX (Xq27-28). Recently, three candidate hereditary prostate cancer genes have been mapped to these loci, HPC1/2'-5'-oligoadenylate dependent ribonuclease L (RNASEL) on chromosome 1q24-25, macrophage scavenger 1 gene (MSR1) located on chromosome 8p22-23, and HPC2/ELAC2 on chromosome 17p11.

It has been estimated that prostate cancer susceptibility genes probably account for only 10% of hereditary prostate cancer cases. Familial prostate cancers are most likely associated with shared environmental factors or more common genetic variants or polymorphisms. Since such variants may occur at high frequencies in the affected population, their impact on prostate cancer risk can be substantial.

Recently, polymorphisms in the genes coding for the androgen-receptor (AR), 5 α -reductase type II (SRD5A2), CYP17, CYP3A, vitamin D receptor (VDR), PSA, GST-T1, GST-M1, GST-P1, insulin-like growth factor (IGF-I), and IGF binding protein 3 (IGFBP3) have been studied.

These studies were performed to establish whether these genes can predict the presence of prostate cancer in patients indicated for prostate biopsies due to PSA levels >3 ng/ml. No associations were found between AR, SRD5A2, CYP17, CYP3A4, VDR, GST-M1, GST-P1, and IGFBP3 genotypes and prostate cancer risk. Only GST-T1 and IGF-I polymorphisms were found to be modestly associated with prostate cancer risk.

Unlike the adenomatous polyposis coli (APC) gene in familial colon cancer, none of the mentioned prostate cancer susceptibility genes and loci is by itself responsible for the largest portion of prostate cancers.

5 Epidemiology studies support the idea that most prostate cancers can be attributed to factors as race, life-style, and diet. The role of gene mutations in known oncogenes and tumor suppressor genes is probably very small in primary prostate cancer. For instance, the frequency of
10 p53 mutations in primary prostate cancer is reported to be low but have been observed in almost 50% of advanced prostate cancers.

Screening men for the presence of cancer-specific gene mutations or polymorphisms is time-consuming and
15 costly. Moreover, it is very ineffective in the detection of primary prostate cancers in the general male population. Therefore, it cannot be applied as a prostate cancer screening test.

Mitochondrial DNA is present in approximately 1,000
20 to 10,000 copies per cell. Due to these quantities, mitochondrial DNA mutations have been used as target for the analysis of plasma and serum DNA from prostate cancer patients. Recently, mitochondrial DNA mutations were
25 detected in three out of three prostate cancer patients who had the same mitochondrial DNA mutations in their primary tumor. Different urological tumor specimens have to be studied and larger patient groups are needed to define the overall diagnostic sensitivity of this method.

Critical alterations in gene expression can lead to
30 the progression of prostate cancer. Microsatellite alterations, which are polymorphic repetitive DNA sequences, often appear as loss of heterozygosity (LOH) or as microsatellite instability. Defined microsatellite

alterations are known in prostate cancer. The clinical utility so far is negligible. Whole genome- and SNP arrays are considered to be powerful discovery tools.

Alterations in DNA, without changing the order of
5 bases in the sequence, often lead to changes in gene expression. These epigenetic modifications include changes such as DNA methylation and histone acetylation/deacetylation. Many gene promoters contain GC-rich regions also known as CpG islands. Abnormal methylation
10 of CpG islands results in decreased transcription of the gene into mRNA.

Recently, it has been suggested that the DNA methylation status may be influenced in early life by environmental exposures, such as nutritional factors or
15 stress, and that this leads to an increased risk for cancer in adults. Changes in DNA methylation patterns have been observed in many human tumors. For the detection of promoter hypermethylation a technique called methylation-specific PCR (MSP) is used. In contrast to microsatellite or LOH
20 analysis, this technique requires a tumor to normal ratio of only 0.1-0.001%. This means that using this technique, hypermethylated alleles from tumor DNA can be detected in the presence of 10^4 - 10^5 excess amounts of normal alleles.

Therefore, DNA methylation can serve as a useful
25 marker in cancer detection. Recently, there have been many reports on hypermethylated genes in human prostate cancer. Two of these genes are RASSF1A and GSTP1.

Hypermethylation of RASSF1A (ras association domain family protein isoform A) is a common phenomenon in breast
30 cancer, kidney cancer, liver cancer, lung cancer and prostate cancer. The growth of human cancer cells can be reduced when *RASSF1A* is re-expressed. This supports a role for *RASSF1A* as a tumor suppressor gene. Initially no *RASSF1A*

hypermethylation was detected in normal prostate tissue. Recently, methylation of the *RASSF1A* gene was observed in both pre-malignant prostatic intra-epithelial neoplasms and benign prostatic epithelia. *RASSF1A* hypermethylation has been observed in 60-74% of prostate tumors and in 18.5% of BPH samples. Furthermore, the methylation frequency is clearly associated with high Gleason score and stage. These findings suggest that *RASSF1A* hypermethylation may distinguish the more aggressive tumors from the indolent ones.

The most described epigenetic alteration in prostate cancer is the hypermethylation of the Glutathione S-transferase P1 (GSTP1) promoter. GSTP1 belongs to the cellular protection system against toxic effects and as such this enzyme is involved in the detoxification of many xenobiotics.

GSTP1 hypermethylation has been reported in approximately 6% of the proliferative inflammatory atrophy (PIA) lesions and in 70% of the PIN lesions. It has been shown that some PIA lesions merge directly with PIN and early carcinoma lesions, although additional studies are necessary to confirm these findings. Hypermethylation of GSTP1 has been detected in more than 90% of prostate tumors, whereas no hypermethylation has been observed in BPH and normal prostate tissues.

Hypermethylation of the GSTP1 gene has been detected in 50% of ejaculates from prostate cancer patients but not in men with BPH. Due to the fact that ejaculates are not always easily obtained from prostate cancer patients, hypermethylation of GSTP1 was determined in urinary sediments obtained from prostate cancer patients after prostate massage. Cancer could be detected in 77% of these sediments.

Moreover, hypermethylation of GSTP1 has been found in urinary sediments after prostate massage in 68% of patients with early confined disease, 78% of patients with locally advanced disease, 29% of patients with PIN and 2% of patients with BPH. These findings resulted in a specificity of 98% and a sensitivity of 73%. The negative predictive value of this test was 80%, which shows that this assay bears great potential to reduce the number of unnecessary biopsies.

Recently, these results were confirmed and a higher frequency of GSTP1 methylation was observed in the urine of men with stage 3 versus stage 2 disease.

Because hypermethylation of GSTP1 has a high specificity for prostate cancer, the presence of GSTP1 hypermethylation in urinary sediments of patients with negative biopsies (33%) and patients with atypia or high-grade PIN (67%) suggests that these patients may have occult prostate cancer.

Recently, a multiplexed assay consisting of 3 methylation markers, *GSTP1*, *RARB*, *APC* and an endogenous control was tested on urine samples from patients with serum PSA concentrations ≥ 2.5 $\mu\text{g/l}$. A good correlation of *GSTP1* with the number of prostate cancer-positive cores on biopsy was observed. Furthermore, samples that contained methylation for either *GSTP1* or *RARB* correlated with higher tumor volumes. Methylated genes have the potential to provide a new generation of cancer biomarkers.

Micro-array studies have been very useful and informative to identify genes that are consistently up-regulated or down-regulated in prostate cancer compared with benign prostate tissue. These genes can provide prostate cancer-specific biomarkers and give us more insight into the etiology of the disease.

For the molecular diagnosis of prostate cancer, genes that are highly up-regulated in prostate cancer compared to low or normal expression in normal prostate tissue are of special interest. Such genes could enable the
5 detection of one tumor cell in a huge background of normal cells, and could thus be applied as a diagnostic marker in prostate cancer detection.

Differential gene expression analysis has been successfully used to identify prostate cancer-specific
10 biomarkers by comparing malignant with non-malignant prostate tissues. Recently, a new biostatistical method called cancer outlier profile analysis (COPA) was used to identify genes that are differentially expressed in a subset of prostate cancers. COPA identified strong outlier profiles
15 for v-ets erythroblastosis virus E26 oncogene (*ERG*) and ets variant gene 1 (*ETV1*) in 57% of prostate cancer cases. This was in concordance with the results of a study where prostate cancer-associated *ERG* overexpression was found in 72% of prostate cancer cases. In >90% of the cases that
20 overexpressed either *ERG* or *ETV1* a fusion of the 5' untranslated region of the prostate-specific and androgen-regulated transmembrane-serine protease gene (*TMPRSS2*) with these ETS family members was found. Recently, another fusion between *TMPRSS2* and an ETS family member has been described,
25 the *TMPRSS2-ETV4* fusion, although this fusion is sporadically found in prostate cancers.

Furthermore, a fusion of *TMPRSS2* with *ETV5* was found. Overexpression of *ETV5* *in vitro* was shown to induce an invasive transcriptional program. These fusions can
30 explain the aberrant androgen-dependent overexpression of ETS family members in subsets of prostate cancer because *TMPRSS2* is androgen-regulated. The discovery of the *TMPRSS2-ERG* gene fusion and the fact that *ERG* is the most-frequently

overexpressed proto-oncogene described in malignant prostate epithelial cells suggests its role in prostate tumorigenesis. Fusions of the 5' untranslated region of the *TMPRSS2* gene with the ETS transcription factors *ERG*, *ETV1* and *ETV4* have been reported in prostate cancer.

Recently, it was shown that non-invasive detection of *TMPRSS2-ERG* fusion transcripts is feasible in urinary sediments obtained after DRE using an RT-PCR-based research assay. Due to the high specificity of the test (93%), the combination of *TMPRSS2-ERG* fusion transcripts with prostate cancer gene 3 (*PCA3*) improved the sensitivity from 62% (*PCA3* alone) to 73% (combined) without compromising the specificity for detecting prostate cancer.

The gene coding for α -methylacyl-CoA racemase (AMACR) on chromosome 5p13 has been found to be consistently up-regulated in prostate cancer. This enzyme plays a critical role in peroxisomal beta oxidation of branched chain fatty acid molecules obtained from dairy and beef. Interestingly, the consumption of dairy and beef has been associated with an increased risk for prostate cancer.

In clinical prostate cancer tissue, a 9-fold over-expression of AMACR mRNA has been found compared to normal prostate tissue. Immunohistochemical (IHC) studies and Western blot analyses have confirmed the up-regulation of AMACR at the protein level. Furthermore, it has been shown that 88% of prostate cancer cases and both untreated metastases and hormone refractory prostate cancers were strongly positive for AMACR. AMACR expression has not been detected in atrophic glands, basal cell hyperplasia and urothelial epithelium or metaplasia. IHC studies also showed that AMACR expression in needle biopsies had a 97% sensitivity and a 100% specificity for prostate cancer detection.

Combined with a staining for p63, a basal cell marker that is absent in prostate cancer, AMACR greatly facilitated the identification of malignant prostate cells. Its high expression and cancer-cell specificity implicate that AMACR may also be a candidate for the development of molecular probes which may facilitate the identification of prostate cancer using non-invasive imaging modalities.

There have been many efforts to develop a body fluid-based assay for AMACR. A small study indicated that AMACR-based quantitative real-time PCR analysis on urine samples obtained after prostate massage has the potential to exclude the patients with clinically insignificant disease when AMACR mRNA expression is normalized for PSA. Western blot analysis on urine samples obtained after prostate massage had a sensitivity of 100%, a specificity of 58%, a positive predictive value (PPV) of 72%, and a negative predictive value (NPV) of 88% for prostate cancer. These assays using AMACR mRNA for the detection of prostate cancer in urine specimens are promising.

Using cDNA micro-array analysis, it has been shown that hepsin, a type II transmembrane serine protease, is one of the most-differentially over-expressed genes in prostate cancer compared to normal prostate tissue and BPH tissue. Using a quantitative real-time PCR analysis it has been shown that hepsin is over-expressed in 90% of prostate cancer tissues. In 59% of the prostate cancers this over-expression was more than 10-fold.

Also there has been a significant correlation between the up-regulation of hepsin and tumor-grade. Further studies will have to determine the tissue-specificity of hepsin and the diagnostic value of this serine protease as a new serum marker. Since hepsin is up-regulated in advanced and more aggressive tumors it suggests a role as a

prognostic tissue marker to determine the aggressiveness of a tumor.

Telomerase, a ribonucleoprotein, is involved in the synthesis and repair of telomeres that cap and protect the ends of eukaryotic chromosomes. The human telomeres consist of tandem repeats of the TTAGGG sequence as well as several different binding proteins. During cell division telomeres cannot be fully replicated and will become shorter.

Telomerase can lengthen the telomeres and thus prevents the shortening of these structures. Cell division in the absence of telomerase activity will lead to shortening of the telomeres. As a result, the lifespan of the cells becomes limited and this will lead to senescence and cell death.

In tumor cells, including prostate cancer cells, telomeres are significantly shorter than in normal cells. In cancer cells with short telomeres, telomerase activity is required to escape senescence and to allow immortal growth. High telomerase activity has been found in 90% of prostate cancers and was shown to be absent in normal prostate tissue.

In a small study on 36 specimens telomerase activity has been used to detect prostate cancer cells in voided urine or urethral washing after prostate massage. This test had a sensitivity of 58% and a specificity of 100%. The negative predictive value of the test was 55%.

Although it has been a small and preliminary study, the low negative predictive value indicates that telomerase activity measured in urine samples is not very promising in reducing the number of unnecessary biopsies.

The quantification of the catalytic subunit of telomerase, hTERT, showed a median over-expression of hTERT mRNA of 6-fold in prostate cancer tissues compared to normal prostate tissues. A significant relationship was found

between hTERT expression and tumor stage, but not with Gleason score. The quantification of hTERT using real-time PCR showed that hTERT could well discriminate prostate cancer tissues from non-malignant prostate tissues. However, hTERT mRNA is expressed in leukocytes, which are regularly present in body fluids such as blood and urine. This may cause false positivity. As such, quantitative measurement of hTERT in body fluids is not very promising as a diagnostic tool for prostate cancer.

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is expressed on the surface of prostate epithelial cells. The expression of PSMA appears to be restricted to the prostate. It has been shown that PSMA is upregulated in prostate cancer tissue compared with benign prostate tissues. No overlap in PSMA expression has been found between BPH and prostate cancer, indicating that PSMA is a very promising diagnostic marker.

Recently, it has been shown that high PSMA expression in prostate cancer cases correlated with tumor grade, pathological stage, aneuploidy and biochemical recurrence. Furthermore, increased PSMA mRNA expression in primary prostate cancers and metastasis correlated with PSMA protein overexpression. Its clinical utility as a diagnostic or prognostic marker for prostate cancer has been hindered by the lack of a sensitive immunoassay for this protein. However, a combination of ProteinChip® (CIPHERGEN Biosystems) arrays and SELDI-TOF MS has led to the introduction of a protein biochip immunoassay for the quantification of serum PSMA. It was shown that the average serum PSMA levels for prostate cancer patients were significantly higher compared with those of men with BPH and healthy controls. These findings implicate a role for serum PSMA to distinguish men with BPH from prostate cancer

patients. However, further studies are needed to assess its diagnostic value.

A combination of ProteinChip® arrays and SELDI-TOF MS has led to the introduction of a protein biochip

5 immunoassay for the quantification of serum PSMA. It was shown that the average serum PSMA levels for prostate cancer patients were significantly higher compared with those of men with BPH and healthy controls. These findings implicate a role for serum PSMA to distinguish men with BPH from
10 prostate cancer patients. However, further studies are needed to assess its diagnostic value.

RT-PCR studies have shown that PSMA in combination with its splice variant PSM' could be used as a prognostic marker for prostate cancer. In the normal prostate, PSM'
15 expression is higher than PSMA expression. In prostate cancer tissues, the PSMA expression is more dominant. Therefore, the ratio of PSMA to PSM' is highly indicative for disease progression. Designing a quantitative PCR analysis which discriminates between the two PSMA forms
20 could yield another application for PSMA in diagnosis and prognosis of prostate cancer.

Because of its specific expression on prostate epithelial cells and its upregulation in prostate cancer, PSMA has become the target for therapies. The proposed
25 strategies range from targeted toxins and radio nuclides to immunotherapeutic agents. First-generation products have entered clinical testing.

Delta-catenin (p120/CAS), an adhesive junction-associated protein, has been shown to be highly
30 discriminative between BPH and prostate cancer. *In situ* hybridization studies showed the highest expression of δ -catenin transcripts in adenocarcinoma of the prostate and low to no expression in BPH tissue. The average over-

expression of δ -catenin in prostate cancer compared to BPH is 15.7 fold.

Both quantitative PCR and in situ hybridization analysis could not find a correlation between δ -catenin
5 expression and Gleason scores.

Increased δ -catenin expression in human prostate cancer results in alterations of cell cycle and survival genes, thereby promoting tumor progression. δ -catenin was detected in cell-free human voided urine prostasomes. The δ -
10 catenin immunoreactivity was significantly increased in the urine of prostate cancer patients. Further studies are needed to assess its potential utility in the diagnosis of prostate cancer.

PCA3, formerly known as DD3, has been identified
15 using differential display analysis. PCA3 was found to be highly over-expressed in prostate tumors compared to normal prostate tissue of the same patient using Northern blot analysis. Moreover, PCA3 was found to be strongly over-expressed in more than 95% of primary prostate cancer
20 specimens and in prostate cancer metastasis. Furthermore, the expression of PCA3 is restricted to prostatic tissue, *i.e.* no expression has been found in other normal human tissues.

The gene encoding for PCA3 is located on chromosome
25 9q21.2. The PCA3 mRNA contains a high density of stop-codons. Therefore, it lacks an open reading frame resulting in a non-coding RNA. Recently, a time-resolved quantitative RT-PCR assay (using an internal standard and an external calibration curve) has been developed. The accurate
30 quantification power of this assay showed a median 66-fold up-regulation of PCA3 in prostate cancer tissue compared to normal prostate tissue. Moreover, a median-up-regulation of 11-fold was found in prostate tissues containing less than

10% of prostate cancer cells. This indicated that PCA3 was capable to detect a small number of tumor cells in a huge background of normal cells.

This hypothesis has been tested using the
5 quantitative RT-PCR analysis on voided urine samples. These urine samples were obtained after digital rectal examination (DRE) from a group of 108 men who were indicated for prostate biopsies based on a total serum PSA value of more than 3 ng/ml. This test had 67% sensitivity and 83%
10 specificity using prostatic biopsies as a gold-standard for the presence of a tumor. Furthermore, this test had a negative predictive value of 90%, which indicates that the quantitative determination of PCA3 transcripts in urinary sediments obtained after extensive prostate massage bears
15 great potential in the reduction of the number of invasive TRUS guided biopsies in this population of men.

The tissue-specificity and the high over-expression in prostate tumors indicate that PCA3 is the most prostate cancer-specific gene described so far. Gen-probe Inc. has
20 the exclusive worldwide licence to the PCA3 technology. Multicenter studies using the validated PCA3 assay can provide the first basis for the molecular diagnostics in clinical urological practice.

Modulated expression of cytoplasmic proteins HSP-27
25 and members of the PKC isoenzyme family have been correlated with prostate cancer progression.

Modulation of expression has clearly identified those cancers that are aggressive - and hence those that may require urgent treatment, irrespective of their morphology.
30 Although not widely employed, antibodies to these proteins are authenticated, are available commercially and are straightforward in their application and interpretation,

particularly in conjunction with other reagents as double-stained preparations.

The significance of this group of markers is that they accurately distinguish prostate cancers of aggressive phenotype. Modulated in their expression by invasive cancers, when compared to non-neoplastic prostatic tissues, those malignancies which express either HSP27 or PKC β at high level invariably exhibit a poor clinical outcome. The mechanism of this association warrants elucidation and validation.

E2F transcription factors, including E2F3 located on chromosome 6p22, directly modulate expression of EZH2. Overexpression of the EZH2 gene has been important in development of human prostate cancer.

Varambally and colleagues identified EZH2 as a gene overexpressed in hormone-refractory metastatic prostate cancer and showed that patients with clinically localized prostate cancers that express EZH2 have a worse progression than those who do not express the protein.

Using tissue microarrays, expression of high levels of nuclear E2F3 occurs in a high proportion of human prostate cancers but is a rare event in non-neoplastic prostatic epithelium. These data, together with other published information, suggested that the pRB-E2F3-EZH2 control axis may have a crucial role in modulating aggressiveness of individual human prostate cancers.

The prime challenge for molecular diagnostics is the identification of clinically insignificant prostate cancer, *i.e.* separate the biologically aggressive cancers from the indolent tumors. Furthermore, markers predicting and monitoring the response to treatment are urgently needed.

In current clinical settings over diagnosis and over treatment become more and more manifest, further underlining the need for biomarkers that can aid in the accurate identification of the patients that do not- and do-
5 need treatment.

The use of AMACR immunohistochemistry is now used in the identification of malignant processes in the prostate thus aiding the diagnosis of prostate cancer. Unfortunately, the introduction of molecular markers on tissue as
10 prognostic tool has not been validated for any of the markers discussed.

Experiences over the last two decades have revealed the practical and logistic complexity in translating molecular markers into clinical use. Several prospective
15 efforts, taking into account these issues, are currently ongoing to establish clinical utility of a number of markers. Clearly, tissue biorepositories of well documented specimens, including clinical follow up data, play a pivotal role in the validation process.

20 Novel body fluid tests based on GSTP1 hypermethylation and the gene PCA3, which is highly over-expressed in prostate cancer, enabled the detection of prostate cancer in non-invasively obtained body fluids such as urine or ejaculates.

25 The application of new technologies has shown that a large number of genes are up-regulated in prostate cancer.

Although the makers outlined above, at least partially, address the need in the art for tumor markers, and especially prostate tumor markers, there is a continuing
30 need for reliable (prostate) tumor markers, and especially markers indicative of the course of the disease.

It is an object of the present invention, amongst others, to meet at least partially, if not completely, the above object.

According to the present invention, the above
5 object, amongst others, is met by tumor markers and methods as outlined in the appended claims.

Specifically, the above object, amongst others, is met by a method for in vitro diagnosing prostate cancer in a human individual comprising:

- 10 - determining the expression of one or more genes chosen from the group consisting of DLX1, ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1, UGT2B15; and
- 15 - establishing up or down regulation of expression of said one or more genes as compared to expression of the respective one or more genes in a sample from an individual without prostate cancer;

20 thereby providing said diagnosis of prostate cancer.

According to the present invention diagnosing prostate cancer preferably comprises diagnosis, prognosis and/or prediction of disease survival.

According to the present invention, expression
25 analysis comprises establishing an increased or decreased expression of a gene as compared to expression of the gene in a non-prostate cancer tissue, i.e., under non-disease conditions. For example establishing an increased expression of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1,
30 MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1, UGT2B15 as compared to expression of these genes under non-prostate cancer conditions, allows diagnosis according to the present invention.

According to a preferred embodiment, the present method is performed on urinary, preferably urinary sediment samples.

According to a preferred embodiment of the present
5 method, determining the expression comprises determining mRNA expression of said one or more genes.

Expression analysis based on mRNA is generally known in the art and routinely practiced in diagnostic labs world-wide. For example, suitable techniques for mRNA
10 analysis are Northern blot hybridisation and amplification based techniques such as PCR, and especially real time PCR, and NASBA.

According to a particularly preferred embodiment, expression analysis comprises high-throughput DNA array chip
15 analysis not only allowing the simultaneous analysis of multiple samples but also an automatic analysis processing.

According to another preferred embodiment of the present method, determining the expression comprises
20 determining protein levels of the genes. Suitable techniques are, for example, matrix-assisted laser desorption-ionization time-of-flight mass spectrometer (MALDI-TOF).

According to the present invention, the present method of diagnosis is preferably provided by expression analysis of two or more, three or more, four or more, five
25 or more, six or more, seven or more, eight or more, nine or more, ten or more, or eleven of the genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and UGT2B15.

30 According to a particularly preferred embodiment, the present method of diagnosis is provided by expression analysis of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1, UGT2B15.

According to the present invention, the present method is preferably carried out using, in addition, expression analysis of one or more or two or more, preferably three or more, more preferably four or more, even
5 more preferably five or more, most preferably six or more or seven of the genes chosen from the group consisting of HOXC6, sFRP2, HOXD10, RORB, RRM2, TGM4, and SNAI2.

According to a particularly preferred embodiment, the present method is carried out by additional expression
10 analysis of at least HOXC6.

Preferably, the present method provides a diagnosing of prostate cancer in a human individual selected from the group consisting of diagnosing low grade PrCa (LG), high grade PrCa (HG), PrCa Met and CRPC.

15 LG indicates low grade PrCa (Gleason Score equal or less than 6) and represent patients with good prognosis. HG indicates high grade PrCa (Gleason Score of 7 or more) and represents patients with poor prognosis. CRPC indicates castration resistant prostate cancer and represents patients
20 with aggressive localized disease. Finally, PrCa Met represents patients with poor prognosis.

According to a particularly preferred embodiment of the present method, the present invention provides diagnosis of CRPC.

25 Considering the diagnosing value of the present genes as biomarkers for prostate cancer, the present invention also relates to the use of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15 for in vitro diagnosing the
30 present prostate cancer.

Again, considering the diagnosing value of the present genes as biomarkers for prostate cancer, the present

invention also relates to a kit of parts for diagnosing the present prostate cancer, comprising:

- expression analysis means for determining the expression of genes as defined above;
- instructions for use.

According to a preferred embodiment, the present kit of parts comprises mRNA expression analysis means, preferably for PCR, rtPCR or NASBA.

In the present description, reference is made to genes suitable as biomarkers for prostate cancer by referring to their arbitrarily assigned names. Although the skilled person is readily capable to identify and use the present genes as biomarkers based on these names, the appended figures provide both the cDNA sequence and protein sequences of these genes in the public database as also the references disclosing these genes. Based on the data provided in the figures, the skilled person, without undue experimentation and using standard molecular biology means, will be capable of determining the expression of the indicated biomarkers in a sample thereby providing the present method of diagnosis.

The present invention will be further elucidated in the following examples of preferred embodiments of the present invention. In the examples, reference is made to figures, wherein:

Figures 1-13: show the mRNA and amino acid sequences of the ACSM1 gene (NM_052956, NP_443188); the ALDH3B2 gene (NM_000695, NP_000686); the CGREF1 gene (NM_006569, NP_006560); the COMP gene (NM_000095, NP_000086); the C19orf48 gene (NM_199249, NP_954857); the DLX1 gene (NM_178120, NP_835221); the GLYATL1 gene

(NM_080661, NP_542392); the MS4A8B gene
(NM_031457, NP_113645); the NKAIN1 gene
(NM_024522, NP_078798); the PPFIA2 gene
(NM_003625, NP_003616); the PTPRT gene
(NM_133170, NP_573400); the TDRD1 gene
(NM_198795, NP_942090); and the UGT2B15 gene
(NM_001076, NP_001067).

Figures 14-26: show boxplots based on the TLDA validation data on the groups normal prostate (NPr), BPH, low grade prostate cancer (LG PrCa), HG, high grade prostate cancer (HG PrCa), CRPC, prostate cancer metastasis (PrCa Met), normal bladder, peripheral blood lymphocytes (PBL) and urinary sediments.

Figures 27-33: show the cDNA and amino acid sequences of the HOXC6 gene (NM_004503.3, NP_004494.1); the SFRP2 gene (NM_003013.2, NP_003004.1); the HOXD10 gene (NM_002148.3, NP_002139.2); the RORB gene (NM_006914.3, NP_008845.2); the RRM2 gene (NM_001034.2, NP_001025.1); the TGM4 gene (NM_003241.3, NP_003232.2); and the SNAI2 gene (NM_003068.3, NP_003059.1, respectively;

Figures 34-40: show boxplot TLDA data based on group LG (low grade), HG (high grade), CRPC (castration resistant) and PrCa Met (prostate cancer metastasis) expression analysis of HOXC6 gene (NM_004503.3); the SFRP2 gene (NM_003013.2); the HOXD10 gene (NM_002148.3); the RORB gene (NM_006914.3,); the RRM2 gene (NM_001034.2); the TGM4 gene (NM_003241.3); and the SNAI2 gene (NM_003068.3), respectively. NP indicates

no prostate cancer, i.e., normal or standard expression levels.

Example 1

5

To identify markers for aggressive prostate cancer, the gene expression profile (Affymetrix exon 1.0 arrays) of samples from patients with prostate cancer in the following categories were used:

10 Prostate samples in the following categories were used:

- Normal prostate (NPr), n=8.
- Benign Prostatic Hyperplasia (BPH), n=12.
- Low grade prostate cancer (LG PrCa): tissue specimens from primary tumors with a Gleason Score ≤ 6 obtained after radical prostatectomy. This group represents patients with a good prognosis, n=25.
- High grade prostate cancer (HG PrCa): tissue specimens from primary tumors with a Gleason Score ≥ 7 obtained after radical prostatectomy. This group represents patients with poor prognosis, n=24.
- Castration resistant prostate cancer (CRPC): tissue specimens are obtained from patients that are progressive under endocrine therapy and who underwent a transurethral resection of the prostate (TURP), n=23
- Prostate cancer metastases (PrCa Met): tissue specimens are obtained from positive lymphnodes after LND or after autopsy. This group represents patients with poor prognosis, n=7.

Furthermore, for diagnosing clinically significant prostate cancer (patients with a poor prognosis), the expression profiles of the categories pT2 (tumor confined to the prostate, n=10) and pT3 (locally advanced prostate cancer, n=9) were determined.

30

The expression analysis is performed according to standard protocols.

Briefly, from patients with prostate cancer (belonging to one of the last four previously mentioned
5 categories) tissue was obtained after radical prostatectomy or TURP. Normal prostate was obtained from cancer free regions of these samples or from autopsy. BPH tissue was obtained from TURP or transvesical open prostatectomy (Hryntschak). The tissues were snap frozen and cryostat
10 sections were H.E. stained for classification by a pathologist.

Tumor- and tumor free areas were dissected and total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) following manufacturer's instructions. The total
15 RNA was purified with the Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). Integrity of the RNA was checked by electrophoresis using the Agilent 2100 Bioanalyzer.

From the purified total RNA, 1 µg was used for the GeneChip Whole Transcript (WT) Sense Target Labeling Assay.
20 (Affymetrix, Santa Clara, CA, USA). According to the protocol of this assay, the majority of ribosomal RNA was removed using a RiboMinus Human/Mouse Transcriptome Isolation Kit (Invitrogen, Carlsbad, CA, USA). Using a random hexamer incorporating a T7 promoter, double-stranded
25 cDNA was synthesized. Then cRNA, was generated from the double-stranded cDNA template through an in-vitro transcription reaction and purified using the Affymetrix sample clean-up module. Single-stranded cDNA was regenerated through a random-primed reverse transcription using a dNTP
30 mix containing dUTP. The RNA was hydrolyzed with RNase H and the cDNA was purified. The cDNA was then fragmented by incubation with a mixture of UDG (uracil DNA glycosylase) and APE1 (apurinic/apyrimidinic endonuclease 1) restriction

endonucleases and, finally, end-labeled via a terminal transferase reaction incorporating a biotinylated dideoxynucleotide.

5.5 µg of the fragmented, biotinylated cDNA was added to a hybridization mixture, loaded on a Human Exon 1.0 ST GeneChip and hybridized for 16 hours at 45 °C and 60 rpm.

Using the Affymetrix exon array, genes are indirectly measured by exons analysis which measurements can be combined into transcript clusters measurements. There are more than 300,000 transcript clusters on the array, of which 90,000 contain more than one exon. Of these 90,000 there are more than 17,000 high confidence (CORE) genes which are used in the default analysis. In total there are more than 5.5 million features per array.

Following hybridization, the array was washed and stained according to the Affymetrix protocol. The stained array was scanned at 532 nm using an Affymetrix GeneChip Scanner 3000, generating CEL files for each array.

Exon-level expression values were derived from the CEL file probe-level hybridization intensities using the model-based RMA algorithm as implemented in the Affymetrix Expression Console™ software. RMA (Robust Multiarray Average) performs normalization, background correction and data summarization.

Differentially expressed genes between conditions are calculated using Anova (ANalysis Of Variance), a T-test for more than two groups.

The target identification is biased since clinically well defined risk groups were analyzed. The markers are categorized based on their role in cancer biology. For the identification of markers different groups were compared: NPr with LG- and HG PrCa, PrCa Met with LG- and HG PrCa, CRPC with LG- and HG PrCa. Finally the samples

were categorized based on clinical stage and organ confined PrCa (pT2) was compared with not-organ confined (pT3) PrCa.

Based on the expression analysis obtained, biomarkers were identified based on 99 prostate samples; the differences in expression levels between the different groups are provided in **Table 1 a,b,c and d.**

Table 1a: *Expression level differences between low grade (LG)- and high grade (HG) PrCa versus normal prostate (NPr) of 25 targets based on the analysis of 99 well annotated specimens*

Gene Symbol	Gene name	Gene assignment	Fold Change	LG + HG vs NPr	rank
CRISP3	cysteine-rich secretory protein 3	NM_006061	17,05	up	1
GLYATL1	glycine-N-acyltransferase-like 1	NM_080661	10,24	up	2
AMACR	alpha-methylacyl-CoA racemase	NM_014324	9,59	up	4
TARP	TCR gamma alternate reading frame protein	NM_001003799	9,42	up	5
ACSM1	acyl-CoA synthetase medium-chain family member 1	NM_052956	8,43	up	7
TDRD1	tudor domain containing 1	NM_198795	7,70	up	8
TMEM45B	transmembrane protein 45B	NM_138788	7,05	up	9
FOLH1	folate hydrolase (prostate-specific membrane antigen) 1	NM_004476	6,47	up	10
C19orf48	chromosome 19 open reading frame 48	NM_199249	5,91	up	12
ALDH3B2	aldehyde dehydrogenase 3 family, member B2	NM_000695	5,66	up	13
NETO2	neuropilin (NRP) and tolloid (TLL)-like 2	NM_018092	5,63	up	14
MS4A8B	membrane-spanning 4-domains, subfamily A, member 8B	NM_031457	5,00	up	18
TLCD1	TLC domain containing 1	NM_138463	4,73	up	21
FASN	fatty acid synthase	NM_004104	4,69	up	22
GRPR	gastrin-releasing peptide receptor	NM_005314	4,51	up	24
HPN	hepsin	NM_182983	4,44	up	25
PTPRT	protein tyrosine phosphatase, receptor type, T	NM_133170	4,21	up	29
TOP2A	topoisomerase (DNA) II alpha 170kDa	NM_001067	3,79	up	37
FAM111B	family with sequence similarity 111, member B	NM_198947	3,77	up	39
NKAIN1	Na ⁺ /K ⁺ transporting ATPase interacting 1	NM_024522	3,76	up	40
DLX1	distal-less homeobox 1	NM_178120	3,54	up	52
TPX2	TPX2, microtubule-associated, homolog	NM_012112	3,47	up	54
CGREF1	cell growth regulator with EF-hand domain 1	NM_006569	3,22	up	66
DPT	dermatopontin	NM_001937	-6,31	down	2
ASPA	aspartoacylase (Canavan disease)	NM_000049	-5,17	down	7

Table 1b: *Expression level differences between prostate cancer metastasis (PrCa Met) versus low grade (LG)- and high grade (HG) PrCa of 11 targets based on the analysis of 99 well annotated specimens*

Gene symbol	Gene name	Gene assignment	Fold Change	PrCa Met vs LG + HG	rank
PPFIA2	protein tyrosine phosphatase receptor type f interacting protein α 2	NM_003625	4,59	up	3
CDC20	cell division cycle 20 homolog (S. cerevisiae)	NM_001255	4,27	up	4
FAM110B	family with sequence similarity 110, member B	NM_147189	3,70	up	6
TARP	TCR gamma alternate reading frame protein	NM_001003799	3,26	up	12
ANLN	anillin, actin binding protein	NM_018685	3,17	up	13
KIF20A	kinesin family member 20A	NM_005733	3,16	up	14
TPX2	TPX2, microtubule-associated, homolog	NM_012112	3,15	up	15
CDC2	cell division cycle 2, G1 to S and G2 to M	NM_001130829	2,88	up	23
PGM5	phosphoglucomutase 5	NM_021965	-15,71	down	10
MSMB	microseminoprotein, beta-	NM_002443	-12,23	down	15
HSPB8	heat shock 22kDa protein 8	NM_014365	-12,10	down	16

5

Table 1c: *Expression level differences between CRPC versus low grade (LG)- and high grade (HG) PrCa of 21 targets based on the analysis of 99 well annotated specimens*

Gene symbol	Gene name	Gene assignment	Fold Change	CRPC vs LG + HG	rank
AR	androgen receptor	NM_000044	4,66	up	1
UGT2B15	UDP glucuronosyltransferase 2 family, polypeptide B15	NM_001076	4,20	up	2
CDC20	cell division cycle 20 homolog (S. cerevisiae)	NM_001255	3,86	up	4
TOP2A	topoisomerase (DNA) II alpha 170kDa	NM_001067	3,54	up	5
MKI67	antigen identified by monoclonal antibody Ki-67	NM_002417	3,47	up	6
TPX2	TPX2, microtubule-associated, homolog	NM_012112	3,40	up	7
AKR1C1	aldo-keto reductase family 1, member C1	NM_001353	3,35	up	8
CDC2	cell division cycle 2, G1 to S and G2 to M	NM_001130829	3,21	up	10
ANLN	anillin, actin binding protein	NM_018685	3,08	up	11
KIF4A	kinesin family member 4A	NM_012310	3,02	up	12
PTTG1	pituitary tumor-transforming 1	NM_004219	2,95	up	13
KIF20A	kinesin family member 2	NM_005733	2,90	up	14
AKR1C3	aldo-keto reductase family 1, member C3	NM_003739	2,88	up	15
FAM111B	family with sequence similarity 111, member B	NM_198947	2,81	up	16
CKS2	CDC28 protein kinase regulatory subunit 2	NM_001827	2,79	up	19
UGT2B17	UDP glucuronosyltransferase 2 family, polypeptide B17	NM_	2,77	up	20
BUB1	budding uninhibited by benzimidazoles 1 homolog	NM_004336	2,75	up	21

MSMB	microseminoprotein, beta-	NM_002443	-6,99	down	6
NR4A1	nuclear receptor subfamily 4, group A, member 1	NM_002135	-6,57	down	7
MT1M	metallothionein 1M	NM_176870	-6,08	down	10
DUSP1	dual specificity phosphatase 1	NM_004417	-5,59	down	12

Table 1d: *Expression level differences between organ confined PrCa (pT2) versus not-organ confined (pT3) PrCa of 21 targets based on the analysis of 99 well annotated specimens*

Gene symbol	Gene name	Gene assignment	Fold Change	pT3 vs pT2	rank
TTN	titin	NM_133378	4,88	up	2
SLN	sarcolipin	NM_003063	3,62	up	3
PPFIA2	protein tyrosine phosphatase, receptor type f interacting protein alpha 2	NM_003625	3,47	up	4
COMP	cartilage oligomeric matrix protein	NM_000095	2,74	up	6
ABI3BP	ABI family, member 3	NM_015429	2,71	up	7
NEB	nebulin	NM_004543	2,58	up	8
MT1M	metallothionein 1M	NM_176870	-6,03	down	1
MT1G	metallothionein 1G	NM_005950	-3,61	down	2

As can be clearly seen in **table 1** an up or down regulation of expression of the shown genes was associated with prostate cancer, CRPC, prostate metastasis or tumor stage.

Considering the above results obtained in 99 tumor samples the expression data clearly demonstrates the suitability of these genes as biomarkers for the diagnosis of prostate cancer.

Example 2

Using the gene expression profile (GeneChip® Human Exon 1.0 ST Array, Affymetrix) on 99 prostate samples several genes were found to be differentially expressed in normal prostate compared with prostate cancer and/or castration resistant prostate cancer (CRPC) or differentially expressed between low grade and high grade prostate cancer

compared with CRPC and/or prostate cancer metastasis.

Together with several other in the GeneChip® Human Exon 1.0 ST Array differentially expressed genes, the expression levels of these genes were validated using the TaqMan® Low Density arrays (TLDA, Applied Biosystems). In **Table 2** an overview of the validated genes is shown.

Table 2: *Gene expression assays used for TLDA analysis*

10

Gene Symbol	Description	Gene-ID	amplicon size (bp)
ABI3BP	ABI family, member 3 (NESH) binding protein	NM_015429	84
ACSM1	acyl-CoA synthetase medium-chain family member 1	NM_052956	74
ALDH3B2	aldehyde dehydrogenase 3 family, member B2	NM_000695	126
AMACR	alpha-methylacyl-CoA racemase	NM_014324	97
ANLN	anillin, actin binding protein	NM_018685	71
ASPA	aspartoacylase (Canavan disease)	NM_000049	63
BUB1	budding uninhibited by benzimidazoles 1 homolog	NM_004336	61
C19orf48	chromosome 19 open reading frame 48	NM_199249	59
CDC2	cell division cycle 2, G1 to S and G2 to M	NM_033379	109
CDC20	cell division cycle 20 homolog (S. cerevisiae)	NM_001255	108
CGREF1	cell growth regulator with EF-hand domain 1	NM_006569	58
CKS2	CDC28 protein kinase regulatory subunit 2	NM_001827	73
COMP	cartilage oligomeric matrix protein	NM_000095	101
CRISP3	cysteine-rich secretory protein 3	NM_006061	111
DLX1	distal-less homeobox 1	NM_178120	95
DPT	dermatopontin	NM_001937	67
DUSP1	dual specificity phosphatase 1	NM_004417	63
ERG	v-ets erythroblastosis virus E26 oncogene homolog	NM_004449	104
FAM110B	family with sequence similarity 110, member B	NM_147189	74
FAM111B	family with sequence similarity 111, member B	NM_198947	68
FASN	fatty acid synthase	NM_004104	62
FOLH1	folate hydrolase (prostate-spec. membrane antigen) 1	NM_004476	110
GLYATL1	glycine-N-acyltransferase-like 1	NM_080661	83
GRPR	gastrin-releasing peptide receptor	NM_005314	68
HPRT1	hypoxanthine phosphoribosyltransferase 1	NM_000194	72
HSPB8	heat shock 22kDa protein 8	NM_14365	66
KIF20A	kinesin family member 20A	NM_005733	71
KIF4A	kinesin family member 4A	NM_012310	88
MKI67	antigen identified by monoclonal antibody Ki-67	NM_002417	66
MS4A8B	membrane-spanning 4-domains, subfam. A, member 8B	NM_031457	62
MSMB	microseminoprotein, beta-	NM138634	149
MT1M	metallothionein 1M	NM_176870	144
NETO2	neuropilin (NRP) and tolloid (TLL)-like 2	NM_018092	66

NKAIN1	Na ⁺ /K ⁺ transporting ATPase interacting 1	NM_024522	96
NR4A1	nuclear receptor subfamily 4, group A, member 1	NM_002135	79
PCA3	prostate cancer antigen 3	AF103907	52
PGM5	phosphoglucomutase 5	NM_021965	121
PPFIA2	protein tyrosine phosphatase receptor type f polypept	NM_003625	66
PTPRT	protein tyrosine phosphatase, receptor type, T	NM_133170	62
PTTG1	pituitary tumor-transforming 1	NM_004219	86
TDRD1	tudor domain containing 1	NM_198795	67
TLCD1	TLC domain containing 1	NM_138463	63
TMEM45B	transmembrane protein 45B	NM_138788	70
TOP2A	topoisomerase (DNA) II alpha 170kDa	NM_001067	125
TPX2	TPX2, microtubule-associated, homolog	NM_012112	89
TTN	titin	NM_133378	85
UGT2B15	UDP glucuronosyltransferase 2 family, polypeptide B15	NM_001076	148

Prostate samples in the following categories were used:

- 5 - Normal prostate (NPr) (n=6)
- Benign Prostatic Hyperplasia (BPH) (n=6)
- Low grade prostate cancer (LG PrCa) (n=14): tissue specimens from primary tumors with a Gleason Score ≤6 obtained after radical prostatectomy. This group
- 10 represents patients with a good prognosis.
- High grade prostate cancer (HG PrCa) (n=14): tissue specimens from primary tumors with a Gleason Score ≥7 obtained after radical prostatectomy. This group represents patients with poor prognosis.
- 15 - Castration resistant prostate cancer (CRPC) (n=14): tissue specimens are obtained from patients that are progressive under endocrine therapy and who underwent a transurethral resection of the prostate (TURP).
- Prostate cancer metastases (PrCa Met) (n=8): tissue
- 20 specimens are obtained from positive lymphnodes after LND or after autopsy. This group represents patients with poor prognosis

All tissue samples were snap frozen and cryostat sections were stained with hematoxylin and eosin (H.E.). These H.E.-stained sections were classified by a pathologist.

5 Tumor- and tumor free areas were dissected. RNA was extracted from 10 µm thick serial sections that were collected from each tissue specimen at several levels. Tissue was evaluated by HE-staining of sections at each level and verified microscopically. Total RNA was extracted with TRIzol® (Invitrogen, Carlsbad, CA, USA) according to
10 the manufacturer's instructions.

RNA quantity and quality were assessed on a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and on an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA).

15 Two µg DNase-treated total RNA was reverse transcribed using SuperScript™ II Reverse Transcriptase (Invitrogen) in a 37.5 µl reaction according to the manufacturer's protocol. Reactions were incubated for 10 minutes at 25°C, 60 minutes at 42°C and 15 minutes at 70°C.
20 To the cDNA, 62.5 µl milliQ was added.

For the validation not only prostate tissue specimens were used. To investigate whether the selected markers could successfully be detected in body fluids also normal bladder tissue specimens, peripheral blood
25 lymphocytes(PBL)- and urinary sediment specimens were included in the marker validation step. The background signal of the markers in normal bladder and urinary sediments from patients without prostate cancer should be low.

30 These urinary sediment specimens were collected at three hospitals after a consent form approved by the institutional review board was signed by all participants. First voided urine samples were collected after digital

rectal examination (DRE) from men scheduled for prostate cancer. After urine specimen collection, the urologist performed prostate biopsies according to a standard protocol. Prostate biopsies were evaluated and in case
5 prostate cancer was present the Gleason score was determined.

First voided urine after DRE (20-30 ml) was collected in a coded tube containing 2 ml 0.5M EDTA pH 8.0. All samples were immediately cooled to 4°C and were mailed
10 in batches with cold packs to the laboratory of NovioGendix. The samples were processed within 48 h after the samples was acquired to guarantee good sample quality. Upon centrifugation at 4°C and 1,800 x g for 10 minutes, urinary sediments were obtained. These urinary sediments were washed
15 twice with ice-cold buffered sodium chloride solution (at 4°C and 1,800 x g for 10 minutes), snap-frozen in liquid nitrogen, and stored at -70°C.

Total RNA was extracted from these urinary sediments, using TriPure Isolation Reagent (Roche
20 Diagnostics, Almere, the Netherlands) according to the manufacturers protocol.

Two additional steps were added. First 2 µl glycogen (15 mg/ml) was added as a carrier (Ambion, Austin (TX), USA) before precipitation with isopropanol.
25 Secondly a second precipitation step with 3M sodium-acetate pH 5.2 and 100% ethanol was performed to discard traces of TriPure Isolation Reagent.

The RNA was dissolved in RNase-free water and incubated for 10 minutes at 55-60°C. The RNA was DNase
30 treated using amplification grade DNaseI (Invitrogen™, Breda, the Netherlands) according to the manufacturers protocol. Again glycogen was added as carrier and the RNA

was precipitated with 3M sodium-acetate pH 5.2 and 100% ethanol for 2hr at -20°C.

After removing the last traces of ethanol, the RNA pellet was dissolved in 16.5 µl RNase-free water. The RNA concentration was determined through OD-measurement (Nanodrop) and 1 µg of total RNA was used for RNA amplification using the Ambion®WT Expression Kit (Ambion, Austin (TX), USA) according to the manufacturers protocol.

To determine gene expressions levels the cDNA generated from RNA extracted from both the tissue specimens and the urinary sediments was used as template in TaqMan® Low Density Arrays (TLDA; Applied Biosystems).

A list of assays used in this study is given in **Table 2**. Of the individual cDNAs, 5 µl is added to 50 µl Taqman® Universal Probe Master Mix (Applied Biosystems) and 50 µl milliQ. One hundred µl of each sample was loaded into 1 sample reservoir of a TaqMan® Array (384-Well Micro Fluidic Card) (Applied Biosystems). The TaqMan® Array was centrifuged twice for 1 minute at 280g and sealed to prevent well-to-well contamination. The cards were placed in the micro-fluid card sample block of an 7900 HT Fast Real-Time PCR System (Applied Biosystems). The thermal cycle conditions were: 2 minutes 50°C, 10 minutes at 94.5°C, followed by 40 cycles for 30 seconds at 97°C and 1 minute at 59.7°C.

Raw data were recorded with the Sequence detection System (SDS) software of the instruments. Micro Fluidic Cards were analyzed with RQ documents and the RQ Manager Software for automated data analysis. Delta cycle threshold (Ct) values were determined as the difference between the Ct of each test gene and the Ct of hypoxanthine phosphoribosyltransferase 1 (HPRT) (endogenous control gene).

Furthermore, gene expression values were calculated based on the comparative threshold cycle (Ct) method, in which a normal prostate RNA sample was designated as a calibrator to which the other samples were compared.

5 For the validation of the differentially expressed genes found by the GeneChip® Human Exon 1.0 ST Array, 60 prostate tissue specimens were used in TaqMan® Low Density arrays (TLDAs). To investigate whether the markers might be used in body fluids also 2 normal bladder tissue specimens,
10 2 peripheral blood lymphocyte specimens and 16 urinary sediments (from which 9 had PrCa in their biopsies and 7 did not) were included.

In the TLDAs, expression levels were determined for the 47 genes of interest. The prostate cancer specimens were
15 put in order from normal prostate, BPH, low Gleason scores, high Gleason scores, CRPC and finally prostate cancer metastasis. Both GeneChip® Human Exon 1.0 ST Array and TLDA data were analyzed using scatter- and box plots.

After analysis of the box- and scatterplots a list
20 of suitable genes indicative for prostate cancer and the prognosis thereof was obtained (**Table 3, Figures 14 t/m 26**).

Table 3: *List of genes identified*

Gene Symbol	Gene description	Up/down in group	Rank	Gene-ID
ACSM1	acyl-CoA synthetase medium-chain family member 1	Up in LG/HG vs NPr	7	NM_052956
ALDH3B2	aldehyde dehydrogenase 3 family, member B2	Up in LG/HG vs NPr	13	NM_000695
CGREF1	cell growth regulator with EF-hand domain 1	Up in LG/HG vs NP	66	NM_006569
COMP	cartilage oligomeric matrix protein	Up in pT3 vs pT2	6	NM_000095
C19orf48	chromosome 19 open reading frame 48	Up in LG/HG vs NPr	12	NM_199249
DLX1	distal-less homeobox 1	Up in LG/HG vs NPr	52	NM_178120
GLYATL1	glycine-N-acyltransferase-like 1	Up in LG/HG vs NPr	1	NM_080661
MS4A8B	membrane-spanning 4-domains, subfam. A, member 8B	Up in LG/HG vs NPr	18	NM_031457
NKAIN1	Na ⁺ /K ⁺ transporting ATPase interacting 1	Up in LG/HG vs NPr	40	NM_024522

PPFIA2	protein tyrosine phosphatase, receptor type, f polypept. (PTPRF)	Up in Meta vs LG/HG	3	NM_003625
		Up in pT3 vs pT2	4	
PTPRT	protein tyrosine phosphatase receptor type T	Up in LG/HG vs NPr	29	NM_133170
TDRD1	tudor domain containing 1	Up in LG/HG vs NPr	8	NM_198795
UGT2B15	UDP glucuronosyltransferase 2 family, polypeptide B15	Up in CRPC vs LG/HG	2	NM_001076

ACSM1 (**Figure 14**): The present GeneChip® Human Exon 1.0 ST Array data showed that ACSM1 was upregulated in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this upregulation in PrCa. Therefore, ACSM1 has diagnostic potential.

The expression of ACSM1 in normal bladder and PBL is very low. Furthermore, the expression of ACSM1 in urinary sediments obtained from patients with PrCa is higher compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, ACSM1 has diagnostic potential as a urinary marker for prostate cancer.

ALDH3B2 (**Figure 15**): The present GeneChip® Human Exon 1.0 ST Array data showed that ALDH3B2 was upregulated in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed the upregulation in these groups with exception of PrCa Met. Therefore, ALDH3B2 has diagnostic potential.

The expression of ALDH3B2 in normal bladder and PBL is very low. Furthermore, the expression of ALDH3B2 in urinary sediments obtained from patients with PrCa is higher compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, ALDH3B2 has diagnostic potential as a urinary marker for prostate cancer.

CGREF1 (**Figure 16**): The present GeneChip® Human Exon 1.0 ST Array data showed that CGREF1 was upregulated in the

groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this upregulation. Therefore, CGREF1 has diagnostic potential.

5 The expression of CGREF1 in normal bladder and PBL is very low. Furthermore, the expression of CGREF1 in urinary sediments obtained from patients with PrCa is higher (almost two separate groups) compared to its expression in urinary sediments obtained from patients without PrCa.

10 Therefore, CGREF1 has diagnostic potential as a urinary marker for prostate cancer.

 COMP (**Figure 17**): The present GeneChip® Human Exon 1.0 ST Array data showed that COMP was upregulated (up to 3.5 fold) in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 32.5 fold). Therefore, we conclude that COMP has diagnostic potential.

20 The expression of COMP in normal bladder and PBL is very low to undetectable levels. Furthermore, the expression of COMP in urinary sediments obtained from patients with PrCa is higher compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, COMP has diagnostic potential as a urinary marker for prostate cancer.

 The expression of COMP in locally advanced PrCa (pT3) is higher than in organ confined PrCa (pT2). Therefore, COMP can be used as a prognostic marker for prostate cancer (GeneChip® data).

30 C19orf48 (**Figure 18**): The present GeneChip® Human Exon 1.0 ST Array data showed that C19orf48 was upregulated in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared

to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this upregulation. Therefore, C19orf48 has diagnostic potential.

The expression of C19orf48 in normal bladder and PBL is very low. The mean expression of C19orf48 in urinary sediments obtained from patients with PrCa is not higher compared to its expression in urinary sediments obtained from patients without PrCa. However, in two out of nine urinary sediments obtained from patients with PrCa the expression is extremely higher (stars in boxplot) and these two patients would not be detected by most other biomarkers. Therefore, C19orf48 has complementary diagnostic potential as a urinary marker for prostate cancer.

DLX1 (**Figure 19**): The present GeneChip® Human Exon 1.0 ST Array data showed that DLX1 was upregulated (up to 5.6-fold) in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH.

Validation experiments using TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 183.4 fold). Therefore, DLX1 has diagnostic potential.

The expression of DLX1 in normal bladder and PBL is undetectable to very low. Furthermore, the expression of DLX1 in urinary sediments obtained from patients with PrCa is much higher compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, DLX1 has diagnostic potential as a urinary marker for prostate cancer.

GLYATL1 (**Figure 20**): The present GeneChip® Human Exon 1.0 ST Array data showed that GLYATL was upregulated in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using TaqMan® Low

Density arrays confirmed this. Therefore, GLYATL has diagnostic potential.

The expression of GLYATL1 in normal bladder and PBL is undetectable to very low. Furthermore, the expression of GLYATL1 in urinary sediments obtained from patients with PrCa is higher compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, GLYATL1 has diagnostic potential as a urinary marker for prostate cancer.

MS4A8B(**Figure 21**): The present GeneChip® Human Exon 1.0 ST Array data showed that MS4A8B was upregulated in LG PrCa, HG PrCa, CRPC and PrCa Met (up to 8.3 fold) compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 119.8 fold). Therefore, MS4A8B has diagnostic potential.

The expression of MS4A8B in normal bladder and PBL is undetectable. Furthermore, the expression of MS4A8B in urinary sediments obtained from patients with PrCa is higher compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, MS4A8B has diagnostic potential as a urinary marker for prostate cancer.

NKAIN1(**Figure 22**): The present GeneChip® Human Exon 1.0 ST Array data showed that NKAIN1 was upregulated in LG PrCa, HG PrCa, CRPC and PrCa Met (up to 4.6 fold) compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 61.4 fold). Therefore, NKAIN1 has diagnostic potential.

The expression of NKAIN1 in normal bladder and PBL is undetectable. Furthermore, the expression of NKAIN1 in urinary sediments obtained from patients with PrCa is higher (almost two separate groups in boxplot) compared to its

expression in urinary sediments obtained from patients without PrCa. Therefore, NKAIN1 diagnostic potential as a urinary marker for prostate cancer.

PPFIA2 (**Figure 23**): The present GeneChip® Human Exon 1.0 ST Array data showed that PPFIA2 was upregulated in LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. This upregulation was highest in PrCa Met.

Validation experiments using TaqMan® Low Density arrays confirmed the upregulation in these groups.

Therefore, PPFIA2 has diagnostic potential

The expression of PPFIA2 in normal bladder and PBL is low to undetectable. Furthermore, the expression of PPFIA2 in urinary sediments obtained from patients with PrCa is much higher (almost two separate groups in boxplot) compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, PPFIA2 has diagnostic potential as a urinary marker for prostate cancer.

PTPRT (**Figure 24**): The present GeneChip® Human Exon 1.0 ST Array data showed that PTPRT was upregulated (up to 11.1 fold) in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 55.1 fold). Therefore, PTPRT has diagnostic potential.

The expression of PTPRT in normal bladder and PBL is very low to undetectable. Furthermore, the expression of PTPRT in urinary sediments obtained from patients with PrCa is much higher (almost two separate groups in boxplot) compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, PTPRT has diagnostic potential as a urinary marker for prostate cancer.

TDRD1 (**Figure 25**): The present GeneChip® Human Exon 1.0 ST Array data showed that TDRD1 was upregulated (up to 12.6 fold) in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments using

5 TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 184.1 fold), especially in the group of LG PrCa. Therefore, TDRD1 has diagnostic potential.

The expression of TDRD1 in normal bladder is very
10 low. Furthermore, the expression of TDRD1 in urinary sediments obtained from patients with PrCa is much higher (two separate groups in boxplot) compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, TDRD1 has diagnostic potential as a urinary
15 marker for prostate cancer.

UGT2B15 (**Figure 26**): The present GeneChip® Human Exon 1.0 ST Array data showed that UGT2B15 was upregulated (up to 5.2 fold) in the groups LG PrCa, HG PrCa, CRPC and PrCa Met compared to NPr and BPH. Validation experiments
20 using TaqMan® Low Density arrays confirmed this and showed an even larger upregulation in PrCa versus NPr tissue (up to 224.4 fold). The expression of UGT2B15 in normal bladder is very low. Furthermore, the expression of UGT2B15 in urinary sediments obtained from patients with PrCa is higher
25 compared to its expression in urinary sediments obtained from patients without PrCa. Therefore, UGT2B15 has diagnostic potential as a urinary marker for prostate cancer.

Since UGT2B15 is highly upregulated in CRPC
30 patients, it is a suitable marker to monitor patients who undergo hormonal therapy for their locally advanced prostate cancer. Therefore, UGT2B15 has also prognostic value.

Example 2

To identify markers for aggressive prostate cancer, the gene expression profile (GeneChip® Human Exon 1.0 ST Array, Affymetrix) of samples from patients with prostate cancer in the following categories were used:

- LG: low grade PrCa (Gleason Score equal or less than 6). This group represents patients with good prognosis;
- HG: high grade PrCa (Gleason Score of 7 or more). This group represents patients with poor prognosis; sample type, mRNA from primary tumor;
- PrCa Met. This group represents patients with poor prognosis; sample type; mRNA from PrCa metastasis;
- CRPC: castration resistant prostate cancer; mRNA from primary tumor material from patients that are progressive under endocrine therapy. This group represents patients with aggressive localized disease.

The expression analysis is performed according to standard protocols. Briefly, from patients with prostate cancer (belonging to one of the four previously mentioned categories) tissue was obtained after radical prostatectomy or TURP. The tissues were snap frozen and cryostat sections were H.E. stained for classification by a pathologist.

Tumor areas were dissected and total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) following manufacturer's instructions. The total RNA was purified with the Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). Integrity of the RNA was checked by electrophoresis using the Agilent 2100 Bioanalyzer.

From the purified total RNA, 1 µg was used for the GeneChip Whole Transcript (WT) Sense Target Labeling Assay

(Affymetrix, Santa Clara, CA, USA). According to the protocol of this assay, the majority of ribosomal RNA was removed using a RiboMinus Human/Mouse Transcriptome Isolation Kit (Invitrogen, Carlsbad, CA, USA). Using a random hexamer incorporating a T7 promoter, double-stranded cDNA was synthesized. Then cRNA, was generated from the double-stranded cDNA template through an in-vitro transcription reaction and purified using the Affymetrix sample clean-up module. Single-stranded cDNA was regenerated through a random-primed reverse transcription using a dNTP mix containing dUTP. The RNA was hydrolyzed with RNase H and the cDNA was purified. The cDNA was then fragmented by incubation with a mixture of UDG (uracil DNA glycosylase) and APE1 (apurinic/apyrimidinic endonuclease 1) restriction endonucleases and, finally, end-labeled via a terminal transferase reaction incorporating a biotinylated dideoxynucleotide.

5.5 µg of the fragmented, biotinylated cDNA was added to a hybridization mixture, loaded on a Human Exon 1.0 ST GeneChip and hybridized for 16 hours at 45 °C and 60 rpm.

Using the GeneChip® Human Exon 1.0 ST Array (Affymetrix), genes are indirectly measured by exons analysis which measurements can be combined into transcript clusters measurements. There are more than 300,000 transcript clusters on the array, of which 90,000 contain more than one exon. Of these 90,000 there are more than 17,000 high confidence (CORE) genes which are used in the default analysis. In total there are more than 5.5 million features per array.

Following hybridization, the array was washed and stained according to the Affymetrix protocol. The stained array was scanned at 532 nm using an Affymetrix GeneChip Scanner 3000, generating CEL files for each array.

Exon-level expression values were derived from the CEL file probe-level hybridization intensities using the model-based RMA algorithm as implemented in the Affymetrix Expression Console™ software. RMA (Robust Multiarray Average) performs normalization, background correction and data summarization. Differentially expressed genes between conditions are calculated using Anova (ANalysis Of Variance), a T-test for more than two groups.

The target identification is biased since clinically well defined risk groups were analyzed. The markers are categorized based on their role in cancer biology. For the identification of markers the PrCa Met group is compared with 'HG' and 'LG'.

Based on the expression analysis obtained, biomarkers were identified based on 30 tumors; the expression profiles of the biomarkers are provided in **Table 4**.

Table 4: *Expression characteristics of 7 targets characterizing the aggressive metastatic phenotype of prostate cancer based on the analysis of 30 well annotated specimens*

Gene name	Gene assignment	Expression in PrCa Met	Met-LG	Rank	Met-HG	Rank	Met-CRPC
PTPR	NM_003625	Up	15.89	4	8.28	4	11.63
EPHA6	NM_001080448	Up	15.35	5	9.25	2	8.00
Plakophilin 1	NM_000299	Up	5.28	28	4.92	8	5.46
HOXC6	NM_004503	Up	5.35	27	3.34	43	3.51
HOXD3	NM_006898	Up	1.97	620	2.16	238	1.40
sFRP2	NM_003013	Down	-6.06	102	-13.93	15	-3.53
HOXD10	NM_002148	Down	-3.71	276	-3.89	238	-5.28

Example 3

The protocol of example 1 was repeated on a group of 70 specimens. The results obtained are presented in

5 **Table 5.**

Table 5: *Expression characteristics of 7 targets validated in the panel of 70 tumors*

Gene name	Gene assignment	Expression in PrCa met	Met-LG	Rank	Met-HG	Rank	Met-CRPC	Rank
PTPR	NM_003625	Up	6,92	1	2,97	11	3,66	2
EPHA6	NM_001080448	Up	4,35	4	3,97	3	3,18	3
Plakophilin 1	NM_000299	Up	3,18	12	4,00	2	4,11	5
HOXC6	NM_004503	Up	1,77	271	1,75	208	1,44	6
HOXD3	NM_006898	Up	1,62	502	1,66	292	1,24	7
sFRP2	NM_003013	Down	-6,28	46	-10,20	10	-5,86	1
HOXD10	NM_002148	Down	-2,48	364	-2,55	327	-2,46	4

10

As can be clearly seen in **Tables 4** and **5**, an up regulation of expression of PTPR, EPHA6, Plakophilin 1, HOXC6 (**Figure 27**) and HOXD3 was associated with prostate cancer. Further, as can be clearly seen in **Tables 4** and **5**, a
 15 down-regulation of expression of sFRP2 (**Figure 28**) and HOXD10 (**Figure 29**) was associated with prostate cancer.

Considering the above results obtained in 70 tumour samples, the expression data clearly demonstrates the suitability of these genes as bio- or molecular marker for
 20 the diagnosis of prostate cancer.

Example 4

Using the gene expression profile (GeneChip® Human
 25 Exon 1.0 ST Array, Affymetrix) on 70 prostate cancers several genes were found to be differentially expressed in

low grade and high grade prostate cancer compared with prostate cancer metastasis and castration resistant prostate cancer (CRPC). Together with several other in the GeneChip® Human Exon 1.0 ST Array differentially expressed genes, the expression levels of these genes were validated using the TaqMan® Low Density arrays (TLDA, Applied Biosystems). In **Table 6** an overview of the validated genes is shown.

Table 6: *Gene expression assays used for TLDA analysis*

Symbol	Gene description	Accession number	Amplicon size
AMACR	alpha-methylacyl-CoA racemase	NM_014324	97-141
B2M	Beta-2-microglobulin	NM_004048	64-81
CYP4F8	cytochrome P450, family 4, subfamily F	NM_007253	107
CDH1	E-Cadherin	NM_004360	61-80
EPHA6	ephrin receptor A6	NM_001080448	95
ERG	v-ets erythroblastosis virus E26 oncogene homolog	NM_004449	60-63
ETV1	ets variant 1	NM_004956	74-75
ETV4	ets variant 4	NM_001986	95
ETV5	ets variant 5	NM_004454	70
FASN	fatty acid synthase	NM_004104	144
FOXD1	forkhead box D1	NM_004472	59
HOXC6	homeobox C6	NM_004503	87
HOXD3	homeobox D3	NM_006898	70
HOXD10	homeobox D10	NM_002148	61
HPRT	hypoxanthine phosphoribosyltransferase 1	NM_000194	72-100
HSD17B6	hydroxysteroid (17-beta) dehydrogenase 6 homolog	NM_003725	84
CDH2	N-cadherin (neuronal)	NM_001792	78-96
CDH11	OB-cadherin (osteoblast)	NM_001797	63-96
PCA3	prostate cancer gene 3	AF103907	80-103
PKP1	Plakophilin 1	NM_000299	71-86
KLK3	prostate specific antigen	NM_001030047	64-83
PTPR	protein tyrosine phosphatase, receptor type, f	NM_003625	66

	polypeptide		
RET	ret proto-oncogene	NM_020975	90-97
RORB	RAR-related orphan receptor B	NM_006914	66
RRM2	ribonucleotide reductase M2	NM_001034	79
SFRP2	secreted frizzled-related protein 2	NM_003013	129
SGP28	specific granule protein (28 kDa)/ cysteine-rich secretory protein 3 CRISP3	NM_006061	111
SNAI2	snail homolog 2 SNAI2	NM_003068	79-86
SNAI1	snail homolog 1 Snai1	NM_005985	66
SPINK1	serine peptidase inhibitor, Kazal type 1	NM_003122	85
TGM4	transglutaminase 4 (prostate)	NM_003241	87-97
TMPRSS2	transmembrane protease, serine 2	NM_005656	112
TWIST	twist homolog 1	NM_000474	115

Prostate cancer specimens in the following categories were used:

- 5 - Low grade prostate cancer (LG): tissue specimens from primary tumors with a Gleason Score ≤ 6 obtained after radical prostatectomy. This group represents patients with a good prognosis.
- 10 - High grade prostate cancer (HG): tissue specimens from primary tumors with a Gleason Score ≥ 7 obtained after radical prostatectomy. This group represents patients with poor prognosis.
- 15 - Prostate cancer metastases: tissue specimens are obtained from positive lymphnodes after LND or after autopsy. This group represents patients with poor prognosis
- Castration resistant prostate cancer (CRPC): tissue specimens are obtained from patients that are progressive under endocrine therapy and who underwent a transurethral resection of the prostate (TURP).

All tissue samples were snap frozen and cryostat sections were stained with hematoxylin and eosin (H.E.). These H.E.-stained sections were classified by a pathologist.

Tumor areas were dissected. RNA was extracted from
5 10 µm thick serial sections that were collected from each tissue specimen at several levels. Tissue was evaluated by HE-staining of sections at each level and verified microscopically. Total RNA was extracted with TRIzol® (Invitrogen, Carlsbad, CA, USA) according to the
10 manufacturer's instructions. Total RNA was purified using the RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA quantity and quality were assessed on a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and on an Agilent 2100 Bioanalyzer (Agilent
15 Technologies Inc., Santa Clara, CA, USA).

Two µg DNase-treated total RNA was reverse transcribed using SuperScript™ II Reverse Transcriptase (Invitrogen) in a 37.5 µl reaction according to the manufacturer's protocol. Reactions were incubated for 10
20 minutes at 25°C, 60 minutes at 42°C and 15 minutes at 70°C. To the cDNA, 62.5 µl milliQ was added.

Gene expression levels were measured using the TaqMan® Low Density Arrays (TLDA; Applied Biosystems). A list of assays used in this study is given in **Table 5**. Of
25 the individual cDNAs, 3 µl is added to 50 µl Taqman® Universal Probe Master Mix (Applied Biosystems) and 47 µl milliQ. One hundred µl of each sample was loaded into 1 sample reservoir of a TaqMan® Array (384-Well Micro Fluidic Card) (Applied Biosystems). The TaqMan® Array was
30 centrifuged twice for 1 minute at 280g and sealed to prevent well-to-well contamination. The cards were placed in the micro-fluid card sample block of an 7900 HT Fast Real-Time PCR System (Applied Biosystems). The thermal cycle

conditions were: 2 minutes 50°C, 10 minutes at 94.5°C, followed by 40 cycles for 30 seconds at 97°C and 1 minute at 59.7°C.

Raw data were recorded with the Sequence detection
5 System (SDS) software of the instruments. Micro Fluidic
Cards were analyzed with RQ documents and the RQ Manager
Software for automated data analysis. Delta cycle threshold
(Ct) values were determined as the difference between the Ct
of each test gene and the Ct of hypoxanthine
10 phosphoribosyltransferase 1 (HPRT) (endogenous control
gene). Furthermore, gene expression values were calculated
based on the comparative threshold cycle (Ct) method, in
which a normal prostate RNA sample was designated as a
calibrator to which the other samples were compared.

15 For the validation of the differentially expressed
genes found by the GeneChip® Human Exon 1.0 ST Array, 70
prostate cancer specimen were used in TaqMan® Low Density
arrays (TLDA). In these TLDA, expression levels were
determined for the 33 genes of interest. The prostate cancer
20 specimens were put in order from low Gleason scores, high
Gleason scores, CRPC and finally prostate cancer metastasis.
Both GeneChip® Human Exon 1.0 ST Array and TLDA data were
analyzed using scatter- and box plots.

In the first approach, scatterplots were made in
25 which the specimens were put in order from low Gleason
scores, high Gleason scores, CRPC and finally prostate
cancer metastasis. In the second approach, clinical follow-
up data were included. The specimens were categorized into
six groups: prostate cancer patients with curative
30 treatment, patients with slow biochemical recurrence (after
5 years or more), patients with fast biochemical recurrence
(within 3 years), patients that became progressive, patients
with CRPC and finally patients with prostate cancer

metastasis. After analysis of the box- and scatterplots using both approaches, a list of suitable genes indicative for prostate cancer and the prognosis thereof was obtained (**Table 7, Figures 34-40**).

5

Table 7: *List of genes identified*

Symbol	Gene description	Accession number	Amplicon size
HOXC6	homeobox C6	NM_004503	87
SFRP2	secreted frizzled-related protein 2	NM_003013	129
HOXD10	homeobox D10	NM_002148	61
RORB	RAR-related orphan receptor B	NM_006914	66
RRM2	ribonucleotide reductase M2	NM_001034	79
TGM4	transglutaminase 4 (prostate)	NM_003241	87-97
SNAI2	snail homolog 2 SNAI2	NM_003068	79-86

HOXC6 (**Figure 34**): The present GeneChip® Human Exon
 10 1.0 ST Array data showed that HOXC6 was upregulated in prostate cancer metastases compared with primary high and low grade prostate cancers. Validation experiments using TaqMan® Low Density arrays confirmed this upregulation. Furthermore, HOXC6 was found to be upregulated in all four
 15 groups of prostate cancer compared with normal prostate. Therefore, HOXC6 has diagnostic potential.

Using clinical follow-up data, it was observed that all patients with progressive disease and 50% of patients with biochemical recurrence within 3 years after initial
 20 therapy had a higher upregulation of HOXC6 expression compared with patients who had biochemical recurrence after 5 years and patients with curative treatment. The patients with biochemical recurrence within 3 years after initial therapy who had higher HOXC6 expression also had a worse

prognosis compared with patients with lower HOXC6 expression. Therefore, HOXC6 expression is correlated with prostate cancer progression.

SFRP2 (**Figure 35**): The present GeneChip® Human Exon 1.0 ST Array data showed that SFRP2 was downregulated in prostate cancer metastases compared with primary high and low grade prostate cancers. Validation experiments using TaqMan® Low Density arrays confirmed this downregulation. Furthermore, SFRP2 was found to be downregulated in all four groups of prostate cancer compared with normal prostate. Therefore, SFRP2 has diagnostic potential.

Using clinical follow-up data, differences were observed in SFRP2 expression between the patients with curative treatment, biochemical recurrence after initial therapy and progressive disease. More than 50% of metastases showed a large downregulation of SFRP2. Moreover, also a few CRPC patients showed a very low SFRP2 expression. Therefore, SFRP2 can be used for the detection of patients with progression under endocrine therapy (CRPC) and patients with prostate cancer metastasis. It is therefore suggested, that in combination with a marker that is upregulated in metastases, a ratio of that marker and SFRP2 could be used for the detection of circulating tumor cells.

HOXD10 (**Figure 36**): The present GeneChip® Human Exon 1.0 ST Array data showed that HOXD10 was downregulated in prostate cancer metastases compared with primary high and low grade prostate cancers. Validation experiments using TaqMan® Low Density arrays confirmed this downregulation. Furthermore, HOXD10 was found to be downregulated in all four groups of prostate cancer compared with normal prostate. Therefore, HOXD10 has diagnostic potential.

Using clinical follow-up data, differences were observed in HOXD10 expression between the patients with

curative treatment, biochemical recurrence after initial therapy and progressive disease. All metastases showed a large downregulation of HOXD10. Moreover, also a few CRPC patients showed a low HOXD10 expression. Therefore, HOXD10 can be used for the detection of patients with progression under endocrine therapy (CRPC) and patients with prostate cancer metastases.

RORB (**Figure 37**): The present GeneChip® Human Exon 1.0 ST Array data showed that RORB was upregulated in prostate cancer metastases and CRPC compared with primary high and low grade prostate cancers. Validation experiments using TaqMan® Low Density arrays confirmed this upregulation. Furthermore, RORB was found to be downregulated in all low and high grade prostate cancers compared with normal prostate. In CRPC and metastases RORB is re-expressed at the level of normal prostate. Therefore, RORB has diagnostic potential.

Using clinical follow-up data, differences were observed in RORB expression between the patients with curative treatment, biochemical recurrence after initial therapy and progressive disease. However, in a number of cases in the CRPC and metastases the upregulation of RORB coincides with a downregulation of SFRP2. Using a ratio of RORB over SFRP2 could detect 75% of prostate cancer metastases. Furthermore, a number of CRPC patients had a high RORB/SFRP2 ratio. Therefore, this ratio can be used in the detection of patients with circulating tumor cells and progressive patients under CRPC.

RRM2 (**Figure 38**): Experiments using TaqMan® Low Density arrays showed upregulation of RRM2 in all four groups of prostate cancer compared with normal prostate. Therefore, RRM2 has diagnostic potential. Moreover, the expression of RRM2 is higher in CRPC and metastasis showing

that it may be involved in the invasive and metastatic potential of prostate cancer cells. Therefore, RRM2 can be used for the detection of circulating prostate tumor cells.

Using clinical follow-up data, differences were observed in RRM2 expression between the patients with curative treatment, biochemical recurrence after initial therapy and progressive disease.

TGM4 (**Figure 39**): The present GeneChip® Human Exon 1.0 ST Array data showed that TGM4 was downregulated in prostate cancer metastases compared with primary high and low grade prostate cancers. Validation experiments using TaqMan® Low Density arrays confirmed this downregulation. Furthermore, TGM4 was found to be extremely downregulated in all four groups of prostate cancer compared with normal prostate. Therefore, TGM4 has diagnostic potential.

Using clinical follow-up data, it was observed that patients with progressive disease showed a stronger downregulation of TGM4 (subgroup of patients) compared with patients with curative treatment and biochemical recurrence after initial therapy. In metastases the TGM4 expression is completely downregulated. Therefore, TGM4 has prognostic potential.

SNAI2 (**Figure 40**): The present GeneChip® Human Exon 1.0 ST Array data showed that SNAI2 was downregulated in prostate cancer metastases compared with primary high and low grade prostate cancers. Validation experiments using TaqMan® Low Density arrays confirmed this downregulation. Furthermore, SNAI2 was found to be downregulated in all four groups of prostate cancer compared with normal prostate. Therefore, SNAI2 has diagnostic potential.

Using clinical follow-up data, differences were observed in SNAI2 expression between the patients with

curative treatment, biochemical recurrence after initial therapy and progressive disease.

CLAIMS

1. Method for in vitro diagnosing prostate cancer in a human individual comprising:

- 5 - determining the expression of one or more genes chosen from the group consisting of DLX1, ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and UGT2B15; and
- 10 - establishing up or down regulation of expression of said one or more genes as compared to expression of the respective one or more genes in a sample from an individual without prostate cancer;
- 15 thereby providing said diagnosis of prostate cancer.

2. Method according to claim 1, wherein determining said expression comprises determining mRNA expression of said one or more genes.

3. Method according to claim 1, wherein determining said expression comprises determining protein levels from said one or more genes.

4. Method according to any of the claims 1 to 3, wherein said one or more is two or more.

5. Method according to claim 4, wherein said two or more is three or more.

6. Method according to claim 5, wherein said three or more is four or more.

7. Method according to claim 6, wherein said three or more is four or more.

8. Method according to claim 7, wherein said four
5 ore more is five or more.

9. Method according to claim 8, wherein said five or more is six or more.

10 10. Method according to claim 9, wherein said six or more is seven or more.

11. Method according to any of the claims 1 to 10, wherein diagnosing prostate cancer in a human individual is
15 selected from the group consisting of diagnosing low grade PrCa (LG PrCa), high grade PrCa (HG PrCa), PrCa Met and CRPC.

12. Method according to claim 11, wherein
20 diagnosing prostate cancer in a human individual comprises diagnosing CRPC.

13. Use of ACSM1 expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.

25

14. Use of ALDH3B2 expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.

15. Use of CGREF1 expression for in vitro
30 diagnosing prostate cancer as defined in any of the claims 1 to 12.

16. Use of COMP expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.

17. Use of C19orf48 expression for in vitro
5 diagnosing prostate cancer as defined in any of the claims 1 to 12.

18. Use of DLX1 expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.
10

19. Use of GLYATL1 expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.

20. Use of MS4A8B expression for in vitro
15 diagnosing prostate cancer as defined in any of the claims 1 to 12.

21. Use of NKAIN1 expression for in vitro
20 diagnosing prostate cancer as defined in any of the claims 1 to 12.

22. Use of PPFIA2 expression for in vitro
25 diagnosing prostate cancer as defined in any of the claims 1 to 12.

23. Use of PTPRT expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.

24. Use of TDRD1 expression for in vitro diagnosing
30 prostate cancer as defined in any of the claims 1 to 12.

25. Use of UGT2B15 expression for in vitro diagnosing prostate cancer as defined in any of the claims 1 to 12.

5 26. Kit of parts for diagnosing prostate cancer as defined in any of the claims 1 to 12, comprising:

- expression analysis means for determining the expression of genes as defined in any of the claims 1 to 12;
- 10 - instructions for use.

27. Kit of parts according to claim 26, wherein said expression analysis means comprises mRNA expression analysis means, preferably for PCR, rtPCR or NASBA.

15

FIGURE 1**ACSM1** NM_052956.2 → NP_443188.2 acyl-coenzyme A synthetase ACSM1. mitochondrial

```

1 agccatctct tcccaaggca ggtggtgact tgagaactct gtgcctgggt tctgaggact
61 gtttcaccat gcagtggcta atgaggttcc ggaccctctg gggcatccac aaatccttcc
121 acaacatcca ccctgccctt tcacagctgc gctgccggtc tttatcagaa tttggagccc
181 caagatggaa tgactatgaa gtaccggagg aatttaactt tgcaagttat gtactggact
241 actgggctca aaaggagaag gagggcaaga gaggtccaaa tccagctttt tgggtgggtga
301 atggccaagg ggatgaagta aagtggagct tcagagagat gggagaccta acccgccgtg
361 tagccaacgt cttcacacag acctgtggcc tacaacaggg agaccatctg gccttgatgc
421 tgccctcagt tccctgagtgg tggctggtgg ctgtgggctg catgcgaaca gggatcatct
481 tcattcctgc gaccatcctg ttgaaggcca aagacattct ctatcgacta cagttgtcta
541 aagccaaggg cattgtgacc atagatgccc ttgcctcaga ggtggactcc atagcttctc
601 agtggccctc tctgaaaacc aagctcctgg tgtctgatca cagccgtgaa ggggtggctgg
661 acttccgata gctggttaaa tcagcatccc cagaacacac ctgtgttaag tcaaagacct
721 tggacceaat ggtcatcttc ttcaccagtg ggaccacagg cttccccaag atggcaaaac
781 actcccatgg gttggcetta caacctcctt tcccaggaag taggaaatta cggagcctga
841 agacatctga tgtctcctgg tgccctgctg actcaggatg gattgtggct accatttgga
901 ccctggtaga accatggaca gggggttgta cagtctttat ccaccatctg ccacagtttg
961 acaccaaggt catcatacag acattgttga aatacccat taaccacttt tggggggtat
1021 catctatata tgaatgatt ctgcagcagg atttcaccag catcagggtc cctgccctgg
1081 agcactgcta tactggcggg gaggtcgtgt tgcccaagga tcaggaggag tggaaaagac
1141 ggacgggctt tctgctctac gagaactatg ggcagtcgga aacgggacta atttgtgcca
1201 cctactgggg aatgaagatc aagccgggtt tcatggggaa ggccactcca ccctacgacg
1261 tccaggtcat tgatgacaag ggcagcatcc tgccacctaa cacagaagga aacattggca
1321 tcagaatcaa acctgtcagg cctgtgagcc tcttcatgtg ctatgagggt gaccagaga
1381 agacagctaa agtggaatgt ggggacttct acaacactgg ggacagaggt aagatggatg
1441 aagagggcta catttgtttc ctggggagga gtgatgacat cattaatgcc tctgggtatc
1501 gcatcgggcc tgcagaggtt gaaagcgctt tgggtggagca cccagcggtg gcgagtcag
1561 ccgtggtggg cagcccagac ccgattcgag gggaggtggt gaaggccttt attgtcctga
1621 cccacagtt cctgtcccat gacaaggatc agctgaccaa ggaactgcag cagcatgtca
1681 agtcagtga agccccatac aagtaccaa ggaagtgga gtttgtctca gagctgcaa
1741 aaaccatcac tggcaagatt gaacggaagg aacttcgga aaaggagact ggtcagatgt
1801 aatcggcagt gaactcagaa cgcactgcac acctaaaggca aatccctggc cacttttagtc
1861 tccccactat ggtgaggacg aggggtgggc attgagagtg ttgatttggg aaagtatcag
1921 gagtgccatg attccaatgt tttccttctt ttaaattaaa ttcagttgct ctgcttcctc
1981 caagtcctct gtatctttag aatttcccag gtgagcactc ataacgcaag taataaaata
2041 ctgatatcaa c

```

```

MQWLRFRTLWGIHKSFHNIHPAPSQLRCRSLSEFGAPRWNDYEVPEEFNFASYVLDYWAQKEKEGKRGPN
PAFWVVGQDEVKWSFREMGLTRRVANVFTQTCGLQQGDHLALMLPRVPEWWLVAVGCMRTGIIIFIPAT
ILLKAKDILYRLQLSKAKGIVTIDALASEVDSIASQCPSLKTLLVSDHSREGWLDFRSLVKASPEHTCV
KSKTLDPMVIFFTSGTTGFPMKAKHSHGLALQPSFPGSRKLRLSLKTSVSWCLSDSGWIVATIWTLVPEPWT
AGCTVFIHHLPPQFDTKVIIQTLLKYPINHFVGWVSSIIYRMILQQDFTSIRFPALHCHYTGGEVVLPKDQEEW
KRRTGLLLYENYGQSETGLICATYWGMIKPGFMGKATPPYDVQVIDDKGSILPPNTEGNIGIRIKPVRPV
SLFMCYEGDPEKTAKVECGDFYNTGDRGKMDEEGYICFLGRSDDIINASGYRIGPAEVESALVEHPAVAES
AVVGSPDPIRGEVVKAFIVLTPQFLSHDKDQLTKELQQHVKSVTAPYKYPRKVEFVSELPKTITGKIERKE
LRKKETGQM

```

FIGURE 2**ALDH3B2** NM_000695.3 → NP_000686.2 aldehyde dehydrogenase family 3 member B2

```

1  accccattga ttacccatt gccaggcgtg ggcacgggag ttggtttggg agctgccagt
61  ctctctgggag gatcgagtc agcagagcag ggctgaggcc tgggggtagg agcagagcct
121  ggcacatctgg aggcagcatg tccaagaaag ggagtggagg tgcagcgaag gaccagggg
181  cagagccac gctgggatgg accccttcga ggacacgctg cggcggtgc gtgaggcctt
241  caactgaggg cgcacgcggc cggccgagtt cgggctgcg cagctccagg gcctgggcca
301  ctcccttcaa gaaaacaagc agcttctgcg cgacgtgctg gcccaggacc tgcataagcc
361  agctttcgag gcagacatat ctgagctcat cctttgccag aacgaggttg actacgctct
421  caagaacctg caggcctgga tgaaggatga aecacggtcc acgaacctgt tcatgaagct
481  ggactcggtc ttcacttgga aggaaccctt tggcctggte ctcatcatcg caccctggaa
541  ctaccactg aacctgacct tgggtgctcct ggtgggcgc ctcgccgcag ggagtgtcgt
601  ggtgctgaag ccgtcagaaa tcagccaggg cacagagaag gtcctggctg aggtgctgcc
661  ccagtacctg gaccagagct gctttgccgt ggtgctgggc ggacccagg agacagggca
721  gctgctagag cacaagttgg actacatctt cttcacaggg agcctcgtg tgggcaagat
781  tgtcatgact gctgccacca agcacctgac gcctgtcacc ctggagctgg ggggcaagaa
841  cccctgctac gtggacgaca actgcgacct ccagaccgtg gccaacgcg tggcctgggt
901  ctgctacttc aatgccggcc agacctgcgt ggcccctgac tacgtcctgt gcagccccga
961  gatgcaggag aggtgctgc cggccctgca gagcaccatc acccgtttct atggcgacga
1021  ccccagagc tccccaaacc tgggcgcgt catcaaccag aaacagttcc agcggctgcg
1081  ggcatgtctg ggctgcggcc gcgtggccat tgggggcccag agcaacgaga gcatcgcta
1141  catgcccccc acggtgctgg tggacgtgca ggagacggag cctgtgatgc aggaggagat
1201  ctccgggccc atcctgcccc tcgtgaacgt gcagagcgtg gacgaggcca tcaagttcat
1261  caaccggcag gagaagcccc tggccctgta cgcttctcc aacagcagcc aggttgtgaa
1321  ccagatgctg gagcggacca gcagcggcag ctttgagggc aatgagggtc tcacctacat
1381  atctctgctg tccgtgccat tcgggggagt cggccacagt gggatgggccc ggtaccacgg
1441  caagttcacc ttcgacacct tctcccacca ccgcacctgc ctgctcgcgc cctccggcct
1501  ggagaaatta aaggagatcc actaccacc ctataccgac tggaaaccagc agctgttacg
1561  ctggggcatg ggctcccaga gctgcacct cctgtgagcg tcccaccgc ctccaacggg
1621  tcacacagag aaacctgagt ctagccatga ggggcttatg ctcccaactc acattgttcc
1681  tccagaccgc aggttcccccc agcctcaggt tgctggagct gtcacatgac tgcactctgc
1741  ctgccagggc tgcaaagcaa ggtcttgctt ctatctgggg gacgtgctc gagagaggcc
1801  aagaggccgc agaactgccc aggtgtcctc actaccccca cctccccaat tccagccct
1861  ttgccctctc ggtcagggtt ggccaggccc agtcacaggg gcagtgtcac cctggaaaat
1921  acagtgcctt gccttcttag gggcatcagc cctgaacggt tgagagcgtg gagccctcca
1981  ggcctttgct ctccccctca ggcacacgcg cacttccatc tctgccccat cccaactgca
2041  ccagcactgc ctccccaggg gatcctctca catccacac tggctctctg accaccctc
2101  tggttcacac cgcacctgc actacccac agcagctcca tccactggga aaactggggt
2161  ttgcatcact ccaactgcaca gtgttagtgg gacctggggg caagtcctt gacttctctg
2221  agcctcagtt tccttatgtg aaagttgctg gaacaaaat ggagtcactt atgccaaact
2281  ctaataaaat ggagtcgggg ggccacatag aagccctcac acacacatgc ccgtaacagg
2341  atttatcaca agacacgcct gcatgtagac cagacacagg gcgtatggaa agcacgtcct
2401  caagactgta gtattccaga tgagctgcag atgcttacct accacggcgc tctccaccag
2461  aaaaccatcg ccaactcctg cgatcagctt gtgacttaca aaccttgttt aaaagctgct
2521  tacatggact tctgtccttt aaaagcttcc ccttggtgtg ggccctctgt gtatgcctgg
2581  gatccttcca agcactcata gccagatag gaatcctctg ctctcccaa ataaattcat
2641  ctgttctgga aaaaaaaaaa

```

MKDEPRSTNLFMKLDSVFIWKEPFLGLVLI IAPWNYPLNLTLLVGLAAGSCVVLKPSEISQGTEKVLAE
 VLPQYLDQSCFAVVLGGPQETGQLLEHKLDYI FFTGSPRVGKIVMTAATKHLTPVTLELGKNPCYVDDNC
 DPQTVANRVAWFCYFNAGQTCVAPDYVLCSPQMQRLLPALQSTITRFYGDGDPQSSPNLGRI INQKQFQRL
 RALLGCGRVAIGGQSNESDRYIAPTFLVDVQETEPVMQEEIFGPILPIVNVQSVDEAIKFINRQEKPLALY
 AFSNSSQVVNQMLERTSSGSFGGNEGFTYISLLSVFPGGVGHSGMGRYHGKFTFDTFSHHRTCLLAPSGLE
 KLKEIHYPPTYDWNQQLLRWGMGSQSCTLL

FIGURE 3

CGREF1 NM_006569.5 → NP_006560.3 cell growth regulator with EF hand domain protein 1 isoform a

```

1  cacacgcgca cactcacacg ggcgcgcgca gcccctccgg ccgcggggcg agcgggggcg
61  ctggtggagc tgcgaagggc caggtccggc gggcgggggc gcggtgggca ctggtccgg
121 actctgcccg gccagggcg cggctccagc cgggagggcg acgtggagcg gccacgtgga
181 gcggcccggg ggaggtggc ggcgggagcg gaggcgcggg cggcgcagca gccaggagcg
241 cccacggagc tggaccccc aagccgcgcg gcgcgcagc agttccagga aggatgttac
301 ctttgacgat gacagtgtta atcctgctgc tgctccccc gggtcaggct gcccacaaagg
361 atggagtcac aaggccagac tctgaagtgc agcatcagct cctgcccac cccttcagc
421 caggccagga gcagctcgga cttctgcaga gctacctaaa gggactagga aggacagaag
481 tgcaactgga gcatctgagc cgggagcagg ttctctctta cctctttgcc ctccatgact
541 atgaccagag tggacagctg gatggcctgg agctgctgtc catgttgaca gctgctctgg
601 cccctggagc tgccaactct cctaccacca acccgggtgat cttgatagtg gacaaagtgc
661 tcgagaccca ggacctgaat ggggatgggc tcatgacccc tgctgagctc atcaacttcc
721 cgggagtagc cctcaggcac gtggagcccg gagagcccct tgctccatct cctcaggagc
781 cacaagctgt tggaaggcag tccctattag ctaaaagccc attaagacaa gaaacacagg
841 aagcccctgg tcccagagaa gaagcaagg gccaggtaga ggccagaagg gagtctttgg
901 atcctgtcca ggagcctggg ggccaggcag aggtgatgg agatgttcca gggccagag
961 ggggaagctga gggccaggca gaggtctaaag gagatgcccc tggggccaga ggggaagctg
1021 ggggcccaggc agaggctgaa ggagatgccc ccggggccag aggggaagct gggggccagg
1081 cagaggctga aggagatgcc cccgggccc aaggggaagc tgggggcccag gcagaggcca
1141 gggagaatgg agaggaggcc aaggaacttc caggggaaac actggagtct aagaacccc
1201 aaaatgactt tgaggtgcac attgttcaag tggagaatga tgagatctag atcttgaaga
1261 tacaggtacc ccacgaagtc tcagtgccag aacataagcc ctgaagtggg caggggaaat
1321 gtacgtggg acaaggacca tctctgtgcc ccctgcctgg tcccagtagg tatcaggtct
1381 ttctgtgcag ctcagggaga ccctaagtta aggggcagat taccaataaa gaactgaatg
1441 aattcatccc cccggccacc tctctacccg tccagcctgc ccagaccctc tcagaggaac
1501 ggggttgggg accgaaagga cagggatgcc gcctgcccag tgtttctggg cctcacggtg
1561 ctccggcagc agagcgcag gtgctagcca tggccggctg cagaggaccc agtgaggaaa
1621 gctcagtcta tccctggggc ccaaaccctc accggttccc cctcacctgg tgttcagaca
1681 ccccatgctc tcctgcagct cagggcagg gaccccatcc ccagtaatat taatcatcac
1741 tagaactttt tgagagcctt gtacacatca ggcatcatgc tgggcatttt atatatgatt
1801 ttatcctcac aataattctg tagccaagca gaattgggtc catttgacag atgaagaaat
1861 tgaggcagat tgcgttaagt gctgtaccct aaggtgatat gcagctaatt aaatggcaga
1921 tttgaatcca aaaa

```

MLPLTMTVLILLLLPTGQAAPKDGVTTRPDSEVQHQLLPNPFQPGQEQLGLLQSYLKGLGRTEVQLEHLSRE
QVLLYLFALHDYDQSGQLDGLLELLSMLTAALAPGAANSPTTNPVILIVDKVLETQDLNGDGLMTPAELINF
PGVALRHVEPGEPLAPSPQEPQAVGRQSLLAKSPLRQETQEAPGPREEAKGQVEARRESLDPVQEPGGQAE
ADGDVPGPRGEAEAGQAEAKGDAPGPRGEAGGQAEAEAGDAPGPRGEAGGQAEAEAGDAPGPRGEAGGQAEARE
NGEEAKELPGETLESKNTQNDFEVHIVQVENDEI

FIGURE 4**COMP** NM_000095.2 → NP_000086.2 cartilage oligomeric matrix protein precursor

```

1  agaaagcgag cagccaccca gctccccgcc accgccatgg tccccgacac cgcctgcggt
61  cttctgctca ccttggtgc cctcggcgcg tccggacagg gccagagccc gttgggctca
121  gacctggggc cgcagatgct tcgggaactg caggaaacca acgcggcgct gcaggacgtg
181  cgggagctgc tgcggcagca ggtcaggagg atcacgttcc tgaaaaacac ggtgatggag
241  tgtgacgcgt gcgggatgca gcagtcagta cgcaccggcc taccagcgt gcggccctg
301  ctccactgcg cgcgggctt ctgcttcccc ggctggcctt gcattccagac ggagagcggc
361  gcgcgctgcg gccctgccc cgcgggcttc acgggcaacg gctcgcactg caccgacgtc
421  aacgagtgca acgcccaccc ctgcttcccc cgagtcgctt gtatcaacac cagcccgggg
481  ttccgctgcg aggcttgccc gccgggggtac agcgcccca cccaccaggg cgtggggctg
541  gctttcgcca aggccaacaa gcaggtttgc acggacatca acgagtgtga gaccgggcaa
601  cataactgcg tcccactc cgtgtgcatc aacaccggg gctccttcca gtgcggcccg
661  tgccagcccg gcttcgtggg cgaccaggcg tccggctgcc agcggcgcg c acagcgcttc
721  tgccccgacg gctcggccag cgagtgcac gagcatgcag actgcgtcct agagcgcgat
781  ggctcgcggt cgtgcgtgtg tgccgttggc tgggcccggc acgggatcct ctgtggtcgc
841  gacactgacc tagacggctt cccggacgag aagctgcgtt gcccgagcgc ccagtgcctg
901  aaggacaact gcgtgactgt gcccaactca gggcaggagg atgtggaccg cgatggcatc
961  ggagacgcct gcgatccgga tgccgacggg gacgggggtc ccaatgaaaa ggacaactgc
1021  ccgctggtgc ggaaccaga ccagcgcaac acggacgagg acaagtgggg cgatgcgtgc
1081  gacaactgcc ggtcccagaa gaacgacgac caaaaggaca cagaccagga cggccggggc
1141  gatgcgtgcg acgacgacat cgacggcgac cggatccgca accaggccga caactgcctt
1201  agggtagcca actcagacca gaaggacagt gatggcgatg gtatagggga tgctgtgac
1261  aactgtcccc agaagagcaa cccgatcag gcgatgtgg accacgactt tgtgggagat
1321  gcttgtgaca gcgatcaaga ccaggatgga gacggacatc aggactctcg ggacaactgt
1381  cccacggtgc ctaacagtgc ccaggaggac tcagaccacg atggccaggg tgatgcctgc
1441  gacgacgacg acgacaatga cggagtccct gacagtcggg acaactgccg cctggtgcct
1501  aaccccggcc aggaggacgc ggacagggac ggctggggcg acgtgtgcca ggacgacttt
1561  gatgcagaca aggtggtaga caagatcgac gtgtgtccgg agaacgctga agtcacgctc
1621  accgacttca gggccttcca gacagtcgtg ctggaccggg aggtgacgc gcagattgac
1681  cccaactggg tgggtgctca ccagggaagg gagatcgtgc agacaatgaa cagcgaccca
1741  ggctggtgct tgggttacac tgcttcaat ggctggact tcgagggcac gttccatgtg
1801  aacacggtca cggatgacga ctatgcgggc ttcatctttg gctaccagga cagctccagc
1861  ttctacgtgg tcatgtggaa gcagatggag caaacgtatt ggcaggcgaa ccccttccgt
1921  gctgtggccg agcctggcat ccaactcaag gctgtgaagt cttccacagg ccccggggaa
1981  cagctgcgga acgctctgtg gcatacagga gacacagagt cccagggtgc gctgctgtgg
2041  aaggacccgc gaaacgtggg ttggaaggac aagaagtcct atcgttggtt cctgcagcac
2101  cggccccaag tgggctacat cagggtgcga ttctatgagg gccctgagct ggtggccgac
2161  agcaacgtgg tcttgacac aaccatgcgg ggtggccgcc tgggggtctt ctgcttctcc
2221  caggagaaca tcatctgggc caacctgcgt taccgctgca atgacacat cccagaggac
2281  tatgagaccc atcagctgcg gcaagcctag ggaccagggt gaggaccgc cggatgacag
2341  ccaccctcac cgcggtgga tgggggctct gcaccagcc ccaaggggtg gccgtcctga
2401  gggggaagtg agaagggtc agagaggaca aaataaagt tgtgtgcagg gaaaaaaaaa
2461  aaaaaaaaaa a

```

MVPDTACVLLLTALALGASGQGQSPLGSDLGPQMLRELQETNAALQDVRELLRQQVREITFLKNTVMECD
ACGMQQSVRTGLPSVRPLHLCAPGFCFPGVACIQTESGARCGPCPAGFTGNGSHCTDVNECNHPCFPRVR
CINTSPGFRCEACPPGYSGPTHQGVGLAFKANKQVCTDINECETGQHNCVPNSVCINTRGSFQCGPCQPG
FVGDAQSGCQRRARFCPDGSPSECHEHADCVLERDGSRSVCVAVGWAGNGILCGRDTLDGFPDEKLRCF
ERQCRKDNCVTVPSNGQEDVDRDGIGDACPDADGDGPVNEKDNCLVRNPDQRNTDEDKWGDACDNCRSQ
KNDDQKDTDQDGRGDACDDDDIDGDRIRNQADNCPRVNSDQKSDSDGIGDACDNCPSNPQADVDHDF

VGDACDSQDQDGDGHQDSRDNCPTVPNSAQEDSDHDGQGDACDDDDDDNDGVPSRDNCRLVPNPGQEDAD
RDGVGDVCQDDFDADKVVDKIDVCPENAEVTLTDFRAFQTVVLDPEGDAQIDPNWVVLNQGREIVQTMNSD
PGLAVGYTAFNGVDFEGTFHVNTVTDDDYAGFI FGYQDSSSFYVVMWKQMEQTYWQANPFRAVAEPGIQLK
AVKSSTGPGEQLRNALWHTGDTESQVRLWLDPRNVGWKDKKSYRWFLQHRPQVGYIRVRFYEGPELVADS
NVVLDTTMRGGRLGVFCFSQENIIWANLRYRCNDTIPEDYETHQLRQA

FIGURE 5**C19orf48** NM_199249.1 → NP_954857.1 multidrug resistance-related protein

```

1  tgaaatgggg tttcccaaac aggcgtgtgt attggacgcc tcgggaggag cgcgggctgg
61  cgccgaggac cggccttgcg agcggcgcgc actataaaat ggcgcgtgct gcaacccgcg
121  cccgcttcgg agagagaaat gctgggagac agggtttcac catattggcc aggctgggtct
181  cgaactcctg acttcgtgat ctgccacact cggcttccca aagtgctgag gttgcaggcg
241  tgagccaccg tgcccggccg cgtttcctac tctttaagct ctgttagctt ggccctctgtc
301  cctgaagggtg cagcttcaag cttaggacca cccaccatgc ctatccaggt gctgaagggc
361  ctgaccatca ctcatthaaga acagaggagg ctgcctgtta ctccctgggtg tgcattccctc
421  cagacactct gctgtttcct gcctaggcgt ggctgcagcc atggctagga aagcgtgcc
481  acccaccacac ctgggccaga gctgggtctg ctccctgctgc agggacactg agctggctat
541  ctggcgctt cgggcaagaa ctgcaacagg ctctcctggg tcctgcaggt gtacagcccg
601  gcccctgcct tgtgcctcag ctctcgagag ctgctgctgc cgggtgacct gatccaacct
661  gataaggtgc catcttcagc taccactgca aggcctgag ggcaacagca gcacggcact
721  gcccaccggg ctgctgatgg cctgggtgcc gctgggagtc ctcccgacac ttcgaggcca
781  ctgagccacc cttccagccc cagcccacca tggacagggg tatccagctt cctcctcaac
841  ctgctcctct gcccctgagc cagtgcagcc caaggacatg cctgttacct aggtcctgta
901  ccagcactag ctggtcaagg gcatgacagt gctggaggcc gtcttgagga tccaggccat
961  cactggcagc aggtgctct ccatggtgcc agggcccgcc agggccaccg gctcatgctg
1021  ggacccaacc cagtgcacaa ggacttggtc gctgagccac acaccagga gaaggtggat
1081  aagtgggcta ccaagggtct cctgcaggct aggggaggag ccacccccgc ttccctattg
1141  tgaccaggcc tatggggagg agctgtccat acgccaccgt gagacctggg cctggctctc
1201  aaggacagac accgcctggc ctggtgctcc aggggtgaag caggccagaa tcctggggga
1261  gctgctcctg gtttgagctg cattcaggaa gtgcgggaca tggtagggga ggcaaaaagc
1321  cttgggcact accctccctg tggagctgtt cgggtgtccg cgagctagcc acaccctgac
1381  accatgttca agggtagcgg aagagaaggg tgtctgcccc caacctcccc tgtgggtgtc
1441  actggccaga tgtcatgagg gaagcaggcc ttgtgagtgg aactgacca tgagtccctg
1501  gggggagtga tccccaggc atcgtgtgcc atgttgact tctgccagg cagcagggtg
1561  ggtgggtacc atgggtgcc acccctccac cacatggggc ccaaagcac tgcaggccaa
1621  gcagggaac cccacaccct tgacataaaa gcatcttgaa gcttttaaaa aaaaaaaaaa
1681  aaaaaaaaaa aa

```

MTVLEAVLEIQAITGSRLISMVPGPARPPGSCWDPTQCTRTWLLSHTPRRRWISGLPRASCRLGEEPPLP
YCDQAYGEELSIRHRETWAWLSRTDTAWPGAPGVKQARILGELLV

FIGURE 6**DLX1** NM 178120.4 → NP 835221.2 homeobox protein DLX-1 isoform 1

```

1 aagcttttgaa ccgagtttgg ggagctcagc agcatcatgc ttagactttt caaagagaca
61 aactccattt tcttatgaat ggaaagtga aacccctgtt ccgcttaaat tgggttcctt
121 cctgtcctga gaaacataga gacccccaaa agggaagcag aggagagaaa gtcccacacc
181 cagacccccgc gagaagagat gaccatgacc accatgccag aaagtctcaa cagccccgtg
241 tccgggcaagg cgggtgtttat ggagtttggg ccgcccaacc agcaaagtgc tctttctccc
301 atgtcccacg ggcactactc catgcactgt ttacactcgg cgggccattc gcagcccagc
361 ggcgcctaca gctcagcctc gtccttctcc cgaccgctgg gctacccta cgtcaactcg
421 gtcagcagcc acgcatccag cccctacatc agttcgggtg agtcctacc gggcagcgcc
481 agcctcgccc agagccgcct ggaggacca ggggcggact cggagaagag cacggtggtg
541 gaaggcggtg aagtgcgctt caatggcaag ggaaaaaaga tccgtaaacc caggacgatt
601 tattccagtt tgcagttgca ggctttgaac cggaggttcc agcaaactca gtacctagct
661 ctgccggaga gggcggagct cgcggcctct ttgggactca cacagactca ggtcaagatc
721 tggttccaaa acaagcgatc caagttcaag aagctgatga agcagggtgg ggcggctctg
781 gagggtagtg cgttggccaa cggtcggggc ctgtctgctg gctccccacc cgtgccgccc
841 ggctggaacc ctaactcttc atccgggaag ggctcaggag gaaacgcggg ctctatatc
901 cccagctaca catcgtggta cccttcagcg caccaagaag ctatgcagca accccaactt
961 atgtgaggtt gccgcgccgt ctcttctctt tctccccggc ccaggtcctt cccgcctcca
1021 ggtccatcca tcccgctccg aaaagaagga cccagaggga agaaggaaca gtggaggcgg
1081 gacgccctcc atctcctcgg agccccgcga ggtccggccc agcaacttcc cggcatccgc
1141 gctctagcct gaacctcggc ctgggcccag cagtggcagc agagagtggc ctcgaggga
1201 agccactgcc acctgagaca gcccaagcag caagataaac ccgctccacc cgaccgcgcg
1261 accttcagct ttgtgggact atcaggaaaa aacaaaaaca aaacaaaatg tagaaaaagc
1321 aaaagctctt ttctgtcctg tcagtctcct gtctcctttt gctctgtctg tgcgtggtg
1381 aagtccaggt cctcatccgt ccgctgtcct cattctgcgg cctcagcaaa aagccacaag
1441 gtctgagcgg ccgggtcct gccgggctga ccatctccgg atcctgggac actctgcctg
1501 accatctgtg tagctgggtg gggaatctgg gggcattgga gggagggggg tttatttatt
1561 gagaaatgga ctctgcctga ggctgtttgc caattcaggg ttctgctggg cgcaagggaac
1621 gcaactgttca aacgcactgt ttactttaag cgcacgggga gaaacgaata aggaggacgt
1681 ggtgattttt aattttataca gtaacttttg tacttctctg gtatggagag tttggagccg
1741 aatgatttgc atttttttaca tgtccgacat tattttaataa ataattttta aaagaaaaga
1801 acgataaatg aagccaacat gattttctca tttcgggagg aactctgttg cttcgcctgg
1861 acaagaagga aaatgctgat ttcctccttg ggtagaaaga gggagcgagg gcaaatgggg
1921 agtagagaga aaacaggcga gaacaagcac tctaattcca gtgggcttta aaataagaca
1981 aaatcagctt tacaacaatc cctagaggct cgaccacaga ataatgccag tcaccaccct
2041 gaacgcacaa tctccagtgc aggatctaag gactgtacat attattgtta ttattattat
2101 tgttatttatt gttgttctgt aaacatgttg cacaagctta gcctttttgc gttctgttgt
2161 gtgtggctgt aaaaccccat gctttgtgaa atgagaatct tgacattttt cttgtgaaat
2221 ttggaaaatg tgatcaattg aaatcaactg tgttttgtgt tctctatgtc aaagtttagt
2281 tttatattga gaatgttaac ttattgcttt gtatcttggg aaaaaaactt tgtaataaag
2341 ttataaagtt tctttgagac agtaaaatta tgatttcttg aaaaaaaaaa aaaaaaaaaa
2401 aaa

```

MTMTMPESLNSPVSGKAVFMEFGPPNQMSPPMSHGHYSMHCLHSAGHSQPDGAYSSASSFSRPLGYP
YVNSVSSHASSPYISSVQSYPGSASLAQSRLEDPGADSEKSTVVEGGEVRFNGKGKKIRKPRTIYSSLQL
QALNRRFQQTQYLALPERAELAASLGLTQTQVKIWFQNKRSKFKKLMKQGGALEGSALANGRALSAGSP
PVPPGWNPNSSSGKSGGNAGSYIPSYTSWYPSAHQEAMQQPQLM

FIGURE 7**GLYATL1** NM_080661.2 → NP_542392.2 glycine N-acyltransferase-like protein 1

```

1 agtggttgcc aatcccagca gccatacttc aactactcat agactgctga atgttcaaac
61 tgtgtttcaa taagatggtg tcacaagaag gatctgaagt ggagcttcta gtatccccag
121 gagcgcgaa tgaacacgga aggtacctgc aggatccaat tgtgtccatt gatctctcag
181 agtggctgag gataatagag tttcttcttc aaggtctcaa ggtgtatggc tctgtgtatc
241 acatcaatca cgggaacccc ttcaacatgg aggtgctggg ggattcctgg cctgaatatc
301 agatggttat tatccggcct caaaagcagg agatgactga tgacatggat tcatacacia
361 acgtatatcg tatgtttctc aaagagcctc aaaaatcaga agaagttttg aaaaattgtg
421 agatcgtaaa ctggaaacag agactccaaa tccaaggtct tcaagaaagt ttaggtgagg
481 ggataagagt ggctacattt tcaaagtcag tgaaagtaga gcattcgaga gcactcctct
541 tggttacgga agatattctg aagctcaatg cctccagtaa aagcaagctt ggaagctggg
601 ctgagacagg ccaccagat gatgaatttg aaagtgaac tccaactttt aagtatgccc
661 agctggatgt ctcttattct gggctggtaa atgacaactg gaagcgaggg agaatagaga
721 ggagcctgca ttacatcaag cgctgcatag aagacctgcc agcagcctgt atgtctggcc
781 cagagggagt cccggtctca tgggtaacca tggacccttc ttgtgaagta ggaatggcct
841 acagcatgga aaaataccga aggacaggca acatggcacg agtgatgggt cgatacatga
901 aatatctgag tcagaagaat attccatttt acatctctgt gttggaagaa aatgaagact
961 cccgcagatt tgtggggcag tttggtttct ttgaggcctc ctgtgagtgg caccaatgga
1021 cttgctaccc acagaatcta gttccatttt agacaatgaa gctgcttagt aatctctgcc
1081 aagccatctc ttaatatata agcagacacc acagaataga tttcttcaat tacaatatga
1141 tattgggcac ttataataca gcaggaactc ttctcacctg gagccttgat gttaaaagac
1201 acagccatgc tcttgaggag cttacaatcc tggctggagg caggggaggg tatattcttt
1261 aaatatgctt aagtgttata gggaaagacg gggttaccag taaacatgta actagaaagc
1321 caggctcagt tcttacctct gggaatcaga actctttatg caacttgggt aatagaatct
1381 actatctgga agataaatga aggattttta taaaattttc aatagaataa acctaactct
1441 tatggatact ttatcaaaaa tgaatgtccc tgctatttct ggatttatga ggcaatggta
1501 cactaaagaa tggaatcagt tcagtgaagta gaaaggtatc caaggtgaag cctgagacga
1561 atggctttcc caggctacct tccatcactg ttgtacagaa aagaaatcca gagaatcaaa
1621 tggactggcc ttgggggtct ctgctatgga aatgccattt tttgtgtctc ctttctccta
1681 ctctttctca catcctcttc atgattgaag catggcacia ggcaaggtgt tgctgctgag
1741 tctggttgta agttcagcct ttggtgtttg cactactgct atcataaggg gtcagggaca
1801 ttccggggag aagtgaccac taaggtgagg attagagagt gagtagaagt gagccagaca
1861 aaaaaagcag aaatgcaga tgatggaaag gacatgtgcc atgcactatc ataagaactt
1921 cctaactgaa cactgatact acaattctga atccctgac ttaaaaaata attatacttc
1981 accaacaataa cttggcctct tttggttcca ctctgccacc ctgccattgg aacttggatt
2041 actgtgaaca ttgcagctat agcaaaat

```

MFKLCSNKMVSQEGSEVELLVSPGARSEHGRYLQDPIVSIDLSEWLRIIEFLLQGLKVGSVYHINHGPNF
 NMEVLVDSWPEYQMVIIRPQKQEMTDDMSYTNVYRMFSKEPQKSEEVLKNCEIVNWKQRLQIQGLQESLG
 EGIRVATFSKSVKVEHSRALLLVTEIDLKLNASSKSKLSWAETGHPDDEFESETPNFKYAQLDVSYSGLV
 NDNWKRGNERSLHYIKRCIEDLPAACMLGPEGVPVSWVTMDPSCEVGMAYSMEKYRRTGNMARVMVRYMK
 YLRQKNIPFYISVLEENEDSRRFVGQFGFFEASCEWHQWTCYPQNLVPF

FIGURE 8**MS4A8B NM 031457.1 → NP 113645.1 membrane-spanning 4-domains subfamily****A member 8B**

```

1 aaacaggaaa taaatacgaa tgaaactgag ctctaagcag catgtaacct ggcctgcatac
61 caggaaatag aggacttcgg atccttctaa ccctaccacc caactggccc cagtacattc
121 attctctcag gaaaaaaaaac aagggtcccca cagcaaagaa aaggaatagg atcaagagat
181 acgtggctgc tggcagagca agcatgaatt cgatgacttc agcagttccg gtggccaatt
241 ctgtgttggt ggtggcacc cacaatgggt atcctgtgac ccaggaatt atgtctcacg
301 tgccctgta tccaaacagc cagccgcaag tccacctagt tcctgggaac ccacctagtt
361 tgggtgctgaa tgtgaatggg cagcctgtgc agaaagctct gaaagaaggc aaaaccttgg
421 gggccatcca gatcatcatt ggcctggctc acatcggcct cggctccatc atggcgacgg
481 ttctcgtagg ggaataacctg tctatttcat tctacggagg ctttcccttc tggggaggct
541 tgtggtttat catttcagga tctctctccg tggcagcaga aaatcagcca tattcttatt
601 gcctgctgtc tggcagtttg ggcttgaaca tcgtcagtgc aatctgctct gcagttggag
661 tcatactctt catcacagat ctaagtattc cccaccata tgcctacccc gactattatc
721 cttacgcctg ggggtgtgaac cctggaatgg cgatttcttg cgtgctgctg gtcttctgcc
781 tcctggagtt tggcatcgca tgcgcattc cccacttttg ctgccagttg gtctgctgtc
841 aatcaagcaa tgtgagtgtc atctatccaa acatctatgc agcaaaccce gtgatcacc
901 cagaaccggt gacctacca ccaagttatt ccagtgaatg ccaagcaaat aagtaaggct
961 acagattctg gaagcatctt tcaactgggac caaaagaagt cctcctccct ttctgggctt
1021 ccataaccce ggtcgttcct gttctgacag ctgaggaaac gtctctccca ctgtttgtac
1081 tctcaccttc attcttcaat tcagtctagg aaaccatgct gtttctctat caagaagaag
1141 acagagattt taaacagatg ttaaccaaga gggactccct agggcacatg catcagcaca
1201 tatgtgggca tccagcctct ggggccttgg cacacacaca ttcgtgtgct ctgctgcatg
1261 tgagcttgtg ggtagagga acaaatatct agacattcaa tcttactct tccaattgtg
1321 cattcattta ataaatagat actgagcatt caaaaaaaaa aaaaaaaaaa

```

```

MNSMTSAVPVANSVLVVAPHNGYPVTPGIMSHVPLYPNSQPQVHLVPGNPPSLVSNVNGQPQKALKEGKT
LGAIQIIIGLAHIGLSIMATVLVGEYLSISFYGGFPFWGGLWFIISGSLSVAAENQPYSYCLLSGSLGLN
IVSAICSAVGVILFITDLSIPHPYAYPDYYPYAWGVNPGMAISGVLLVFCLEFGIACASSHFGCQLVCCQ
SSNVSVIYPNIYAANPVITPEPVTSPPSYSSEIQANK

```

FIGURE 9

NKAIN1 NM_024522.2 → NP_078798.2 sodium/potassium-transporting ATPase subunit
beta-1-interacting protein 1

```

1  agtgetgctc tgegetgcgc cgegetcggg gctcgetctc cttgetccgc gctccccgcc
61  agccgccccg gggcaggagg cgcgcctgac ggacggcccc ctagacaaag gaggcgcggc
121  tcggcggggc cagcgcgcgg acggacggac catggactcg gagcgcgggc ggccggcccc
181  agccttgggg accggacact cccgggcccc gccctaggcg cccggccccg ccgcccggcg
241  cgcccagcgg ggaggacgtg gagcccgcgc ggcgcgagca ggcggcggcc gcgagcaag
301  aagggcgccg cggcgtgcgg cccgcgcagc ccccgagacc atgggcaagt gcagcgggcg
361  ctgcacgctg gtcgccttct gctgcctgca gctgggtggc gcgctggagc ggcagatctt
421  tgacttctcg ggctaccagt gggctcccat cctagccaac ttctgcaca tcatggcagt
481  catcctgggc atctttggca ccgtgcagta ccgtccccg tacctcatcc tgtatgcagc
541  ctggctgggt ctctgggttg gctggaatgc atttatcatc tgcttctact tggagggttg
601  acagctgtcc caggaccggg acttcatcat gaccttcaac acatccctgc accgctctg
661  gtggatggag aatgggccag gctgctgggt gacacctgtt ctgaactccc gcctggctct
721  ggaggaccac catgtcatct ctgtacttgg ctgcctgctt gactaccctt acattgaagc
781  cctcagcagc gccctgcaga tcttcttggc actgttcggc ttctgttctg cctgctacgt
841  gagcaaagtg ttcttgaggg aggaggacag ctttgacttc atcggcggct ttgactccta
901  cgataaccag gcgccccaga agacgtcgca ttacagctg cagcctctgt acacgtcggg
961  gtagcctctg cccgcgcgcc acccggcgcc ctgcctctgg gctgaccgca gctgccgcga
1021  gctcgggcca aggcgcaggc gtgtccccct ggtggccccg gcgctcactg cagcctgtgc
1081  ccaacccgcg gtctgcatct ggagatgcgg acctggacgt ggacttggac ttggacttgg
1141  atttgagctt ggctcttcgc agcccgactc tcggaggagt ggggcggggc gggggagggg
1201  caccacgggt tttttgtttt ttgtttgttt gtttttaate tcagccttgg cgtgagctgg
1261  ggcttctctc tcttctccag cctctccctt tcaactctca ccagcatcc tgccccctg
1321  tccaaaaaca gcaggacatc agaccatcc cactccacca cactcactca ccagctctgg
1381  ggaaagctac tgtgaactag gagcaggatt cctgggttct aatcgcaggt ccactactga
1441  ctgtgacgtc tagcaaagcc cttgcctctc ctgagcctcg gtttccgcac ctcaagtaat
1501  taatccctta gcaaattggc tcttttagac ttctcattta actcaattcc ctgagctaga
1561  ctgggattaa aattctcatt ttgcagtaca ttaaaactga ggcccagaga tgtgatttgc
1621  ttgaggccac acagctagat ttttggtgga agtgggcctt gaacacagtg tactttctgc
1681  agtttctgac tgtaaaaccc agtgtctgct ctctgagttc catttccaag ccccccctca
1741  tcttggaact atgtggtctc caccatattc acacaccacc accaccactt gccaatgcct
1801  ctcttaaagc aatataccca ttctgttctc tattgggaac tggatggatg aagcccaaaa
1861  ttcagcccca cccacagaga agccttccta cactcagcct ctgtccaccc ttggcaaate
1921  tttcaagctc tctcctccag gaaagtgggg ccccaactca gtcactccac ccccttccag
1981  gtccctgagg ctggttctac tgtatcccca tcacctccac aactccactc acccctgacg
2041  gctccatcca cctcaccagt tggaaggctt gtggtttcag agaggagcaa tgcgtggtcag
2101  cgctgcccag actccagtgt ttacagatca ccagcattta caaccaatcc aatggccaga
2161  agcctcctct aacaagccca gaaggagtct tgaaggggca gatgggggtg tgagtagtcg
2221  gggagtgcgg attgccagca ccctcaccct tccttggggg caagtagagg tgagaacact
2281  ttccccacct ccctccacag aactcctga ggacgtgca tcccacgcac tgccgtgtgc
2341  gtccatagag agaggatcag gtctcagcat ttcatctgtg aaagaggcat ggccctgggt
2401  tagaaaggag ggcaggagac atggaggaaac tggggggcac ccagatgggt cagatgggtt
2461  gcacacctga gcctgtctgt ggtgaccatt ccgtcctctc cccactaccc tccaatctat
2521  cattccctac tctctaaggc caaaatatcc tgagcaagge tggcaacccc accccaccat
2581  cccaaatgca agcagccagg cccaggagtt cctctggccc ccacaggcat ggagctccca
2641  gctgggtgggt acagcttgag aggggggcag ctccctcagg ctaagctact gcccttact
2701  gggccagccc tgctccagc cctcacctct ctaccccaa ctctcccca agccctttc
2761  tactcaacgg gtgtagccac tgggtgctttg aagccttttg tttttataag atggtttttg
2821  caaggggacc aggttctctt ttcactggga ccttgcaagg aggggagtcg tctcctggtt
2881  tctgtgcagg cgggttgatt aaagatggtg ttttcttctc taaaaaaaaa

```

MGKCSGRCTLVAFCCQLVAALERQIFDFLGYQWAPILANFLHIMAVILGIFGTVQYRSRYLILYAAWLVL
WVGWNAFIICFYLEVGLSQDRDFIMTFNTSLHRSWWMENGPCLVTPVLNSRLALEDHHVISVTGCLLDY
PYIEALSSALQIFLALFGFVFACYVSKVFLEEEDSFDFIGGFDSYGYQAPQKTSHLQLQPLYTSG

FIGURE 10

PPFIA2 NM_003625.2 → NP_003616.2 PPFIA2 protein tyrosine phosphatase.
receptor type. f polypeptide (PTPRF). interacting protein (liprin). alpha 2

```

1  gaggcaagtg aggagagaag atgctgtagc gtcctcaccg gctgccagca gggaaatggt
61 ccaggagtgc tgggtgtgag cctcccttct cctcaagccg gagactgcgg ttgtcattga
121 tcaattgaag aagcaaggac ccgaaatcac agacattagc aatgatgtgt gaagtgatgc
181 ccacgattaa tgaggacacc ccaatgagcc aaagggggtc ccaaagcagt ggctcggact
241 cagactccca ttttgagcag ctgatggtga atatgctaga tgaaagggat cgtcttctag
301 acacccttcg ggagaccag gaaagcctct cacttgccca gcaaagactt caggatgtca
361 tctatgaccg agactcactc cagagacagc tcaattcagc cctgccacag gatatcgaat
421 ccctaacagg agggctggct ggttctaagg gggctgatcc accggaattt gctgcaactga
481 caaaagaatt aaatgcctgc agggaacaac ttctagaaaa ggaagaagaa atctctgaac
541 ttaaagctga aagaaacaac acaagactat tactggagca tttggagtgc cttgtgtcac
601 gacatgaaag atcactaaga atgacggtgg taaaacggca agcccagtct ccctcaggag
661 tatccagtga agttgaagtt ctcaaggcac tgaaatcttt gtttgagcac cacaaggcct
721 tggatgaaaa ggtaaggagg cgactgaggg tttctttaga aagagtctct gcactggaag
781 aagaactagc tgctgcta at caggagattg ttgccttgcg tgaacaaaat gttcatatac
841 aaagaaaaat ggcatacagc gagggatcca cagagtcaga acatcttgaa gggatggaac
901 ctggacagaa agtccatgag aagcgtttgt ccaatggttc tatagactca accgatgaaa
961 ctagtcaaat agttgaacta caagaattgc ttgaaaagca aaactatgaa atggcccaga
1021 tgaaagaacg tttagcagcc ctttcttccc gagtgggaga ggtggaacag gaagcagaga
1081 cagcaagaaa ggatctcatt aaaacagaag aaatgaacac caagtatcaa agggacatta
1141 gggaggccat ggcacaaaag gaagatatgg aagaaagaat tacaaccctt gaaaagcgtt
1201 acctcagtgc tcagagagaa tctacctcca tacatgacat gaatgataaa ctagaaaatg
1261 agtttagcaa taaagaagct atcctgcggc agatggaaga gaaaaacaga cagttacaag
1321 aacgtcttga gctagctgaa caaaagttgc agcagaccat gagaaaggct gaaaccttgc
1381 ctgaagtaga ggctgaactg gctcagagaa ttgcagccct aaccaaggct gaagagagac
1441 atggaaatat tgaagaacgt atgagacatt tagaggggtca acttgaagag aagaatcaag
1501 aacttcaaag agctaggcaa agagagaaaa tgaatgagga gcataacaag agattatcgg
1561 atacggttga tagacttctg actgaatcca atgaacgcct acaactacac ttaaaggaaa
1621 gaatggctgc tctagaagaa aagaatgttt taattcaaga atcagaaact ttcagaaaga
1681 atcttgaaga atctttacat gataaggaaa gattagcaga agaaattgaa aagctgagat
1741 ctgaacttga ccaattgaaa atgagaactg gctctttaat tgaaccaca ataccaagaa
1801 ctcatctaga cacctcagct gagttgcggg actcagtggg atccctagtg gacagccagt
1861 ctgattacag aacaactaaa gtaataagaa gaccaaggag aggccgcatg ggtgtgcgaa
1921 gagatgagcc aaaggtgaaa tctcttgggg atcacgagtg gaatagaact caacagattg
1981 gagtactaag cagccaccct tttgaaagtg aactgaaat gtctgatatt gatgatgatg
2041 acagagaaac aatttttagc tcaatggatc ttctctctcc aagtggtc at tccgatgccc
2101 agacgctagc catgatgctt caggaacaat tggatgccat caacaaagaa atcaggctaa
2161 ttcaggaaga aaaagaatct acagagttgc gtgctgaaga aattgaaaat agagtggcta
2221 gtgtgagcct cgaaggcctg aatttggcaa ggggtccacc aggtacctcc attactgcct
2281 ctgttacagc ttcatcgctg gccagttcat cccccccag tggacactca actccaaagc
2341 tcaccctcgc aagccctgcc agggaaatgg atcggatggg agtcatgaca ctgccaaagt
2401 atctgaggaa acatcggaga aagattgcag ttgtggaaga agatggtcga gaggacaaag
2461 caacaattaa atgtgaaact tctcctctc ctaccctag agccctcaga atgactcaca
2521 ctctcccttc ttctaccac aatgatgctc gaagtagttt atctgtctct cttgagccag
2581 aaagcctcgg gcttggtagt gccaacagca gccaaagact tcttcacaaa gccccaaaga
2641 agaaaggaat caagtcttca ataggacgtt tgtttggtaa aaaagaaaaa gctcgacttg
2701 ggcagctccg aggctttatg gagactgaag ctgcagctca ggagtccctg gggttaggca
2761 aactcggaac tcaagctgag aaggatcgaa gactaaagaa aaagcatgaa cttcttgaag
2821 aagctcggag aaagggatta ccttttgccc agtgggatgg gccaaactgtg gtcgcatggc

```

2881 tagagctttg gttgggaatg cctgcgtggt acgtggcagc ctgccgagcc aacgtgaaga
2941 gtggtgccat catgtctgct ttatctgaca ctgagatcca gagagaaatt ggaatcagca
3001 atccactgca tcgcttaaaa cttcgattag caatccagga gatggtttcc ctaacaagtc
3061 cttcagctcc tccaacatct cgaactcctt caggcaacgt ttgggtgact catgaagaaa
3121 tggaaaatct tgcagctcca gcaaaaacga aagaatctga ggaaggaagc tgggccagct
3181 gtccggtttt tctacagacc ctggcttatg gagatatgaa tcatgagtgg attggaaatg
3241 aatggcttcc cagcttgagg ttacctcagt acagaagtta ctttatggaa tgcttggtag
3301 atgcaagaat gttagatcac ctaacaaaaa aagatctccg tgtccattta aaaatggtgg
3361 atagtttcca tcgaacaagt ttacaatatg gaattatgtg cttaaagagg ttgaattatg
3421 acagaaaaga actagaaaga agacgggaag caagccaaca tgaaataaaa gacgtgttgg
3481 tgtggagcaa tgaccgagtt attcgcctgga tacaagcaat tggacttcga gaatatgcaa
3541 ataataact tgagagcggg gtgcatggct cacttatagc cctggatgaa aactttgact
3601 acagcagctt agctttatta ttacagattc caacacagaa caccagga aggagattc
3661 ttgaaagaga atacaataac ctcttgccc tgggaactga aaggcgactg gatgaaagtg
3721 atgacaagaa cttcagacgt ggatcaacct ggagaaggca gtttcctcct cgtgaagtac
3781 atggaatcag catgatgcct gggctcctcag aacattacc agctggattt aggttaacca
3841 caacctctgg gcagtcaga aaaatgacaa cagatgttgc ttcataaga ctgcagaggt
3901 tagacaactc cactgttcgc acatactcat gttgaccagc cactcaaagg aggcagcact
3961 gacctgctat ggcgtctttt cagtctactc tacctaaagt gcactaccat ctaagaagac
4021 gagcagtgaa aacctttgtg aaactgaat tc

MMCEVMPTINEDTPMSQRGSQSSGSDSDSHFEQLMVNMLDERDRLLDRTLRETQESLSLAQQRLQDVIYDR
DSLQRQLNSALPDIESLTGGLAGSKGADPPEFAALTKELNACREQLLEKEEEISELKAERNNTRLLEH
LECLVSRHERSLRMTVVKRQAQSPSGVSSEVEVLKALKSLFEHHKALDEKVRERLRVSLERVSALEEEEL
AANQEIVALREQNVHIQRKMASSEGSTESEHLEGMEPGQKVHEKRLSNGSIDSTDETSQIVELQELLEKQ
NYEMAQMKERLAALSSRVGEVEQEAETARKDLIKTEEMNTKYQRDIREAMAQKEDMEERITTLKRYLSA
QRESTSIHDMNDKLENELANKEAILRQMEKNRQLQERLELAEQKLQOTMRKAETLPEVEAEALQRIAL
TKAEERHGNIEERMRLHLEGQLEEKNOELQARQREKMNEHNKRLSDTVDRLLTESNERLQLHLKERMAA
LEEKVLIQESETFKNLEESLHDKERLAEEIEKLRLSELQDKMRTGSLIEPTIPRTHLDTSALRYSVG
SLVDSQSDYRTTKVIRRRPRGRMGVRRDEPKVKSGLGDHEWNRTQQIGVLSSHFPFESDTEMSDIDDDRET
IFSSMDLLSPSGHSDAQTLAMMLQEQLDAINKEIRLIQEEKESTELRAEEIENRVASVSLEGLNLARVHP
GTSITASVTASSLASSSPSGHSTPKLTPRSPAREMDRMGMVMTLPSDLRKHRRKIAVVEEDGREDKATIK
CETSPPTPRALRMTHTLPSYHNDARSSLSVSLEPESLGLGSANSSQDSLHKAPKKKGIKSSIGRLFGK
KEKARLGQLRGFMETEAQAQESLGLGKLGTAQEKDRRLKKKHELLEEARRGLPFAQWDGPTVVAWLELW
LGMPAWYVAACRANVKSGAIMSALSDTEIQREIGISNPLHRLKLRLAIQEMVSLTSPSAPPTSRTPSGNV
WVTHEEMENLAAPAKTKESEEGSWAQCPVFLQTLAYGDMNHEWIGNEWLPSLGLPQYRSYFMECLVDARM
LDHLTKKDLRVHLKMVDSFHRTSLQYGIMCLKRLNYDRKELERRREASQHEIKDVLVWSNDRVIRWIQAI
GLREYANNILESGVHGSLIALDENFDYSSLALLLQIPTQNTQARQILEREYNNLLALGTERRLDESDDKN
FRRGSTWRRQFPPREVHGISMMPGSSETLPAGFRLTTTSGQSRKMTTDVASSRLQRLDNSTVRTYSC

FIGURE 11

PTPRT NM 133170.3 → NP 573400.3 receptor-type tyrosine-protein phosphatase T isoform 1

precursor

```

1  cctccccgct cagttcgcgc cgcgcctcgg cttggaacgc aggagcgccg gctccgggag
61  cccgagcgga gccagccgcg cgcacagcca gcggccgcgc cggcgatgcg gggccacccc
121  gcgcccgcgc cagtcccggc cccggccccc gcgggaaggg gctgagctgc ccgccgcgc
181  ccggatggcg agcctcgccg cgctcgccct cagcctgctc ctgaggctgc agctgccgcc
241  actgcccggc gcccgggctc agagcgccgc aggtggctgt tcctttgatg agcactacag
301  caactgtggt tatagtgtgg ctctagggac caatgggttc acctgggagc agattaacac
361  atgggagaaa ccaatgctgg accaggcagt gccacacagga tctttcatga tgggtgaacag
421  ctctgggaga gcctctggcc agaaggccca ccttctcctg ccaaccctga aggagaatga
481  caccactgc atcgacttcc attactactt ctccagccgt gacaggcca gccagggggc
541  cttgaacgtc tacgtgaagg tgaatggtgg ccccaaggg aacctgtgt ggaatgtgtc
601  cggggtcgtc actgagggtc ggggtgaagg agagctcgcc atcagcactt tctggccaca
661  tttctatcag gtgataattg aatccgtctc attgaagggt catcctggct acatcgccgt
721  ggacgaggtc cgggtccttg ctcatccatg cagaaaagca cctcattttc tgcactcca
781  aaacgtggag gtgaatgtgg ggcagaatgc cacatttcag tgcattgctg gtgggaagtg
841  gtctcagcat gacaagcttt ggctccagca atggaatggc agggacacgg ccctgatggg
901  caccgtgtg gtcaaccaca ggcgtctctc agccacagtc agtgtggcag acactgccc
961  gcggagcgtc agcaagtacc gctgtgtgat ccgctctgat ggtgggtctg gtgtgtccaa
1021  ctacgcggag ctgatcgtga aagagcctcc cagccccatt gctccccag agctgctggc
1081  tgtggggggc acatacctgt ggatcaagcc aaatgccaac tccatcatcg gggatggccc
1141  catcatcctg aagggaagtgg aatatcgcac caccacaggc acgtgggag agaccacat
1201  agtcgactct cccaactata agctgtggca tctggacccc gatgttgagt atgagatccg
1261  agtgctctc acacgaccag gtgagggggg tacgggaccg ccagggcctc ccctcaccac
1321  caggaccaag tgtgcagatc cggtagatgg ccacagaac gtggaaatcg tagacatcag
1381  agcccggcag ctgacctgc agtgggagcc cttcggctac gcggtgacc gctgccatag
1441  ctacaacctc accgtgcagt accagtatgt gttcaaccag cagcagtac aggccgagga
1501  ggtcatccag acctcctccc actacacctc gcgaggcctg cgccccttca tgaccatccg
1561  gctgcgactc ttgctgtcta accccgaggg ccgaatggag agcgaggagc tgggtggtgca
1621  gactgaggaa gacgttccag gagctgttcc tctagaatcc atccaagggg ggccctttga
1681  ggagaagatc tacatccagt ggaaacctcc caatgagacc aatggggtca tcacgctcta
1741  cgagatcaac tacaaggctg tcggctcgct ggaccaagt gctgacctct cgagccagag
1801  ggggaaagtg ttcaagctcc ggaatgaaac ccaccacctc tttgtgggtc tgtaccagg
1861  gaccacctat tctttacca tcaaggccag cacagcaaag ggctttgggc ccctgtcac
1921  cactcggatt gccacaaaaa tttcagctcc atccatgcct gagtacgaca cagacacccc
1981  attgaatgag acagacacga ccatcacagt gatgtgaaa cccgctcagt cccggggagc
2041  tcctgtcagt gtttatcagc tggttgtcaa ggaggagcga cttcagaagt cacggagggc
2101  agctgacatt attgagtgt tttcggtgcc cgtgagctat cggaatgcct ccagcctcga
2161  ttctctacac tactttgtct ctgagttgaa gcctgccaac ctgcctgtca ccagccatt
2221  tacagtgggt gacaataaga catacaatgg ctactggaac cctcctctct cctccctgaa
2281  aagctacagc atctacttcc aggcactcag caaagccaat ggagagacca aaatcaactg
2341  tgttcgtctg gctacaaaag caccaatggg cagcgcccag gtgaccccg ggactccact
2401  ctgcctcctc accacaggtg cctccacca gaattctaac actgtggagc cagagaagca
2461  ggtggacaac accgtgaaga tggctggcgt gatcgctggc ctctcatgt tcatcatcat
2521  tctcctgggc gtgatgtca ccatcaaaag gagaagaaat gcttattcct actcctatta
2581  cttgaagctg gccagaagc agaaggagac ccagagtgga gccagaggg agatggggcc
2641  tgtggcctct gccgacaaac ccaccacaa gctcagcgcc agccgcaatg atgaaggctt
2701  ctcttctagt tctcaggacg tcaacggatt cacagatggc agccgcgggg agctttccca
2761  gccacccctc acgatccaga ctcatcccta ccgcacctgt gacctgtgg agatgagcta
2821  cccccgggac cagttccaac ccgccatccg ggtggctgac ttgctgcagc acatcacgca

```

```

2881 gatgaagaga ggccagggct acgggttcaa ggaggaatac gaggccttac cagaggggca
2941 gacagcttcg tgggacacag ccaaggagga tgaaaaccgc aataagaatc gatatgggaa
3001 catcatatcc tacgaccatt cccgggtgag gctgctgggtg ctggatggag acccgcactc
3061 tgactacatc aatgccaaact acattgacgg ataccatcga cctcggcact acattgcgac
3121 tcaaggtccg atgcaggaga ctgtaaagga ctttttgaga atgatctggc aggagaactc
3181 cgccagcatc gtcattgggtc caaacctggg ggaagtgggc aggggtgaaat gtgtgcgata
3241 ctggccagat gacacggagg tctacggaga cattaaagtc accctgattg aaacagagcc
3301 cctggcagaa tacgtcatac gcaccttcac agtccagaag aaaggctacc atgagatccg
3361 ggagctccgc ctcttccact tcaccagctg gcctgaccac ggcgttcctt gctatgccac
3421 tggccttctg ggcttcgtcc gccaggtcaa gttcctcaac cccccggaag ctgggcccac
3481 agtgggtccac tgcagtgtcg gggctgggcg gactggctgc ttcattgcca ttgacaccat
3541 gcttgacatg gccgagaatg aaggggtggg ggacatcttc aactgctgct gtgagctccg
3601 ggcccaaagg gtcaacctgg tacagacaga ggagcaatat gtgtttgtgc acgatgccat
3661 cctggaagcg tgcctctgtg gcaacactgc catccctgtg tgtgagtccg gttctctcta
3721 ctacaatatc agcaggctgg acccccagac aaactccagc caaatcaaag atgaatttca
3781 gacctcaac attgtgacac cccgtgtgcg gcccgaggac tgcagcattg ggctcctgcc
3841 ccggaaccat gataagaatc gaagtatgga cgtgctgcct ctggaccgct gcctgccctt
3901 ccttatctca gtggacggag aatccagcaa ttacatcaac gcagcactga tggatagcca
3961 caagcagcct gccgccttcg tggtcaccca gcacctcta cccaacaccg tggcagactt
4021 ctggaggctg gtgttcgatt acaactgctc ctctgtgggtg atgctgaatg agatggacac
4081 tgcccagttc tgtatgcagt actggcctga gaagacctcc ggggtgctatg ggcccatcca
4141 ggtggagttc gtctccgcag acatcgacga ggacatcatc cacagaatat tccgcatctg
4201 taacatggcc cggccacagg atggttatcg tatagtccag cacctccagt acattggctg
4261 gcctgcctac cgggacacgc cccctccaa gcgctctctg ctcaaagtgg tccgacgact
4321 ggagaagtgg caggagcagt atgacgggag ggagggacgt actgtggtcc actgcctaaa
4381 tgggggaggg cgtagtggaa ccttctgtgc catctgcagt gtgtgtgaga tgatccagca
4441 gcaaaacatc attgacgtgt tccacatcgt gaaaacactg cgtaacaaca aatccaacat
4501 ggtggagacc ctggaacagt ataaatttgt atacgagggtg gcactggaat atttaagctc
4561 ctttttagctc aatgggatgg ggaacctgcc ggagtccaga ggctgctgtg accaagcccc
4621 cttttgtgtg aatggcagta actgggctca ggagctctga ggtggcaccg tgccctgactc
4681 caaggagaag actggtggcc ctgtgttcca cggggggctc tgcaccttct gaggggtctc
4741 ctgttgccgt gggagatgct gctccaaaag gccaggctt ccttttcaac ctaaccagcc
4801 acagccaagg gcccaagcag aagtacacc acaagcaagg ccttggattt ctggctccca
4861 gaccacctgc ttttgttctg agtttgtgga tctcttgga agccaactgt gcaggtgctg
4921 gggagtggga ggctccctg cctccttct ccttaggagt ggaggagatg tgtgttctgc
4981 tcctctacgt catggaaaag attgaggctc ttgggggtca ctgctctgct gccccctgca
5041 acctccttca ggggcctctg gcaccagaca tttgcagtct ggaccagtgt gaccttacga
5101 tgttccctag gccacaagag agggccccc tctcacacc taacctgcat ggggcttcgc
5161 ccacaaccat tctgtacccc tccccagcc tgggccttga ccgtccagca ttcactggcc
5221 ggccagctgt gtccacagca gtttttgata aagggtgttct ttgctttttt gtgtggtcag
5281 tgggaggggg tggaactgca ggaacttct ctgctcctcc ttgtctttgt aaaaagggac
5341 cacctcctg gggcagggt tgggtgacc tgtaggatgt aacctctgtg tttcttttgt
5401 ggtagctttc tttggaagag acaaacaga taagatttga ttattttcca aagtgtatgt
5461 gaaaagaaac tttcttttgg aggggtgtaa atcttagtct cttatgtcaa aaagaagggg
5521 gcgggggagt ttgagtatgt acctctaaga caaatctctc gggcctttta tttttcctg
5581 gcaatgtcct taaaagctcc caccctggga cagcatgcca ctgagcaagg agagatgggt
5641 gagcctgaag atggtccctt tggtttctgg ggcaaataga gcaccagctt tgtgcataat
5701 ttggatgtcc aaatttgaac tcttccctaa agaaaccag cagccacctt gaaaaaggcc
5761 attgtggagc ccattatact ttgattttaa ataggccaag agaatcaggc ctggagatct
5821 aggtcttgt ccaaagtgtg agtgagtcaa tgagagggaa ccaacatttg ctaagtctct
5881 actgtatgcc aggatcatg cttggcactt tccataggac atttcacaca gtccttagaa
5941 cccccaggag agagctactg acttgttatc atctccattt gatcatctcc tccaatgagg
6001 aaaccacgc accttcctta gtaatgaaat cctgggttcc aaaggggcag gtaatggcaa

```

6061 tgagacttct cegtgtctgtt ttcttcatct tctctaagcc aagcaattat tttatggagg
6121 gaaaataagg ccagaaactt ctgagcagat aactccacaa atggaaattt agtactttct
6181 tcctgatgcc agttcttctg ggaagcgcag aatttcagat atatttttagt aacacattcc
6241 cagctcccca ggaaagccag tctcatctaa tttcttagtc agtaaaaaca attccctgtt
6301 ccttcaggct atgaatggac cagccaggga aactctcgac cttgatctct agccagtgtc
6361 taggcccaat atctgacagc ctcagggtgg ctgggacctt ggaagctcca tcttgaaggc
6421 tgggtctagcc ccagacaggg catgaggggc agagaattca agaaggtaca gctttggccc
6481 tcaagagccc actgtatgct ggggaaatgg aacctagggt cagtagtgtg gagtggatga
6541 gtgttccatg agcctaggag caagaaagtc tcttcggcct cgggcttccct ggagaagggg
6601 acgtccattc ctgctgggtc ttaacaagca taaaaaggaa aaaaaggaaa ctcaggcaaa
6661 gggatccata tgtgcaatgg caaagaaatg tgaaaaggca ttgggagaag cagtctgggg
6721 gaggccagcc cagtgcgggc acagcacac acggggagca gcaagagatg agccagggtc
6781 caggagacag atgcccctcg cgagtacaga ctttgtccta ttggcaacaa ggagtccatg
6841 gagctttaga gagatgcact cagcttcgtg ttggccaaga ctcttctgtg gccaatgggg
6901 ctgcctcttt tcctttcatc agacactgtg aaaacattcc cttaaagcgt cactttttaa
6961 tatcacatct atttgtctgt ctgctcattg ttttgttgct ggaactaaat atgcaatgga
7021 tcatgagact cagattctat gagaaaccca ggggtctctgc tttaccacgg agcagggtca
7081 ccaaccaga tctccaggcc catgaggatg gaacatgaaa ggagccgaca aaagttgctt
7141 ccattggcat gggctctgga gctgtccaga agtccaggga caccagactt gatcaaggaa
7201 gggctgtcac tttagaggtt caaaaggaa tgcccaaaag caaaggcaag caaaggaaac
7261 ccacgatgaa cttgctcttt tcctttgatg agcctctccc cagggtgtatt tcagcagacc
7321 ccggggaccc acccccactg ggccctgtgg cctccctcgg ctccagccca atgcccagc
7381 tggccttccc cagcctgcaa ggagcctgta gcatggcaaa tctgcctgtc gtatgctatt
7441 ttcttagatc ttggtacatc cagacaggat gaggggtggag ggagagctat ttaacacaaa
7501 tcctaagatt tttttctgct caggaagggg tgaaatagct ggcagataca aaagacagtg
7561 gcttttatca ttttaaattg taggaattta aggtgtgact tcaggggagaa acaaacttgc
7621 aaaaaaaaaa aatctcaggc catgttgggg taaccagca agggccagtg atgatttccc
7681 ccagctcatc cccttatttt cccacaaccc aaccttctc taaagcagga cagtgaatag
7741 gtcttaggcc agtgcacaca ggaagaaatt gaggcttatg gatggggatg acttccctaa
7801 gatcccatgg gacaaggatg tggcaaggct tggatgagat ggggcaccag tgcccaggaa
7861 tttgaacatt ttcccttacc caggaaatct ccggagccaa caccaccacc cccagggggt
7921 ctccccaccc caccctattt acagggtgag ctcagcctgt catgagcaga ggaaaatatt
7981 attaatgctc tctgagtctt tacaacagga gctcttacct catagatgtg ggctctgttt
8041 ggggaagatg caaggaagta atgagaagcc caggaaattt ctccacctgt gtttatggcc
8101 taaatagctt caggatgtat cttagctgca ctccaacatt gcatccttct tgggggtgaag
8161 aatctgggcc aaccaggggt ccttgggcct ctagaaggcc acagtaggcc tctctttgtg
8221 ggaatggaag gggacagttt gcttttagtg ctggccctct ctgtgggtgt ggccctgcaa
8281 ggaaccaaca gaccctatgc tggggactct aacatgtgag ctattaaat tcttcagca
8341 ttctaaagga gggtttgtga ttgtcaccat ttactgatga ggaaactaag gctcctaggg
8401 gagaaatcac ttgcccacag ttccacagct agtgagtga tgaaccagga tttaaaccgg
8461 ttttttctca ctacagagac aatatttttc caccattgta tctcacattt tcccaggag
8521 gttaccata acagaagaga ctagagtga acagatacgt cagtggataa agctcaaagc
8581 aaacaacagt aagcttaaaa ttccttcata gtctcatgtt ttacgttcac aattcatgca
8641 aaatttgcac tccactttct gatttagcct tggttggttt aatatgactc tatgaatatt
8701 tcaaaaaaaaa atgtgctctg ttcctcatgt tggtctgttc tgttcacccc gctatgacgg
8761 accctaggtc agctggtctt cagcttgacc ctagaattga ctctaggagc agtgacctg
8821 ctgcctccca gagccagtta taggctcaag atcaagacca actgaccttc tctaggcag
8881 ctcccttggg gtgtgggtgc tctgacctca ctgttcatga ggggacctca actaaggcat
8941 cttccagttg ggtgctggaa ggaaccatt aactcacact agaattgatg ggatttgctc
9001 atctggcgtg gagaaggatg agccacaaa accctaaagg gaaaagagaa gctggacaca
9061 gctgtactca gcagattcct gaatgctagg ctggaaagtg gtgcctgttg tccaagtgga
9121 gtcacatggt tgctaattgt ggcaagtctg aggacacact tcatgagcag ctggggtctg
9181 gaaggctcct cactttaccc tagccacaca taattactgg gtgcctacag cacctagcac
9241 cttggagggg gcactattag gaaatcgaga ttactatggc acaattaatt cctgggtaag
9301 gcatgggggt gtggtggaca gagctcagtc tttagtttga acgaaaacat acatacatga

```

9361 aaaacataca tgaaaaaagg accctcatca acattagaag gggtagattt ggagcacttt
9421 aggcaggaaa acaggaacgc aaggccagga aactggaacc cagtgaatac tcagaaccga
9481 ggatgcagat gacttattta gcaaaatggg cacttctgtg acatagctgg agaaaggatg
9541 ggtaacagct tgccagagcc acttggaaaca agggcaaato tcagtgtctg gggcaaaaga
9601 tgatgcattt ccctctgacc catcatgttt attcatectc cactcccat tgccacacta
9661 gctcttgctg taagtctca ccaggatcta catttctctg tctgtgtgtg gaaccctta
9721 gagtacatag aggtatcagt ccagtaagac tgctctacac aacagaagtg aggcccaggg
9781 agtagcagcc aggcccttat cctgttacct ctgcaggagt gactgccccaa cccagatcca
9841 gagacattga aggaaatgat aattccttgg tacttactg ccttgggaca aaatgaagaa
9901 agccaccctt ccttaggctg cagcttgcca ctctgggct gggtaaacag gtcacagca
9961 ccaagctcaa ccaggagtaa cactctggaa gacatgggtg agcccaagag gaagcatgaa
10021 caggacgctg ttcctaagtc atgtcaacag gttgtgctgg gccaggatcc ccagggaaaa
10081 aaatggtcaa cccaactgga gggtaggtta gaagaaaaaa aacataaacg tggatagtca
10141 tgtcatctca aatccctgac ttggcttccc cattacttaa cagtctgagc tccttcttag
10201 cctgtgacca gcttcaaata acagccaagt aaaacaagga aataggaaaa gtaaatccaa
10261 ctagaagaga caagctgaga ttcagatttg tttactctc ccatgcaaag tttccctgtt
10321 ggagggtttt catgtatata tgtctagaag tgatagaatg caaggccttg gctttgtctt
10381 gcagggatct gcctttgagg tcatagactg aacagcaggg agagaggtta gtggtggagt
10441 gtggggggag ctgttctagc tccagtttct tctgacacat ttttcaggat catggtctg
10501 atcctccgaa gcacagcaga gatattctaa ccatatttgt gcacatgagc agactcttct
10561 agtttttttag taaccaggga tgggcttttg catggcactg actatagaga tgtctttag
10621 agatcaagcc agtcttttgc atcccacctg cccacctcca gaagagatgg gaaaaggta
10681 tcaaagggca ttcaccaact gaaatccact catgaatgtt aggtctctaa aaggaggcat
10741 caacactcac aatggtagcc tccaaaccta gcacccacc tatctaagag ctgagggtg
10801 gtccactggg gcagatacaa ggaagtgcagg agggctcagg atgaaagaaa atctattggg
10861 aagagtttta ggggcttgat cattatgggg ctctcttcta tatctgagaa ctgctctggg
10921 tgggtgagatg tggactctga tccttaattg gaatgttcgg agaattagtg tctggtggcc
10981 ttgaagtgtt ggacagaaaa gtatcagtat aaaagcctgg agctcagggt aattaatgta
11041 gttcatggtt ccttagtgag caggactctt ggatgtggag gagaaagggt cataggaagt
11101 aaaccaccaa aattacaaaa ttgagtctct gtacaattac ttcagtgcct ttgggcttat
11161 gaatacaaat cagtgggcct tctctatgat ggtccaacaa actctcagtg tccacctgt
11221 ccctgtatct cccatggaag atgaataatg tcagggtgtt tttgggtcaa aggccccagg
11281 gcagtctgga ggcttagagg gcagagtggg gtcattccat gtaaagttag gcttctgagg
11341 ggtcaggcag aatatggtgt ccatatcttc catagctctg cagattcttg gatgaagtca
11401 agcacagttt gctagacca ggtcactcct ctgagtataa ctaggacca tgagtgaac
11461 ttaatatgctg taagggaagaa cctgctgtct gccagagagg ataagctgcc catctcagca
11521 gctgtctaaa agaaggcagg tgtctcttta aagggaagag aagcattggg gaaatggatt
11581 tcaggctcact tccattccag atgggtgaga tcttgtggag ctgggatcat gtttgaactc
11641 attcatacct gttaggcagc aatccaagta gattgtgttt ggtctgtaca ggctgaagcc
11701 ccctgctctc ccaccaagt gccccactg agcaggccaa catgctgttg tggccacata
11761 tactgggctg atccaggctg gttatcacca aacagcaaac catagggaac agctgctttg
11821 ccatagaccc aatacccatg tagatctctc atgagagcag ccataactca gaccactga
11881 ccaacagggc catgagtgc agccagaacc agtgaagggt caagtaggac acagagcagg
11941 gcttttctta ccatacacat tatctccaga gggtattttt accccactcc ctattcaagg
12001 cctgttgagg cacactgcaa aagcaaaagc acagtaactc aatttacaca tgattataat
12061 catttccagt gcacacattt catcaccagg tggatcctga gctagcccat gtaaatccgg
12121 gtttaacccat attggtaatc atactcaaaa gcacttttca ccctacattc tactagccaa
12181 tcaaagacaa agagtgtgtg cctctaccat tgccttggct tctggacacc ctcaagct
12241 atcccaagg tcccgctcaa ctccaggag gctgacatct tcacatccac tgggcatata
12301 atattgcatg agaccaaagt ctccacactc tttgcagcct cctccatgaa tcccaatggc
12361 ctgcacttgt acagtttggg tgtttgatag ataaagcacg tatgagaaga gaaaacaaaa
12421 taaatcaact ttttaaaaaa gccagcactg tgctgtcaat gtttttttt tcttttcaat
12481 tctagctcag aaaagcagaa ggtaaataat gtcagggtcaa tgaatatcag atatattttt
12541 tgactgtaca ttacagtga gtgtaattct tttacacctg caagtccatc ttattttattc
12601 ttgtaaatgt tccctgacaa tgtttgtaat atggctgtgt taaaaaatc atacaataaa
12661 gctgtgaccc tgagattcat gttttcctaa gataaaaaaa a

```

MASLAALALSLLLRLQLPPLPGARAQSAAGGCSFDEHYSNCGYSVALGTNGFTWEQINTWEKPMLDQAVPTG
SFMMVNSSGRASGQKAHLLLPTLKENDTHCIDFHYYFSSRDRSSPGALNVYVKVNGGPQGNPVWNVSGVVTE
GWVKAELAISTFWPHFYQVIFESVSLKGHPGYIAVDEVRLAHPCKAPHFLRLQNVEVNVGQONATFQCIAG
GKWSQHDKLWLQQWNGRDTALMVTRVNVHRRFSATVSVADTAQRSVSKYRCVIRSDGGSGVSNYAELIVKEP
PTPIAPPELLAVGATYLVWIKPNANSIIGDGPILKEVEYRTTGTWAETHIVDSPNYKLWHLDPDVEYEIRV
LLTRPGEGGTGPPGPPLTTRTKCADPVHGPQNVEIVDIRARQLTLQWEPFGYAVTRCHSYNLTVQYQYVFNQ
QQYEAEVVIQTSSHYTLRGLRPFMTIRLRLLLSNPEGRMESEELVVQTEEDVPGAVPLESIQGGPFEEKIYI
QWKPPNETNGVITLYEINYKAVGSLDPSADLSSQRGKVFKLRNETHHLFVGLYPGTTYSTIKASTAKGFGP
PVTTRIATKISAPSMPEYD TDTPLNETDTTITVMLKPAQSRGAPVSVYQLVVKEERLQKSRRADIIECFVS
PVSYRNASSLDSLHYFAAELKPANLPVTQPFTVGDNKTYNGYWNPLSPLKSYSIYFQALSKANGETKINCV
RLATKAPMGSAQVTPGTPLCLLTGASTQNSNTVEPEKQVDNTVKMAGVIAGLLMFIIILLGVMLTIKRRRN
AYSYSYYLKLAKKQKETQSGAQREMGPVASADKPTTKLSASRNDEGFSSSSQDVNGFTDGSRGELSQPTLTI
QTHPYRTC DPVEMSYPRDQFQPAIRVADLLQHITQMKRGQGYGFKEEYEALPEGQTASWDTAKEDENRNKNR
YGNII SYDHSRVRLVLVDGDPHSDYINANYIDGYHRPRHYIATQGPMQETVKDFWRMIWQENSASIVMTNL
VEVGRVKCVRYWPDDTEVYGDIVKTLIETEPLAEYVIRTFTVQKKGYHEIRELRLFHFTSWPDHGVPCYATG
LLGFVRQVKFLNPPEAGPIVVHCSAGAGRTGCFIAIDTMLDMAENEGVVDIFNCVRELRAQRVNLVQTEEQY
VVFVHDAILEACLCGNTAIPVCEFRSLYYNISRLDPQTNSSQIKDEFQTLNIVTPRVRPEDCSIGLLPRNHDK
NRSMDVLPLDRCLPFLISVDGESSNYINAALMDSHKQPAAFVVTQHPLPNTVADFWRLVFDYNCSSVVMLNE
MDTAQFCMQYWPEKTS GCGYPIQVEFVSADIDEDIHRIFRICNMARPQDGYRIVQHLQYIGWPAYRDTPPS
KRSLLKVRRLEKWQEYD GREGRTVVHCLNGGGRSGTFCAICSVCEMIQQQNIIDVFHIVKTLRNNKSNMV
ETLEQYKFVYEVALEYLSSF

FIGURE 12**TDRD1** NM_198795.1 → NP_942090.1 tudor domain-containing protein 1

```

1  gctgaggcca ggagggcgca ctggggattg gaggcgaggg aagtgcaggg cgcattcccag
61  gcggcagggc tcccagcatc ggcagtcgcc atcaccgcca gaccgcagag acagggttcgg
121 atccgcggtc ctcttgccctc tttccaggcc tcgatgagtg ttaaatacgcc atttaattgtg
181 atgtcaagaa ataattttgga agcacctcct tgtaagatga cagagccatt taatttttgag
241 aaaaatgaaa acaagcttcc accacatgag tctttaagaa gtccctggaac acttcctaac
301 caccctaatt tcaggctgaa aagctcagag aatggaaata aaaagaacaa ttttttgctt
361 tgtgagcaaa ccaaacaata tttggctagt caggaagaca attcagtttc ttcaaaccgg
421 aatggcatca acggagaagt agttggctcc aaaggagaca ggaaaaaatt gccagcagga
481 aactcagtgt caccaccaag tgctgaaagt aattcaccac ccaaagaagt gaatattaag
541 cctggaaata atgtacgtcc tgcaaaatca aaaaaactaa acaagttggg cgagaattcc
601 ttgtccataa gtaatccagg gctcttcacc tccttaggac ctctcttcg gtccacaact
661 tgccatcgct gtggcctatt tggatcgctg aggtgctctc agtgcaagca gacctactat
721 tgctccacag catgtcaaag aagagactgg tctgcacaca gcatcgtgtg caggcctggt
781 cagccaaatt tccacaact tgaaaaataa tcatctattg aaacaaagga tgtggaggta
841 aacaataaga gtgactgtcc acttggaggt actaaggaaa tagccatttg ggctgagaga
901 ataatgtttt ctgatttgag aagtctacaa ctcaagaaaa ccatggaaat aaagggtagc
961 gttaccgaat tcaaacaccc aggggacttc tacgtgcagt tatattcttc agaagtttta
1021 gaatacatga accaactctc tgccagctta aaagaaacat atgcaaattg gcatgaaaaa
1081 gactatatcc ctgttaaggg ggaagtttgt attgccaagt acactgttga tcagacctgg
1141 aacagagcaa tcatacaaaa cgttgatgtg cagcaaaaga aggcacatgt cttatatatt
1201 gattatggaa atgaagaaat aattccatta aacagaattt accacctcaa caggaacatt
1261 gacttgtttc ctcttctgtg cataaagtgc tttgtagcca atgttatccc agcagaaggg
1321 aattggagca gtgattgtat caaagctact aaaccactgt taatggagca gtactgctcc
1381 ataaagattg tcgacatctt ggaagaggaa gtgggtaccc ttgctgtaga agttgagctg
1441 ccaaattcag gaaaactttt agaccatgtg cttatagaaa tgggatattg cttgaaaccc
1501 agtggaacaag attctaagaa ggaaaatgca gatcaaagtg atcctgaaga tgttgaaaaa
1561 atgacaactg aaaacaacat tgtcgtagac aaaagtgacc taatcccaaa agtggttaact
1621 ttgaatgtag gtgatgagtt ttgtggtgtg gttgcccaaa ttcaaacacc agaagacttc
1681 ttttgtcaac aactgcaaag tggccgaaag cttgctgaac ttcaggcatc ccttagcaag
1741 tactgtgate agttgcctcc acgctctgat ttttatccag ccattgggtga tatatgttgt
1801 gctcagttct cagaggatga tcagtggtag cgtgcctctg ttttggctta cgcttctgaa
1861 gaatctgtac tggtcggata tgtagattat ggaaactttg aaatccttag tttgatgaga
1921 ctttgtccca taatcccaaa gttgttggaa ttgccaatgc aagctataaa gtgtgtacta
1981 gcaggagtaa agccatcatt aggaatttgg actccagaag ctatttgtct catgaaaaaa
2041 cttgtacaga acaaaataat cacagtgaag gtgggtgaca agttggaaaa cagttccctg
2101 gtggagctta ttgataaata cgagacgcct catgtcagtg ttagcaaagt tctcctagat
2161 gcaggctttg ctgtgggaga acagagtatg gtgacagata aaccagtgga cgtgaaagaa
2221 accagtgttc ccttgggtgt ggaaggaaaa gtaaattccat tggagtggac atgggttgaa
2281 cttggtgttg accaaacagt agatgttgtg gtctgtgtga tatatagtcc tggagaattt
2341 tattgccatg tgcttaaaga ggatgcttta aagaaactca atgatttgaa caagtcatta
2401 gcagaacact gccagcagaa gttacctaata ggtttcaagg cagagatagg acaaccttgt
2461 tgtgcttttt ttgcagggtga tggtagttgg tatcgtgctt tagtcaagga aatcttacca
2521 aatggacatg ttaaagtaca ttttgtggat tatggaaaca tcgaagaagt tactgcagat
2581 gaactccgaa tgatatcatc aacattttta aaccttccct ttcagggaat acggtgccag
2641 ttagcagata tacagtctag aaacaaacat tggctctgaag aagccataac aagattccag
2701 atgtgtgttg ctgggataaa attgcaagcc agagtgggtg aagtcactga aaatgggata
2761 ggagttgaac tcaccgatct ctccacttgt tatcccagaa taattagtga tgttctgatt
2821 gatgaacatc tgggttttaaa atctgcttca ccacataaag acttaccaaa tgacagactt
2881 gttaataaac atgagcttca agttcatgta cagggacttc aagctacctc ttcagctgag
2941 caatggaaga cgatagaatt gccagtggat aaaactatac aagcaaattg attagaaatc

```

3001 ataagcccaa acttgtttta tgctctacca aaagggatgc cagaaaatca ggaaaagctg
3061 tgcatgttga cagctgaatt attagaatac tgcaatgctc cgaaaagtcg accaccctat
3121 agaccaagaa ttggagacgc atgctgtgcc aaatacacaa gtgatgattt ttggtatcgt
3181 gcagttgttc tggggacatc agacactgat gtggaagtgc tctatgcaga ctatggaaac
3241 attgaaaccc tgctcttttg cagagtgcaa ccaatcacct ctagccacct ggcgcttccct
3301 ttccaaatta ttagatgttc acttgaagga ttaatggaat tgaatggaag ctcttctcaa
3361 ttaataataa tgctattaaa aaatttcatg ttgaatcaga atgtaatgct ttctgtgaaa
3421 ggaattacaa agaatgtcca tacagtgtca gttgagaaat gttctgagaa tgggactgtc
3481 gatgtagctg ataagctagt gacatttggt ctggcaaaaa acatcacacc tcaaaggcag
3541 agtgctttta atacagaaaa gatgtatagg atgaattgct gctgcacaga gttacagaaa
3601 caagttgaaa aacatgaaca tattcttctc ttcctcttaa acaattcaac caatcaaaat
3661 aaattttattg aaatgaaaaa actgttaaaa aaaacagcat ctcttgaggg taaaccctta
3721 tgagacagga aacagcaaa gctagcttta ggagagaaa tacagcacct ggtgttttta
3781 tttatgagaa ctttttcttt gtccactttc tctgtaatga ctttctatcc ctccgttttt
3841 gcctgcctgc cattctccta ttaggttggt ggtttttatt ttcctctaag ttccttccac
3901 caaataaata ttacgtaaaa aattcatacc aaatcaatga gaatactggc aaggaataca
3961 tagggacttt ctgctatata tgtaactttt tattacttaa aggtaccgaa ggaaggccag
4021 gtgcagtggc tcacgcccag cactttggga ggctgaggtg ggaggatccc ttgaggccag
4081 gagttcaagg ttacagtga gctatgatag gccactgcac tccagcctgg gtgacagatt
4141 ttgtcttaaa aaaaaaaaaa aaaaagttga tatgagtttt attttctgtc cgtttgaaat
4201 attttgtaat attccctgca ttctctgtcg tctgcctctt ccacataatg tcctttgctt
4261 tcatgtttgt tatcttcttt ttctgttcac tcagaggtca tcaatttctt tctctccgtc
4321 cttaattgga ttatttttct tttggccttt gggcacagag tctgacctct ggaccactct
4381 aactggagaa ggaactttat gtccctctc ctgctgtgtc cacaacctta gaaatctgta
4441 gctagatttt tgttgttata gatagaattt actgtttctg aaacccaaat acagttatca
4501 gtttaaggtt

MSVKSPFNVMsrnnleappckmtepfnfeknenklppheslrspgtlpnhpnfRLKSSengnKknnfLLCEQ
TKQYLASQEDNSVSSNPNGINGEVVGSKGDRKKLPAGNSVSPPSAESNSPPKEVNIKPGNNVRPAKSKKLNK
LVENSLSISNPGFLTSLGPPLRSTTCHRCGLFGSLRCSQCKQTYCYSTACQRRDWSAHSIVCRPVQPNFHKL
ENKSSIETKDVEVNNKSDCPLGVTKEIAIWAERIMFSDLRSLQLKKTMEIKGTVTEFKHPGDFYVQLYSSEV
LEYMNQLSASLKETYANVHEKDYPVKGEVCIKYTVDTWNRAIQNVQVQKKAHVLYIDYGNEEIIPLN
RIYHLNRNIDLFPPCAIKCFVANVIPAEGNWSSDCIKATKPLLMEQYCSIKIVDILEEEVVTFAVEVELPNS
GKLLDHVLIEMGYGLKPSGQDSKKNADQSDPEDVGKMTTENNIVVDKSDLIPKVLTLNVGDEF CGVVAHIQ
TPEDFFCQQLQSGRKLAELOASLSKYCDQLPPRSDFYPAIGDICCQFSEDDQWYRASVLAYASEESVLVGY
VDYGNFEILSLMRLCPIIPKLELPMQAIKCVLAGVKPSLGIWTPEAICLMKKLVQNKIITVKVVDKLENS
LVELIDKSETPHVSVSKVLLDAGFAVGEQSMVTDKPSDVKETSVPPLGVEGKVNPLEWTWVELGVDQTVDVV
CVIYSPGEFYCHVLKEDALKKLNLDLNKSLAEHCQQKL PNGFKAIEIGQPCCAFFAGDGSWYRALVKEILPNGH
VKVHFVDYGNIEEVTADELRMISSTFLNLPFQGI RCQLADIQSRNKHWS EEAITRFQMCVAGIKLQARVVEV
TENGIGVELTDLSTCYPRIISDVLIDEHLVLKSASPHKDL PNDRLVNKHELQVHVQGLQATSSAEQWKTIEL
PVDKTIQANVLEIISPFLFYALPKGMPENQEKLCMLTAELLEYNAPKSRPPYRPRIGDACCAYTSDDFWY
RAVVLGTSDDTDEVLYADYGNIE TLPLCRVQPI TSSHLALPFQIIRCSLEGLMELNGSSSQLIIMLLKNFML
NQNVMLSVKGITKNVHTVSVEKCSENGTVDVADKLVTFLAKNITPQRQSALNTEKMYRMNCCCTELQKQVE
KHEHILLFLLNNSTNQNKFIEMKKLLKKTASLGGKPL

FIGURE 13**UGT2B15 NM 001076.2 → NP 001067.2 UDP-glucuronosyltransferase 2B15 precursor**

```

1 aaacaacaac tggaaaagaa gcattgcata agaccaggat gtctctgaaa tggacgtcag
61 tctttctgct gatacagctc agttgttact ttagctctgg aagctgtgga aaggtgctag
121 tgtggcccac agaatacagc cattggataa atatgaagac aatcctggaa gagcttgctc
181 agaggggtca tgaggtgact gtgttgacat ctcggcttc tactctgtc aatgccagta
241 aatcatctgc tattaaatta gaagtttata ctacatcttt aactaaaaat tatttggaag
301 attctcttct gaaaattctc gatagatgga tatatgggtgt ttcaaaaaat acattttggt
361 catatttttc acaattacaa gaattgtgtt gggaatatta tgactacagt aacaagctct
421 gtaaagatgc agttttgaat aagaaactta tgatgaaact acaagagtca aagtttgatg
481 tcattctggc agatgccctt aatccctgtg gtgagctact ggctgaacta tttaacatac
541 cctttctgta cagtcttcga ttctctgttg gctacacatt tgagaagaat ggtggaggat
601 ttctgttccc tccttcctat gtacctgttg ttatgtcaga attaagtgat caaatgattt
661 tcatggagag gataaaaaat atgatacata tgctttattt tgacttttgg tttcaaattt
721 atgatctgaa gaagtgggac cagttttata gtgaagttct aggaagaccc actacattat
781 ttgagacaat ggggaaagct gaaatgtggc tcattcgaac ctattgggat tttgaatttc
841 ctgcccatt cttaccaaat gttgattttg ttggaggact tcaactgtaa ccagccaaac
901 ccctgcctaa ggaaatggaa gagtttgtgc agagctctgg agaaaatggt attgtggtgt
961 tttctctggg gtcgatgatc agtaacatgt cagaagaaag tgccaacatg attgcatcag
1021 cccttgccca gatcccacaa aaggttctat ggagatttga tggcaagaag ccaaatactt
1081 taggttccaa tactcgactg tacaagtggg taccacagaa tgaccttctt ggtcatccca
1141 aaaccaaagc ttttataact catggtggaa ccaatggcat ctatgaggcg atctaccatg
1201 ggatccctat ggtgggcatt ccctgttttg cggatcaaca tgataacatt gctcacatga
1261 aagccaaggg agcagccctc agtgtggaca tcaggaccat gtcaagtaga gatttgctca
1321 atgcattgaa gtcagtcatt aatgaccctg tctataaaga gaatgtcatg aaattatcaa
1381 gaattcatca tgaccaacca atgaagcccc tggatcgagc agtcttctgg attgagtttg
1441 tcatgcgcca caaaggagcc aagcaccttc gagtcgcagc tcacaacctc acctggatcc
1501 agtaccactc tttggatgtg atagcattcc tgctggcctg cgtggcaact gtgatattta
1561 tcatcacaaa attttgctg ttttgtttcc gaaagcttgc caaaaaagga aagaagaaga
1621 aaagagatta gttatatcaa aagcctgaag tggaatgact gaaagatggg actcctcctt
1681 tatttcagca tggagggttt taaatggagg atttcctttt tctgtgaca aaacatcttt
1741 tcacaactta ccttgtttaag acaaaattta tttccaggg atttaatacg tactttagct
1801 gaattattct atgtcaatga tttttaagct atgaaaaata caatgggggg aaggatagca
1861 tttggagata tacctaattg taaatgacga gttactggat gcagcacgcc aacatggcac
1921 atgtatacat atgtagctaa cctgcacggt gtgcacatgt accctaaaac ttaaagtata
1981 atttaaaaaa agcaaaaaaa aaaaatacaa ctcttttttt taaaccagga aggaaaatgt
2041 gaacatggaa acaacttcta gtattggatc tgaaaataaa gtgtcatcca agccataaaa
2101 aaaaaagaaa agaaaaataa aaataatata aaaccttaaa aaaa

```

```

MSLKWTSVFLLIQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRGHEVTVLTSASTLVNASKSS
AIKLEVYPTSLTKNYLEDSSLKILDRWIYGVSKNTFWSYFSQLQELCWEYYDYSNKLCKDAVLNKKLMMK
LQESKFDVILADALNPCGELLAELFNIPFLYSLRFSVGYTFEKNNGGFLFPPSYVPVVMSELSDQMI FME
RIKNMIHMLYDFWFQIYDLKKWDQFYSEVLGRPTTLFETMGKAEMWLIRTYWDFEFPRPFLPNVDFVGG
LHCKPAKPLPKEMEEFVQSSGENGIVVFSLSMISMSEESANMIASALAIQIPQKVLWRFDGKKPNTLGS
NTRLKYKWLQNDLLGHPKTKAFITHGGTNGIYEAIYHGIPMVGIPLFADQHDNIAHMKAKGAALSVDIRT
MSSRDLLNALKSVINDPVYKENVMKLSRIHHDQPMKPLDRAVFWIEFVMRHKGAHLRVAAHNLTWIQYH
SLDVIAFLLACVATVIFIITKFCLFCFRKLAKKGKKKKRD

```

FIGURE 14

ACSM1	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	4.14	2.17	2.85
BPH	3.69	0.26	0.72
LG	7.21	4.92	15.18
HG	7.22	14.08	27.47
CRPC	5.65	1.07	5.96
Meta	6.50	2.04	4.91
Normal bladder	-	0.04	0.04
PBL	-	0.05	0.05
Urinary sediment no PrCa	-	1.31	2.88
Urinary sediment PrCa	-	3.58	8.03

Boxplots TLDA analyse:




FIGURE 15

ALDH3B2	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip [®]	TLDA	TLDA
NPr	3.42	0.93	0.84
BPH	3.60	1.18	1.19
LG	6.05	10.93	17.81
HG	5.78	9.95	23.00
CRPC	4.64	3.66	9.38
Meta	5.68	1.38	2.90
Normal bladder	-	0.19	0.19
PBL	-	0.01	0.01
Urinary sediment no PrCa	-	28.66	45.41
Urinary sediment PrCa	-	42.61	118.89

Boxplots TLDA analyse:




FIGURE 16

CGREF1	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	4.32	0.78	0.79
BPH	4.25	0.24	0.41
LG	5.74	3.87	4.79
HG	6.28	6.21	6.38
CRPC	6.07	4.10	4.25
Meta	7.19	5.46	5.34
Normal bladder	-	0.08	0.08
PBL	-	0.01	0.01
Urinary sediment no PrCa	-	0.55	0.53
Urinary sediment PrCa	-	1.33	2.19

Boxplots TLDA analyse:




FIGURE 17

COMP	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	4.32	1.02	0.96
BPH	4.75	1.02	0.99
LG	5.48	4.97	8.66
HG	6.33	12.56	20.73
CRPC	6.12	9.13	31.24
Meta	5.12	0.39	3.71
pT2	5.38	-	-
pT3	6.84	-	-
Normal bladder	-	0.33	0.33
PBL	-	0.00	0.00
Urinary sediment no PrCa	-	1.00	1.00
Urinary sediment PrCa	-	1.00	67.29

Boxplots TLDA analyse:





FIGURE 18**C19orf48**

	Mean ² log Genechip®	Median (RQ) TLDA	Mean (RQ) TLDA
NPr	6.07	0.48	0.51
BPH	6.79	0.13	0.27
LG	8.56	1.81	2.07
HG	8.70	1.48	1.76
CRPC	8.49	0.72	1.12
Meta	9.53	1.80	1.56
Normal bladder	-	0.05	0.05
PBL	-	0.06	0.06
Urinary sediment no PrCa	-	1.00	1.05
Urinary sediment PrCa	-	1.10	1.33

Boxplots TLDA analyse:




FIGURE 19

DLX1	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	4.03	0.02	0.18
BPH	4.07	0.00	0.05
LG	6.10	7.62	9.17
HG	5.61	3.06	4.82
CRPC	5.88	2.35	4.03
Meta	6.51	3.42	4.72
Normal bladder	-	0.00	0.00
PBL	-	0.02	0.02
Urinary sediment no PrCa	-	0.01	0.40
Urinary sediment PrCa	-	2.21	11.06

Boxplots TLDA analyse:





FIGURE 20

GLYATL1	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	4.32	1.62	2.45
BPH	4.68	1.24	1.85
LG	7.79	33.11	37.50
HG	7.55	13.92	24.04
CRPC	6.65	6.58	12.35
Meta	6.31	1.70	5.74
Normal bladder	-	0.00	0.00
PBL	-	0.03	0.03
Urinary sediment no PrCa	-	1.38	1.91
Urinary sediment PrCa	-	1.81	3.54

Boxplots TLDA analyse:




FIGURE 21

MS4A8B	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	3.57	1.92	2.52
BPH	3.21	0.17	0.50
LG	5.63	24.14	26.07
HG	6.17	56.03	59.09
CRPC	4.89	16.43	23.79
Meta	6.27	16.10	29.12
Normal bladder	-	0.00	0.00
PBL	-	0.00	0.00
Urinary sediment no PrCa	-	3.40	6.89
Urinary sediment PrCa	-	9.39	28.46

Boxplots TLDA analyse:




FIGURE 22

NKAIN1	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	3.46	0.70	0.65
BPH	3.39	0.23	0.25
LG	5.48	8.82	15.36
HG	5.27	4.69	7.03
CRPC	5.12	2.91	5.51
Meta	5.58	3.34	5.00
Normal bladder	-	0.00	0.00
PBL	-	0.00	0.00
Urinary sediment no PrCa	-	0.00	0.23
Urinary sediment PrCa	-	1.24	1.79

Boxplots TLDA analyse:





FIGURE 23

PPFIA2	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	3.60	16.37	20.07
BPH	3.18	8.37	11.72
LG	4.48	23.66	153.69
HG	5.92	32.09	187.28
CRPC	5.71	80.95	480.83
Meta	7.40	84.10	222.19
Normal bladder	-	2.95	2.95
PBL	-	0.00	0.00
Urinary sediment no PrCa	-	158.13	197.22
Urinary sediment PrCa	-	844.53	6002.15

Boxplots TLDA analyse:





FIGURE 24

PTPRT	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	3.09	0.96	1.16
BPH	3.11	0.41	0.74
LG	5.08	6.61	20.58
HG	5.25	14.85	28.94
CRPC	6.17	6.15	40.79
Meta	6.56	14.41	38.11
Normal bladder	-	0.38	0.38
PBL	-	0.00	0.00
Urinary sediment no PrCa	-	44.63	64.48
Urinary sediment PrCa	-	200.30	2472.46

Boxplots TLDA analyse:




FIGURE 25

TDRD1	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	3.59	5.56	8.56
BPH	3.64	3.41	13.20
LG	6.60	1259.10	1575.97
HG	6.46	405.62	781.12
CRPC	7.24	669.06	917.54
Meta	6.85	343.05	567.62
Normal bladder	-	0.02	0.02
PBL	-	8.20	8.20
Urinary sediment no PrCa	-	1.53	69.46
Urinary sediment PrCa	-	36.08	103.11

Boxplots TLDA analyse:





FIGURE 26

UGT2B15	Mean ² log	Median (RQ)	Mean (RQ)
	Genechip®	TLDA	TLDA
NPr	3.51	49.36	59.65
BPH	3.63	49.18	51.20
LG	3.90	98.95	259.68
HG	3.77	39.29	1466.99
CRPC	5.90	1117.45	11490.74
Meta	4.06	76.94	162.62
Normal bladder	-	1.00	1.00
PBL	-	18.34	18.34
Urinary sediment no PrCa	-	1.00	13.52
Urinary sediment PrCa	-	42.52	84.53

Boxplots TLDA analyse:





FIGURE 27**Homo sapiens homeobox C6 (HOXC6), transcript variant 1**

```

ttttgtctgt cctggattgg agccgtccct ataaccatct agttccgagt acaaactgga
gacagaaata aatattaaag aaatcataga ccgaccaggt aaaggcaaag ggatgaattc
ctacttcact aacccttcct taccctgcca cctcgccggg ggccaggacg tcctcccaa
cgtcgccctc aattccaccg cctatgatcc agtgaggcat ttctcgacct atggagcggc
cgttgcccag aaccggatct actcgactcc cttttattcg ccacaggaga atgtcgtgtt
cagttccage cggggggcgt atgactatgg atctaattcc ttttaccagg agaaagacat
gctctcaaac tgcagacaaa acaccttagg acataacaca cagacctcaa tcgctcagga
ttttagtctt gagcagggga ggactgcgcc ccaggaccag aaagccagta tccagattta
cccctggatg cagcgaatga attcgcacag tggggtcggc tacggagcgg accggaggcg
cggccgccag atctactcgc ggtaccagac cctggaactg gagaaggaat ttcacttcaa
tcgctaccta acgcggcgcc ggcgcacga gatcgccaac gcgctttgcc tgaccgagcg
acagatcaaa atctggttcc agaaccgccg gatgaagtgg aaaaaagaat ctaatctcac
atccactctc tcggggggcg gcggaggggc caccgccgac agcctgggcg gaaaagagga
aaagcgggaa gagacagaag aggagaagca gaaagagtga ccaggactgt ccctgccacc
cctctctccc tttctccctc gctccccacc aactctcccc taatcacaca ctctgtattt
atcactggca caattgatgt gttttgatcc cctaaaacaa aattagggag tcaaactgtg
acctgaaagt cagctctgga cccctccct caccgcacaa ctctctttca ccacgcgcct
cctcctcctc gctcccttgc tagctcgttc tcggcttgtc tacaggccct tttcccgcctc
caggccttgg gggctcggac cctgaactca gactctacag attgccctcc aagtgaggac
ttggctcccc cactccttcg acgccccac ccccgcccc cgtgcagaga gccggctcct
gggcctgctg gggcctctgc tccagggcct cagggcccg cctggcagcc ggggagggcc
ggaggcccaa ggagggcgcg ccttggtccc acaccaacc ccagggcctc ccgcagtcct
ctgcctagcc cctctgcccc agcaaatgcc cagcccaggc aaattgtatt taaagaatcc
tggggggtcat tatggcattt tacaaactgt gaccgtttct gtgtgaagat ttttagctgt
atgtgtggtc tctgtattta tatttatgtt tagcaccgtc agtggtccta tccaatttca
aaaaaggaaa aaaaagaggg aaaattacaa aaagagagaa aaaaagtga tgacgtttgt
ttagccagta ggagaaaata aataaataaa taaatccctt cgtgttacc tcctgtataa
atccaacctc tgggtccggt ctogaatatt taataaaact gatattattt ttaaaacttt
a

```

```

MNSYFTNP SLSCHLAGGQDVL P NVALNSTAYDPVRH FSTYGA AVAQNR IYSTPFYSPQ ENVVFSSSRG PYDY
GSNSFYQE K DMLSNC RQNTLGHNTQTSIAQDFSSEQGR TAPQDQKASI QIYPWMQRMNSHSGVGYGADRRRG
RQIYSRYQTLELEKEFHFNRYL TRRRRIEIANALCLTERQIKIWFQNR RMKWKESNL TSTLSGGGGGATAD
SLGGKEEKREETEEEEKQKE

```

FIGURE 28**Homo sapiens secreted frizzled-related protein 2 (SFRP2)**

```

caacggetca ttctgctccc ccgggtcgga gccccccgga gctgcgcgcg ggcttgacgc
gcctcgcccc cgctgtcctc ccgggtgtccc gcttctccgc gccccagccg ccggctgcca
gcttttcggg gccccgagtc gcacccagcg aagagagcgg gcccgggaca agctcgaact
ccggccgcct cgcccttccc cggctccgct ccctctgccc cctcggggte gcgcgcccac
gatgctgcag ggccctggct cgctgtctgt gctcttctc gcctcgcaact gctgcctggg
ctcggcgcgcg gggctcttcc tctttggcca gcccgaactc tcctacaagc gcagcaattg
caagcccata cctgccaacc tgcagctgtg ccacggcata gaataccaga acatgcggct
gcccacactg ctgggccacg agaccatgaa ggaggtgctg gagcaggccg gcgcttgat
cccgtgggtc atgaagcagt gccacccgga caccaagaag ttctgtgtgt cgtcttctgc
ccccgtctgc ctcatgacc tagacgagac catccagcca tgccactcgc tctgcgtgca
ggtgaaggac cgctgcgccc cggctcatgt cgcttctggc ttccctggc ccgacatgct
tgagtgcgac cgtttcccc aggacaacga cctttgcata cccctcgcta gcagcgacca
cctcctgcca gccaccgagg aagctccaaa ggtatgtgaa gcctgcaaaa ataaaaatga
tgatgacaac gacataatgg aaacgctttg taaaaatgat tttgactga aaataaaagt
gaaggagata acctacatca accgagatac caaaatcata ctggagacca agagcaagac
catttacaag ctgaacggtg tgtccgaaag ggacctgaag aaatcggtgc tgtggctcaa
agacagcttg cagtgcacct gtgaggagat gaacgacata aacgcgcctt atctggctat
gggacagaaa cagggtgggg agctgggtgt cacctcgggtg aagcgggtggc agaaggggca
gagagagttc aagcgcattc cccgcagcat ccgcaagctg cagtgtagat cccggcatcc
tgatggctcc gacaggcctg ctccagagca cggctgacca tttctgctcc gggatctcag
ctcccgttcc ccaagcacac tcctagctgc tccagtctca gcctgggcag cttccccctg
ccttttgca cgtttgcatcc ccagcatttc ctgagttata aggccacagg agtggataga
tgttttcacc taaaggaaaa gccacccga atctttaga aatattcaaa ctaataaaat
catgaatatt ttatgaagt taaaaaatag ctacttttaa agctagtttt gaatagggtgc
aactgtgact tgggtctggg tgggtgttgt ttgttgtttt gactcagctg attttcaact
ccactgagg ttgtcataac atgcaaattg cttcaatttt ctctgtggcc caaacttgtg
ggtcacaac cctgttgaga taaagctggc tgttatctca acatcttcat cagctccaga
ctgagactca gtgtctaagt cttacaacaa ttcattcatt tataccttca atgggaactt
aaactgttac atgtatcaca ttccagctac aatacttcca tttattagaa gcacattaac
catttctata gcatgatttc ttcaagtaaa aggcaaaaga tataaatttt ataattgact
tgagtacttt aagccttggt taaaacattt ctacttaac ttttgcaaat taaaccattt
gtagcttacc tgtaatatata atagtagttt accttataaa gttgtaaaaa tattgcttta
accaacactg taaatatttc agataaacat tatattcttg tatataaact ttacatcctg
ttttacctat aaaaaaaaaa aaaaa

```

```

MLQGPGLLLLLFLASHCCLGSARGLFLFGQPDFSYKRSNCKPIPANLQLCHGIEYQNMRLPNLLGHETMKE
VLEQAGAWIPLVMKQCHPDTKKFLCSLFAPVCLDDLDLDTIQPCHSLCVQVKDRCAVMSAFGFPWPDMLEC
DRFPQDNDLCIPLASSDHLPLATEEAPKVCEACKNKNDNDNDIMETLCKNDFALKIKVKEITYINRDTKII
LETSKSTIYKLVNSERDLKKSVLWLKDSLQCTCEEMNDINAPYLVMGQKQGGELVITSVKRWQKGQREFK
RISRSIRKLQC

```

FIGURE 29**Homo sapiens homeobox D10 (HOXD10)**

cggggaatgt tttcctagag atgtcagcct acaaaggaca caatctctct tcttcaaatt
 cttcccaaaa atgtcctttc ccaacagctc tcctgctgct aatacttttt tagtagattc
 cttgatcagt gcctgcagga gtgacagttt ttattccagc agcgccagca tgtacatgcc
 accacctagc gcagacatgg ggacctatgg aatgcaaacc tgtggactgc tcccgtctct
 ggccaaaaga gaagtgaacc accaaaatat gggatatgaat gtgcatcctt atatacctca
 agtagacagt tggacagatc cgaacagatc ttgtcgaata gagcaacctg ttacacagca
 agtccccact tgctccttca ccaccaacat taaggaagaa tccaattgct gcatgtattc
 tgataagcgc aacaaactca tttcggccga ggtcccttcg taccagaggc tggccctga
 gtcttgtccc gttgagaacc ctgaggttcc cgtccctgga tatttttagac tgagtcagac
 ctacgccacc gggaaaaccc aagagtacaa taatagcccc gaaggcagct ccactgtcat
 gctccagctc aaccctcgtg gcgcggccaa gcgcagctc tccgctgcc agctgcagat
 ggaaaagaag atgaacgagc ccgtgagcgg ccaggagccc accaaagtct cccaggtgga
 gagccccgag gccaaaggcg gccttcccga agagaggagc tgcttggtg aggtctccgt
 gtccagtcct gaagtgcagg agaaggaaag caaagaggaa atcaagtctg atacaccaac
 cagcaattgg ctactgcaa agagtggcag aaagaagagg tgcccttaca ctaagcacca
 aacgctggaa ttagaaaaag agttcttgtt caatatgtac ctaccccgcg agcgccgct
 agagatcagt aagagcgta acctcaccga caggcaggtc aagatttggt ttcaaaaccg
 ccgaatgaaa ctcaagaaga tgagccgaga gaaccggatc cgagaactga ccgccaacct
 cacgttttct taggtctgag gccgggtctga ggccggtcag aggccaggat tggagagggg
 gcaccgcgtt ccaggggcca gtgctggagg actgggaaag cggaaacaaa accttcaccg
 ctctttgttt gttgttttgt tgtattttgt tttcctgcta gaatgtgact ttgggggtcat
 tatgttcgtg ctgcaagtga tctgtaatcc ctatgagtat atatatatat atatatatat
 atatatataa acttagcacg tgtaatttat tattttttca tcgtaatgca gggtaactat
 tattgcgcat tttcatttgg gtcttaactt attggaactg tagagcatcc atccatccat
 catccagca atgtgacttt ttcattgtct tcctaacaca aaaggctctat gtgtgtggtt
 agtccatgaa ctcatggcat tttgaataca tccagtactt taaaaatgac atatatattt
 aaaaaaaaaa gattaagaaa acccacaagt tggaggggagg gggacttaaa aagcacatta
 caatgtatct tttcacaaat gaatttagca gttgtccttg gtgagatggg atattggcga
 tttatgcctt gtagcctttc ccttggtggt catctgtggt ttggtagaag tacaacagca
 acctgtcctt tctgtgcatg ttctggtcgc atgtataatg caataaactc tggaaatgag
 ttcaaaaaaa aaaa

MSFPNSSPAANTFLVDSLISACRSDSFYSSSASMYMPPPSADMGTYGMQTCGLLPSLAKREVNHQNMG
 MNVHPYIPQVDSWTDPNRSCRIEQPVTQQVPTCSFTTNIKEESNCCMYSDKRNKLISAEVPSYQRLVP
 ESCPVENPEVPVPGYFRLSQTATGKTQEYNNSPESGSTVMLQLNPRGAAKPQLSAAQLQMEKKMNEP
 VSGQEPKTVSQVESPEAKGGLPEERSCLAEVSVSSPEVQEKESKEEIKSDTPTS NWLTAKSGRKKRCP
 YTKHQ TLELEKEFLFNMYLTRERRLEISKSVNLTD RQVKIWFQNR RMKLKKMSRENRI RELTANLTF S

FIGURE 30**Homo sapiens RAR-related orphan receptor B (RORB)**

```

tctctcccct ctctttctct ctcgctgctc ccttcctccc tgtaactgaa cagtgaaaat
tcacattgtg gatccgctaa caggcacaga tgtcatgtga aaacgcacat gctctgccat
ccacaccgcc tttctttctt ttctttctgt ttcttttttt ccccttggtt ccttctccct
cttctttgta actaacaaaa ccaccaccaa ctcctcctcc tgctgctgcc cttcctcctc
ctcctcagtc caagtgatca caaaagaaat cttctgagcc ggaggcgggt gcatttttta
aaaagcaagc acattggaga gaaagaaaaa gaaaaacaaa accaaaacaa aaccagggca
ccagacagcc agaacatttt tttttcaccc ttcttgaaaa caaacaaaca aacaaacaat
catcaaaaca gtcaccacca acatcaaaac tgtaaacata ggggcggcgg cggcaaacgt
caccctgcag ccacggcgct cgcctaaagg gatggttttc tcggcagagc agctcttcgc
cgaccacctt cttcactcgt gctgagcggg atttttgggc tctccggggg tcgggctggg
agcagcttca tgactacgcg gagcgggaga gcggccacac catgcgagca caaattgaag
tgataccatg caaaatttgt ggcgataagt cctctgggat ccactacgga gtcatcacat
gtgaaggctg caagggatct tttaggagga gccagcagaa caatgcttct tattcctgcc
caaggcagag aaactgttta attgacagaa cgaacagaaa ccgttgccaa cactgccgac
tgcagaagtg tcttgcccta ggaatgtcaa gagatgctgt gaagtttggg aggatgtcca
agaagcaaa ggcagacctg tatgctgagg tgcagaagca ccagcagcgg ctgcaggaac
agcggcagca gcagagtggg gaggcagaag cccttgccag ggtgtacagc agcagcatta
gcaacggcct gagcaacctg aacaacgaga ccagcggcac ttatgccaac gggcacgtca
ttgacctgcc caagtctgag ggttattaca acgtcgattc cggtcagccg tcccctgac
agtcaggact tgacatgact ggaatcaaac agataaagca agaacctatc tatgacctca
catccgtacc caacttgttt acctatagct ctttcaacaa tgggcagtta gcaccaggga
taaccatgac tgaaatcgac cgaattgcac agaacatcat taagtcccat ttggagacat
gtcaatacac catggaagag ctgcaccagc tggcgtggca gaccacacc tatgaagaaa
ttaaagcata tcaaagcaag tccagggaag cactgtggca acaatgtgcc atccagatca
ctcacgccat ccaatacgtg gtggagtttg caaagcggat aacaggcttc atggagctct
gtcaaaatga tcaaattcta cttctgaagt caggttgctt ggaagtgggt ttagtgagaa
tgtgccgtgc cttcaaccca ttaaacaaca ctgttctgtt tgaaggaaaa tatggaggaa
tgcaaatgtt caaagcctta ggttctgatg acctagtga tgaagcattt gactttgcaa
agaatttgtg ttcttgagc ctgaccgagg aggagatcgc tttgttctca tctgctgttc
tgatatctcc agaccgagcc tggcttatag aaccaaggaa agtccagaag cttcaggaaa
aaattttatt tgcaattcaa catgtgattc agaagaatca cctggatgat gagaccttgg
caaagttaat agccaagata ccaaccatca cggcagtttg caacttgcac ggggagaagc
tgcaggtatt taagcaatct catccagaga tagtgaatac actgtttcct cgttataca
aggagctctt taatcctgac tgtgccaccg gctgcaaatg aaggggacaa gagaactgtc
tcatagtcat ggaatgcatc accattaaga caaaagcaat gtgttcatga agacttaaga
aaaatgtcac tactgcaaca ttaggaatgt cctgcactta atagaattat ttttcaccgc
tacagtttga agaattgaaa tatgcacctg agtggggctc ttttatttgt ttgtttgttt
ttgaaatgac cataaatata caaatatagg aactgggtg ttatcctttt ttaatttta
ttcgggtatg ttttgggaga caactgttta tagaatttta ttgtagatat atacaagaaa
agagcggtag tttacatgat tacttttctt gttgattgtt caaatataat ttaagaaaat
tccacttaat aggccttacct atttctatgt ttttaggtag ttgatgcatg tgtaaatttg

```

tagctgtcctt ggaaagtact gtgcatgtat gtaataagta tataatatgt gagaatatta
tatatgacta ttacttatac atgcacatgc actgtggcctt aaataccata cctactagca
atggagggttc agtcaggctc tcttctatga tttaccttct gtgttatatg ttacctttat
gtagacaat caggatTTTTG ttttcccagc cagagttttc atctatagtc aatggcagga
cggtaccaac tcagagttaa gtctacaaag gaataaacat aatgtgtggc ctctatatac
aaactctatt tctgtcaatg acatcaaagc cttgtcaaga tggttcatat tgggaaggag
acagtatttt aagccatttt cctgtttcaa gaattaggcc acagataaca ttgcaaggtc
caagactttt ttgaccaaac agtagatatt ttctattttt caccagaaca cataaaaaa
ctttttttct tttggatttc tggttgtgaa acaagcttga tttcagtgtc tattgtgtct
tcaactgaaa aatacaatct gtggattatg actaccagca atttttttct aggaaagtta
aaagaataaa tcagaaccca gggcaacaat gccatttcat gtaaaccattt tctctctcac
catgttttgg caagaaaagg tagaaagaga agaccagag tgaagaagta attctttata
ttcctttctt taatgtattt gtaggaaaa gtggcaataa agggggaggc atattataaa
atgctataat ataaaaatgt agcaaaaact tgacagacta gaaaaaaaa gatctgtgtt
attctaggga actaatgtac ccaaagcca aaactaattc ctgtgaagtt tacagttaca
tcatccattt accctagaat tattttttta gcaactttta gaaataaaga atacaactgt
gacattagga tcagagattt tagacttcct tgtacaaatt ctcacttctc cacctgtc
ccaatgaaat taatcataag aaaagcatat attccaagaa atttgttctg cctgtgtcct
ggaggcctat acctctgtta ttttctgata caaataaaa cttaaaaaaa agaaaacaag
ctaa

MRAQIEVIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQNNASYSCPRQRNCLIDRTNRNRCQHCRLO
KCLALGMSRDAVKFGRMSKKQRDSLYAEVQKHQQRLQEQRQQQSGEAEALARVYSSSISNGLSNLNNE
TSGTYANGHVIDLPKSEGYYNVDGQSPDQSGGLDMTGKQIKQEPIYDLTSVPNLFYSSFNNGQLA
PGITMTEIDRIAQNIKSHLETCQYTMELHQLAWQHTYEEIKAYQSKSREALWQQCAIQITHAIQY
VVEFAKRITGFMELCQNDQILLKSGCLEVVLRMCRAFNPNNNTVLFEGKYGGMMQMFALGSDDLNVN
EAFDFAKNLCSLQLTEEEIALFSSAVLISPDRAWLIEPRKVQKLQEKIYFALQHVQKNHLDDETLAK
LIAKIPTITAVCNLHGEKLQVFKQSHPEIVNTLFPPLYKELFNPDCATGCK

FIGURE 31**Homo sapiens ribonucleotide reductase M2 (RRM2)**

```

aggcgcagcc aatgggaagg gtcggaggca tggcacagcc aatgggaagg gccggggcac
caaagccaat gggaagggcc gggagcgcgc ggcgcgggag atttaaaggc tgctggagtg
aggggtcgcc cgtgcaccct gtcccagccg tcctgtcctg gctgctcgct ctgcttcgct
gcgcctccac tatgctctcc ctccgtgtcc cgctcgcgcc catcacggac ccgcagcagc
tgcagctctc gccgctgaag gggctcagct tggctgacaa ggagaacacg ccgcggcccc
tgagcgggac ccgcgtcctg gccagcaaga ccgcgaggag gatcttccag gagcccacgg
agccgaaaac taaagcagct gccccggcg tggaggatga gccgctgctg agagaaaacc
cccgccgctt tgtcatcttc cccatcgagt accatgatat ctggcagatg tataagaagg
cagaggcttc cttttggacc gccgaggagg tggacctctc caaggacatt cagcactggg
aatccctgaa acccgaggag agatatttta tatcccatgt tctggctttc tttgcagcaa
gcgatggcat agtaaatgaa aacttgggtg agcgatttag ccaagaagtt cagattacag
aagcccgtg tttctatggc ttccaaattg ccatggaaaa catacattct gaaatgtata
gtcttcttat tgacacttac ataaaagatc ccaaagaaag ggaatttctc ttcaatgccaa
ttgaaacgat gccttgtgtc aagaagaagg cagactgggc cttgcgctgg attggggaca
aagaggctac ctatggtgaa cgtgtttag cctttgctgc agtgggaaggc attttctttt
ccggttcttt tgcgtcgata ttctggctca agaaacgagg actgatgcct ggctcacat
tttctaata gaactattagc agagatgagg gtttacactg tgattttgct tgcctgatgt
tcaaacacct ggtacacaaa ccatcgagg agagagtaag agaaataatt atcaatgctg
ttcggataga acaggagttc ctactgagg ccttgccctg gaagctcatt gggatgaatt
gcactcta at gaagcaatac attgagtttg tggcagacag acttatgctg gaactgggtt
ttagcaaggt tttcagagta gagaacccat ttgactttat ggagaatatt tctactggaag
gaaagactaa cttcttttgag aagagagtag gcgagtatca gaggatggga gtgatgtcaa
gtccaacaga gaattctttt accttggatg ctgacttcta aatgaactga agatgtgccc
ttacttggct gatttttttt ttccatctca taagaaaaat cagctgaagt gttaccaact
agccacacca tgaattgtcc gtaatgttca ttaacagcat ctttaaaact gtgtagctac
ctcacaacca gtccgtgtctg tttatagtgc tggtagtata accttttgcc agaaggcctg
gctggctgtg acttaccata gcagtgacaa tggcagtctt ggctttaaag tgaggggtga
ccctttagt agcttagcac agcgggatta aacagtcctt taaccagcac agccagttaa
aagatgcagc ctactgctt caacgcagat tttaatgttt acttaaatat aaacctggca
ctttacaaac aaataaacat tgtttgtact cacaaggcga taatagcttg atttatttgg
tttctacacc aaatacatte tcctgaccac taatgggagc caattcacia ttcactaagt
gactaaagta agttaactt gtgtagacta agcatgtaat ttttaagttt tattttaatg
aattaaaata tttgttaacc aactttaaag tcagtcctgt gtatacctag atattagtca
gttggtgcca gatagaagac aggttgtgtt tttatcctgt ggcttggtga gtgtcctggg
attctctgcc ccctctgagt agagtgttgt gggataaagg aatctctcag ggcaaggagc
ttcttaagtt aaatcactag aaatttaggg gtgatctggg ccttcatatg tgtgagaagc
cgtttcattt tatttctcac tgtattttcc tcaacgtctg gttgatgaga aaaaattctt
gaagagtttt catatgtggg agctaaggta gtattgtaaa atttcaagtc atccttaaac
aaaatgatcc acctaaagatc ttgccctgt taagtgggtga aatcaactag aggtggttcc
tacaagttgt tcattctagt tttgtttggg gtaagtaggt tgtgtgagtt aattcattta
tatttactat gtctgttaaa tcagaaattt tttattatct atgttcttct agattttacc
tgtagttcat acttcagtca ccagtgctt tattctggca ttgtctaaat ctgagcattg

```

tctaggggga tcttaaaactt tagtaggaaa ccatgagctg ttaatacagt ttccattcaa
atattaattt cagaatgaaa cataatTTTT tttttttttt ttgagatgga gtctcgctct
gttgcccagg ctggagtgca gtggcgcat tttggctcac tgtaacctcc atctcctggg
ttcaagcaat tctcctgtct cagcctccct agtagctggg actgcaggta tgtgctacca
cacctggcta atttttgtat ttttagtaga gatggagttt caccatattg gtcaggctgg
tcttgaactc ctgacctcag gtgatccacc cacctcggcc tcccaaagtg ctgggattgc
aggcgtgata aacaaatatt cttaataggg ctactttgaa ttaatctgcc tttatgtttg
ggagaagaaa gctgagacat tgcataaag atgatgagag ataaatgttg atcttttggc
cccatttggt aattgtattc agtatttgaa cgctgcctg tttattgtta gttttcttca
tcatttattg tatagacaat ttttaaactc ctgtaatatg atacattttc ctatctttta
agttattgtt acctaaagt aatccagatt atatggctc tatatgtgta caacattaaa
atgaaaggct ttgtcttgca ttgtgaggta caggcggaag ttggaatcag gttttaggat
tctgtctctc attagctgaa taatgtgagg attaacttct gccagctcag accatttctc
aatcagttga aagggaaca agtatttcag tctcaaaatt gaataatgca caagtcttaa
gtgattaaaa taaaactgtt cttatgtcag tttcaaaaaa aaaaaaaaaa aa

MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTPEPKTKAAAPGVED
EPLLRENPRRFVIFPIEYHDIWQMYKKAEEASFMTAEVDLSKDIQHWESLKPEERYFISHVLAFFAASD
GIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLIDTYIKDPKEREFLFNAIETMPCVKKKA
DWALRWIGDKEATYGERVVAFAAVEGIFFSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLM
FKHLVHKPSEERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGF SKVFRVEN
PFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTENSFTLDADF

FIGURE 32**Homo sapiens transglutaminase 4 (prostate) (TGM4)**

```

ggaccgactg tgtggaagca ccaggcatca gagatagagt cttccctggc attgcaggag
agaatctgaa gggatgatgg atgcatcaaa agagctgcaa gttctccaca ttgacttctt
gaatcaggac aacgccgttt ctcaccacac atgggagttc caaacgagca gtctgtgttt
ccggcgagga caggtgtttc acctgcggtt ggtgctgaac cagcccctac aatcctacca
ccaactgaaa ctggaattca gcacagggcc gaatcctagc atcgccaaac acaccctggt
ggtgctcgac ccgaggacgc cctcagacca ctacaactgg caggcaaccc ttcaaaatga
gtctggcaaa gaggtcacag tggctgtcac cagttccccc aatgccatcc tgggcaagta
ccaactaaac gtgaaaactg gaaaccacat ccttaagtct gaagaaaaca tcctatacct
tctcttcaac ccatggtgta aagaggacat ggttttcatg cctgatgagg acgagcgcaa
agagtacatc ctcaatgaca cgggctgcca ttacgtgggg gctgccagaa gtatcaaagt
caaaccctgg aactttggtc agtttgagaa aaatgtcctg gactgctgca tttccctgct
gactgagagc tcctcaagc ccacagatag gagggacccc gtgctggtgt gcagggccat
gtgtgctatg atgagctttg agaaaggcca gggcgctgctc attgggaatt ggactgggga
ctacgaaggt ggcacagccc catacaagtg gacaggcagt gcccgatcc tgcagcagta
ctacaacacg aagcaggctg tgtgcttttg ccagtgtgtg gtgtttgctg ggatcctgac
tacagtgtgt agagcgttgg gcatcccagc acgcagtgtg acaggcttcg attcagctca
cgacacagaa aggaacctca cggtgagcac ctatgtgaat gagaatggcg agaaaatcac
cagtatgacc cagcactctg tctggaattt ccatgtgtgg acggatgcct ggatgaagcg
accgatctg cccaagggtt acgacggctg gcaggctgtg gacgcaacgc cgcaggagcg
aagccagggt gtcttctgct gtgggccatc accactgacc gccatccgca aaggtgacat
ctttattgtc tatgacacca gattcgtctt ctcagaagtg aatggtgaca ggctcatctg
gttgggtgaag atggtgaatg ggcaggagga gttacacgta atttcaatgg agaccacaag
catcgggaaa aacatcagca ccaaggcagt gggccaagac aggcggagag atatcaccta
tgagtacaag tatccagaag gtcctcttga ggagaggcag gtcatggatc atgccttcct
ccttctcagt tctgagaggg agcacagacg acctgtaaaa gagaactttc ttcacatgtc
ggtacaatca gatgatgtgc tgcctggaaa ctctgttaat ttcaccgtga tttttaaag
gaagaccgct gcctacaga atgtcaacat cttgggctcc tttgaactac agttgtacac
tggcaagaag atggcaaaac tgtgtgacct caataagacc tcgcagatcc aaggtcaagt
atcagaagtg actctgacct tggactccaa gacctacatc aacagcctgg ctatattaga
tgatgagcca gttatcagag gtttcatcat tgcggaaatt gtggagtcta aggaaatcat
ggcctctgaa gtattcacgt ctttccagta ccctgagttc tctatagagt tgcctaacac
aggcagaatt ggccagctac ttgtctgcaa ttgtatcttc aagaataccc tggccatccc
tttgactgac gtcaagttct ctttgaaaag cctgggcac tctcactac agacctctga
ccatgggacg gtgcagcctg gtgagaccat ccaatcccaa ataaaatgca cccaataaaa
aactggaccc aagaaattta tcgtcaagtt aagttccaaa caagtgaaag agattaatgc
tcagaagatt gttctcatca ccaagtagcc ttgtctgatg ctgtggagcc ttagttgaga
tttcagcatt tcctaccttg tgcttagctt tcagattatg gatgattaaa tttgatgact
tatatgaggg cagattcaag agccagcagg tcaaaaaggc caacacaacc ataagcagcc
agaccacaaa ggccagggtc tgtgctatca cagggtcacc tcttttacag ttagaaacac
cagccgaggg cacagaatcc catccctttc ctgagtcatg gcctcaaaaa tcagggccac
cattgtctca attcaaatcc atagatttcg aagccacaga gtctctccct ggagcagcag

```

actatgggca gccagtgct gccacctgct gacgaccctt gagaagctgc catatcttca
ggccatgggt tcaccagccc tgaaggcacc tgtcaactgg agtgctctct cagcactggg
atgggcctga tagaagtga ttctcctcct attgcctcca ttctcctctc tctatccctg
aaatccagga agtccctctc ctggtgctcc aagcagtttg aagcccaatc tgcaaggaca
tttctcaagg gccatgtggt tttgcagaca accctgtcct caggcctgaa ctcaccatag
agacccatgt cagcaaacgg tgaccagcaa atcctcttcc cttattctaa agctgccct
tgaggagactc cagggagaag gcattgcttc ctccctgggtg tgaactcttt ctttggtatt
ccatccacta tcctggcaac tcaaggctgc ttctgttaac tgaagcctgc tccttcttgt
tctgccctcc agagatttgc tcaaatgatc aataagcttt aaattaaact ctacttcaaa
aaaaaaaaa aaaaaaaaaa aaaaaaa

MMDASKELQVLHIDFLNQDNAVSHHTWEFQTSSPVFRRGQVFHLRLVLNQPLQSYHQLKLEFSTGPNP
SIAKHTLVVLDPRTPSDHYNWQATLQNESGKEVTVAVTSSPNAILGKYQLNVKTGNHILKSEENILYL
LFNPWCKEDMVFMPEDEDERKEYILNDTGCHYVGAARSIKCKPWNFGQFEKNVLDCCISLLTESSLKPT
DRRDPVLVCRAMCAMMSFEKGQGV LIGNWTGDYEGGTAPYKWTGSAPILQQYYNTKQAVCFGQCWVFA
GILTTVLRALGIPARSVTGFD SAHDTERNLTVDTYVNENGEKITSMT HDSVWNFHVWTD AWMKRPDLP
KGYD GWQAVDATPQERSQGV FCCGPSPLTAIRKGDIFIVYDTRFVFEVNGDR LIWLVKMVNGQEELH
VISMETTSIGKNISTKAVGQDRRRDITYEYKYPEGSSEERQVMDHAFLLLSSEREHRRPVKENFLHMS
VQSDDVLLGNSVNFTVILKRKTAALQNVN ILGSFELQLYTGKKMAKLCDLNKTSQIQGVSEVTLTLD
SKTYINSLAILDDEPVIRGFIIAEIVESKEIMASEVFTSFQYPEFSIELPNTGRIGQLLVCNCIFKNT
LAIPLTDVKFSLESLSLQTS DHGTVQPGETIQSQIKCTPIKTGPKKFIVKLSSKQVKEINAQKIV
LITK

FIGURE 33**Homo sapiens snail homolog 2 (Drosophila) (SNAI2)**


```

agttcgtaaa ggagccgggt gacttcagag gcgcgggccc gtccgtctgc cgcacctgag
cacggcccct gcccgagcct ggcccgcgc gatgctgtag ggaccgccgt gtccctccgc
cggaccgtta tccgcgcgg gcgcccgcga gaccgcgtgg caagatgccg cgctccttcc
tgggtcaagaa gcatttcaac gcctccaaaa agccaaacta cagcgaactg gacacacata
cagtgattat ttcccgtat ctctatgaga gttactccat gcctgtcata ccacaaccag
agatcctcag ctcaggagca tacagcccca tcaactgtgtg gactaccgct gctccattcc
acgcccagct acccaatggc ctctctcctc ttcccgata ctccatctct ttggggcgag
tgagtccccc tcctccatct gacacctcct ccaaggacca cagtggctca gaaagcccca
ttagtgatga agaggaaaga ctacagtcca agctttcaga ccccatgcc attgaagctg
aaaagtttca gtgcaattta tgcaataaga cctattcaac tttttctggg ctggccaaac
ataagcagct gcactgcgat gccagtgcta gaaaatcttt cagctgtaaa tactgtgaca
aggaatatgt gagcctgggc gccctgaaga tgcataatcg gaccacaca ttacctgtg
tttgcaagat ctgcggcaag gcgttttcca gaccctgggt gcttcaagga cacattagaa
ctcacacggg ggagaagcct ttttcttgcc ctactgcaa cagagcattt gcagacaggt
caaatctgag ggctcatctg cagaccctatt ctgatgtaaa gaaataccag tgcaaaaact
gtccaaaaac cttctccaga atgtctctcc tgcacaaaca tgaggaaatct ggctgctgtg
tagcacactg agtgacgcaa tcaatgttta ctgaacaga atgcatttct tcactccgaa
gccaaatgac aaataaagtc caaaggcatt ttctcctgtg ctgaccaacc aaataatatg
tatagacaca cacacatatg cacacacaca cacacacacc cacagagaga gagctgcaag
agcatggaat tcatgtgttt aaagataatc ctttccatgt gaagtttaaa attactatat
atttgctgat ggctagattg agagaataaa agacagtaac ctttctcttc aaagataaaa
tgaaaagcac attgcatctt ttcttcctaa aaaaatgcaa agatttacat tgctgccaaa
tcatttcaac tgaaaagaac agtattgctt tgtaatatag tctgtaatat gatitcccat
aggaagagat ctgccagacg cgaactcagg tgccttaaaa agtattccaa gtttactcca
ttacatgtcg gttgtctggt tgccattggt gaactaaagc ctttttttga ttacctgtag
tgctttaaag tatattttta aaaggaggga aaaaaataac aagaacaaaa cacaggagaa
tgtattaaaa gtatttttgt tttgttttgt ttttgccaat taacagtatg tgccttgggg
gaggagggaa agattagctt tgaacattcc tggcgcatgc tccattgtct tactatttta
aaacatttta ataatttttg aaaattaatt aaagatggga ataagtcaa aagaggattc
ttacaaattc attaatgtac ttaaaactatt tcaaatgcat accacaaatg caataataca
ataccccttc caagtgcctt tttaaattgt atagttgatg agtcaatgta aatttgtgtt
tatttttata tgattgaatg agttctgtat gaaactgaga tgttgtctat agctatgtct
ataaacaacc tgaagacttg tgaaatcaat gtttcttttt taaaaaaca ttttcaagtt
ttttttacaa taaacagttt tgatttataaa tctcgtttgt atactatttt cagagacttt
acttgcttca tgattagtac caaaccactg tacaagaat tgtttgtaa caagaaaaaa


```

a


MPRSFLVKKHFNASKKPNYSELDHTVII SPYLYESYSMPVIPQPEILSSGAYSPITVWTTAAPFHAQLP
NGLSPLSGYSSSLGRVSPPPPSDTSSKDHSGSESPISDEEERLQSKLSDPHAIEAEKFQCNLCNKTYSTF
SGLAKHKQLHCDAQSRKSFCKYCDKEYVSLGALKMHIRTHTLPCVCKICGKAFSRPWLLQGHIRTHTGE
KPFSCPHCNRAFADRSNLRAHLQTHSDVKKYQCKNCSKTFSRMSLLHKHEESGCCVAH

FIGURE 34


	Median (RQ)	Mean (RQ)	Mean ² log
	TLDA	TLDA	Genechip®
NP	0,79	0,66	
LG	4,56	7,60	5,21
HG	5,98	6,24	5,22
CRPC	4,87	5,71	5,50
Meta	6,05	9,13	6,03

FIGURE 35


	Median (RQ)	Mean (RQ)	Mean ² log
	TLDA	TLDA	Genechip®
NP	1,00	0,99	
LG	0,50	0,61	7,01
HG	0,70	0,75	7,72
CRPC	0,37	0,68	6,92
Meta	0,02	0,09	4,36

FIGURE 36

	Median (RQ)	Mean (RQ)	Mean ² log
	TLDA	TLDA	Genechip®
NP	1,00	1,02	
LG	0,23	0,35	4,93
HG	0,26	0,47	4,97
CRPC	0,09	0,20	4,92
Meta	0,02	0,03	3,62


FIGURE 37

	Median (RQ)	Mean (RQ)	Mean ² log
	TLDA	TLDA	Genechip®
NP	0,81	0,86	
LG	0,31	0,43	5,60
HG	0,18	0,74	5,50
CRPC	0,50	1,24	6,56
Meta	0,10	1,27	6,13


FIGURE 38

	Median (RQ)	Mean (RQ)	Mean ² log
	TLDA	TLDA	Genechip®
NP	1,08	1,24	
LG	6,06	7,49	4,83
HG	7,16	12,38	5,23
CRPC	15,10	28,63	5,14
Meta	25,60	68,92	5,70

FIGURE 39



	Median (RQ)	Mean (RQ)	Mean ² log
	TLDA	TLDA	Genechip®
NP	0,89	0,63	
LG	0,01	0,03	7,53
HG	0,001	0,010	5,81
CRPC	0,0001600	0,002700	5,59
Meta	0,0000075	0,0000160	3,40

FIGURE 40

	Median (RQ) TLDA	Mean (RQ) TLDA	Mean ² log Genechip®
NP	1,04	2,06	
LG	0,42	0,54	6,95
HG	0,30	0,42	7,33
CRPC	0,22	0,28	6,29
Meta	0,19	0,34	5,57

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/058502A. CLASSIFICATION OF SUBJECT MATTER
INV. C12Q1/68
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MICHELLE R. DOWNES ET AL: "Urinary markers for prostate cancer", BJU INTERNATIONAL, vol. 99, no. 2, 1 February 2007 (2007-02-01), pages 263-268, XP055014164, ISSN: 1464-4096, DOI: 10.1111/j.1464-410X.2006.06610.x the whole document ----- -/--	1-12,18, 26,27



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 June 2012

Date of mailing of the international search report

08/10/2012

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bruma, Anja

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2012/058502

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	VAN GILS M P M Q ET AL: "Innovations in Serum and Urine Markers in Prostate Cancer", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 48, no. 6, 1 December 2005 (2005-12-01), pages 1031-1041, XP027606458, ISSN: 0302-2838 [retrieved on 2005-12-01] the whole document -----	1-12,18, 26,27
A	TALESA VINCENZO N ET AL: "Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers", CANCER BIOMARKERS, IOS PRESS, AMSTERDAM, NL, vol. 5, no. 6, 1 January 2009 (2009-01-01), pages 241-251, XP009148896, ISSN: 1574-0153 the whole document -----	1-12,18, 26,27
A	Bussemakers et al.: "DD3: A New Prostate-specific Gene, highly Overexpressed in Prostate Cancer", 1 December 1999 (1999-12-01), XP055030609, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/content/59/23/5975.full.pdf [retrieved on 2012-06-21] the whole document -----	1-12,18, 26,27
A	YVES FRADET ET AL: "uPM3, a new molecular urine test for the detection of prostate cancer", UROLOGY, vol. 64, no. 2, 1 August 2004 (2004-08-01), pages 311-315, XP055030611, ISSN: 0090-4295, DOI: 10.1016/j.urology.2004.03.052 the whole document -----	1-12,18, 26,27
A	WO 2010/037735 A1 (NOVIOGENDIX RES BV) 8 April 2010 (2010-04-08) claims 1-13 -----	1-12,18, 26,27
A	WO 2004/060304 A2 (SAGRES DISCOVERY INC [US]; MORRIS DAVID W [US]; MALANDRO MARC S [US]) 22 July 2004 (2004-07-22) paragraphs [0268], [0282] ----- -/--	1-12,18, 26,27

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/058502

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/042742 A1 (UNIV MICHIGAN [US]; CHINNAIYAN ARUL M [US]; TOMLINS SCOTT A [US]) 2 April 2009 (2009-04-02) claims 1-8 page 2, paragraph 4 - page 4, paragraph 2 page 10, last paragraph - page 12, paragraph 2 page 24, paragraph 5 - page 25, paragraph 2 -----	1-12, 18, 26, 27
X	WO 2009/015229 A1 (UNIV COLORADO [US]; WITTA SAMIR E [US]; BUNN PAUL A [US]; DRABKIN HARR) 29 January 2009 (2009-01-29) paragraph [0150] -----	26, 27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2012/058502

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

18(completely); 1-12, 26, 27(partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 18(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using DLX1 expression as a marker for prostate cancer.

2. claims: 13(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using ACSM1 expression as a marker for prostate cancer.

3. claims: 14(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using ALDH3B2 expression as a marker for prostate cancer.

4. claims: 15(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using CGREFlexpression as a marker for prostate cancer.

5. claims: 16(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using COMP expression as a marker for prostate cancer.

6. claims: 17(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using C19orf48 expression as a marker for prostate cancer.

7. claims: 19(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using GLYATL1 expression as a marker for prostate cancer.

8. claim: 20

Method and kits for diagnosing prostate cancer using MS4A8B expression as a marker for prostate cancer.

9. claims: 21(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using NKAIN1 expression as a marker for prostate cancer.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: 22(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using PPFIA2 expression as a marker for prostate cancer.

11. claims: 23(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using PTPRT expression as a marker for prostate cancer.

12. claims: 24(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using TDRD1 expression as a marker for prostate cancer.

13. claims: 25(completely); 1-12, 26, 27(partially)

Method and kits for diagnosing prostate cancer using UGT2B15 expression as a marker for prostate cancer.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2012/058502

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010037735 A1	08-04-2010	AU 2009299862 A1 CA 2739140 A1 CN 102272324 A JP 2012504397 A US 2012108453 A1 WO 2010037735 A1	08-04-2010 08-04-2010 07-12-2011 23-02-2012 03-05-2012 08-04-2010
WO 2004060304 A2	22-07-2004	AU 2003303638 A1 CA 2511817 A1 EP 1587476 A2 JP 2006518991 A US 2006040262 A1 US 2006166213 A1 WO 2004060304 A2	29-07-2004 22-07-2004 26-10-2005 24-08-2006 23-02-2006 27-07-2006 22-07-2004
WO 2009042742 A1	02-04-2009	US 2009104120 A1 WO 2009042742 A1	23-04-2009 02-04-2009
WO 2009015229 A1	29-01-2009	GB 2454376 A US 2008182865 A1 US 2012141479 A1 WO 2009015229 A1	06-05-2009 31-07-2008 07-06-2012 29-01-2009